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Abstract 
During the normal menstrual cycle, the human endometrium undergoes 
extensive tissue remodelling under the influence of ovarian-derived hormones. The 
endometrium has well defined stromal and epithelial compartments with the former 
containing both a well-developed vasculature as well as a diverse population of 
immune cells. Mast cells (MCs) are long-lived tissue resident immune cells 
characterised by the presence of granules containing proteases. Mast cells have been 
detected in the human uterus but little is known about their regulation or the impact of 
steroids on their differentiation status. Recently MCs have been implicated as key 
players in physiological and pathological pain pathways but little is known about their 
role in endometrial pathologies. Endometriosis is a chronic incurable condition 
characterized by the presence of endometrial tissue outside the uterine cavity: women 
with endometriosis can suffer from a debilitating range of symptoms including chronic 
pain. Whilst the aetiology of endometriosis is uncertain, close proximity between MCs 
and nerves has implicated them in aberrant activation of pain pathways.  
The aims of the current project were: 1. To determine the spatial and temporal 
location of uterine MCs and to explore their phenotype including expression of steroid 
receptors. 2. To explore the activation status of MCs in women with endometriosis 
and/or pain, 3. To explore the use of cells and mice as models to investigate the 
phenotype of mast cells and their regulation by steroids. 
Mast cell proteases tryptase and chymase were detected by RTPCR and 
immunohistochemistry in “full thickness” (uterine lumen to endometrial-myometrial 
junction) biopsies from women undergoing hysterectomy. In agreement with previous 
findings MCs were most abundant in the myometrium. Uterine MCs were 
predominantly of the classical MC subtypes: tryptasepos/chymaseneg and 
tryptasepos/chymasepos but a rare third subtype was also identified as 
tryptaseneg/chymasepos. Mast cell activation/degranulation was cycle stage dependent 
and for the first time their steroid receptor phenotype was identified as 
ERαneg/ERβpos/GRpos, suggesting potential regulation by the uterine steroid 
microenvironment. 
A role of mast cells in women health and disorders of the endometrium 
  v 
Studies on tissue samples from women with endometriosis revealed MCs with 
an altered activation status in the pelvic peritoneal wall, compared to controls, which 
showed an intense diffuse immunoexpression of chymase suggestive of MC activation 
and release of this protease during normal physiology of the peritoneum. Surprisingly, 
analysis of peritoneal fluids from controls, women with pain but no endometriosis, and 
pain with endometriosis did not detect differences in numbers of MCs or 
concentrations of tryptase or chymase. Analysis of peritoneal biopsies also provided 
the first evidence for a striking increase in immunoexpression of PAR-2, a protease-
activated receptor, in women suffering from chronic pelvic pain and/or endometriosis 
which may provide a mechanism by which mast cell derived factors may alter pain 
pathways. 
Studies in a mouse model of endometriosis identified MCs within endometrial-
like lesions and offer a platform for future studies. In vitro explorations using MCs 
derived from peripheral blood precursors and HMC-1, a cell line derived from a patient 
with MC leukaemia confirmed expression of ERβ but did not support previous studies 
claiming cells were ERαpos. 
In summary, this study has provided novel insights into the phenotype of 
endometrial mast cells in the normal cycling endometrium and contrasted them with 
those in women with endometriosis and pelvic pain. This is the first study to identify 
MCs as ERβpos. Further studies are required to determine whether inhibition of PAR-
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Layman Abstract 
Mast cells (MCs) are cells of our immune system, which are considered to be 
the main players in common allergic reactions such as itch and pain but can also be 
involved in asthma. However, MCs are not just “allergy cells”, as they are versatile 
and present in almost every organ of the body supporting other aspects of our health. 
For example, MCs, together with other immune cells, are resident in the different 
layers of the human womb. They are thought to help the inner layer of the womb 
termed endometrium to shed, which is a key event in the menstrual cycle. 
Understanding how MCs behave during normal conditions can help us to comprehend 
their role in different diseases. Endometriosis is a condition recognised as a social 
problem because it affects one in ten young women and impacts their quality of life. 
Although, approximately 50% of women with endometriosis experience constant and 
debilitating pain that drastically affects their lives, an efficient treatment for 
endometriosis has yet to be found. Recent studies reported the presence of MCs in 
endometriosis lesions, which are small pieces of tissue that behaves like the 
endometrium outside the womb. Specifically, MCs were found in lesions growing on 
the thin surface of the abdomen (the peritoneum) that covers and keeps the internal 
organs together. These lesions are the real cause of the disease and its pain. 
MCs consist of well-organised granules, which act as “storage boxes” for all 
the molecules they need in order to do their job. When MCs receive a stimulus, they 
release the granule content. MCs are the only immune cells that can produce, store and 
release two particular molecules: tryptase and chymase. It is thought that female 
hormones called oestrogens can stimulate MCs. Therefore, the aim of this project was 
to study whether MCs are equipped with tools to be able to respond to oestrogens. In 
particular, we examined whether MCs have oestrogen receptors, which act as the 
“lock” for the “key” oestrogens to activate MCs. Indeed, this research has revealed 
that MCs in the normal endometrium expressed only one of oestrogen receptors, the b 
form and not the a form, which others had previously reported. MCs have also been 
found in the endometrium from women with endometriosis, and they looked different: 
higher in numbers and containing both tryptase and chymase, a feature not present in 
those detected in a normal uterine tissue during this study. Moreover, this study 
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confirmed the presence of MCs in the endometriotic lesions, which were in an 
activated state with chymase located outside of the cell and in the surrounding tissue. 
This project also studied the population of MCs and the levels of tryptase and 
chymase that were present in the peritoneal fluid of patients suffering from 
endometriosis. Peritoneal fluid is a small volume of liquid that surrounds the organs 
and help them to avoid friction and distress. Unexpectedly, lower number of MCs was 
detected in the fluid of endometriosis sufferers compared to unaffected women. 
Endometriosis patients also had a lower amount of tryptase and chymase in their fluid. 
Once tryptase is released from the cytoplasm of MCs, it can interact with a specific 
protein, called PAR-2. PAR-2 is a receptor, which is in turn triggered by tryptase. 
Tryptase functions like a “pair of scissors” and cuts a small string of amino acids from 
PAR-2 protein. The latter subsequently enables PAR-2 to action further. The presence 
of PAR-2 may reflect a mediator role in a chain reaction that follows MC activation 
and PAR-2 is reportedly involved in the perception of pain. Our results indicate 
extremely higher concentration of PAR-2 in the abdomen of women with 
endometriosis compared to healthy women.  
Lastly, another aim of this project was to model possible MCs behaviours with 
cells grown of a dish, as well with animals, which mimic the endometriosis condition 
and symptoms. Taken together, our results provide an excellent stepping-stone for 
future studies on MC-targeted endometriosis therapeutics. 
In summary, this study has carefully described MCs in the normal womb and 
showed for the first time that these cells are different in women suffering from 
endometriosis compared to healthy women, both in the womb and in peritoneum, 
suggesting that MCs may be involved in endometriosis-related and chronic pain. 
Further work will help inform on the role of MCs in endometriosis.  
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Chapter 1 Literature review 
1.1 The endometrium and the menstrual cycle 
1.1.1 Architecture of the human uterus 
The uterus is a thick-walled, muscular organ that is situated in the pelvic cavity 
between the bladder and the rectum (Gray and Lewis, 1918). Three layers constitute 
the uterus: an external layer called the perimetrium, a middle layer called the 
myometrium and an internal layer called the endometrium (Figure 1-1). The 
perimetrium is a serous coat which derives from the peritoneum; it covers the fundus 
and the whole of the intestinal surface of the uterus (Blackbum, 2014). It provides a 
relatively inelastic base upon which the myometrium develops tension. The 
myometrium represents the principal volume of the uterus. It consists of muscular 
fibres, arranged in layers, intermixed with blood vessels, lymphatic vessels, and nerves 
(Naftalin and Jurkovic, 2009). The myometrium is responsible for uterine contractions 
at the time of menstruation and during labour (Wilson and Worthen, 1979, Bulletti et 
al., 2000); it also provides a blood supply to the endometrium (Farrer-Brown et al., 
1970, Rogers, 1996).  
Figure 1-1 The anatomy of the human uterus. 
Retrieved from Martini et al. (2013). 
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The endometrium is adherent to the myometrium, and is a multi-cellular tissue 
that undergoes monthly tissue remodelling in response to fluctuating levels of sex 
steroid hormones produced by the ovaries (reviewed in Critchley and Saunders 
(2009)). The endometrium has a luminal epithelium, which lines the uterine cavity and 
epithelial lined secretory glands as well as a heterogeneous stromal compartment. The 
endometrial stroma contains fibroblasts, blood vessels lined by endothelial cells, 
perivascular cells (pericytes and myofibroblasts) and a heterogeneous population of 
immune cells (reviewed in Evans and Salamonsen (2012b)). The secretory epithelium 
that covers the endometrial glands can extend to the endometrial-myometrial junction.  
Two layers form the endometrial compartment: the functional and the basal 
endometrium. The functional layer is the region, which breaks down and sheds during 
menstruation; it is comprised of the luminal epithelium, sub-adjacent stroma and the 
luminal section of the secretory glands (Padykula et al., 1989). The region of the 
endometrium adjacent to the myometrium is the basal layer, this layer persists 
throughout the cycle and is believed to contain progenitor cells that reconstruct a new 
functional layer following menstruation or parturition (Gargett and Ye, 2012). The 
basal endometrium is represented by the mid-region of glands, which are surrounded 
by a compact stroma and the portion of the endometrium adjacent to the myometrium, 
where glands end and the endometrial-myometrial junction is located. The 
endometrial-myometrial junction, otherwise known as the inner myometrium, is 
defined as the zone between the endometrium, and the outer smooth muscle layer of 
the myometrium (Naftalin and Jurkovic, 2009). The inner myometrium is more highly 
vascularized than other regions of the muscle layer and the muscle fibres are also more 
densely packed (Tetlow et al., 1999).  
1.1.2 Hormonal changes during the menstrual cycle 
The endometrium plays an essential role in female fertility by acting as the tissue 
requires for establishing and successfully sustaining a pregnancy. In 1908, histological 
changes in the endometrium were first described by Hitschmann and Adler (1908), 
and half a century later a central dogma was postulated that changes in the cellular 
behaviour of the endometrium, including cellular proliferation, differentiation and 
apoptosis were strictly controlled by sex steroid hormones produced by the ovary 
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(Good and Moyer, 1968). This insight prompted Noyes et al. (1975) to precisely define 
the various histological changes of the endometrium in response to fluctuating levels 
of oestradiol and progesterone. 
1.1.2.1 Hypothalamus-pituitary-ovary axis 
The secretion of female hormones from the ovaries is controlled by endocrine 
signals and feedback loops within the hypothalamic-pituitary-ovarian axis as 
illustrated in Figure 1-2 (Yen, 1977). The signals that initiate secretion of ovarian 
hormones originate in the central nervous system, specifically from the hypothalamus, 
and subsequent secretion from the small endocrine organ found at the base of the brain, 
the pituitary. 
The hypothalamus accounts for approximately 0.3% of the female adult brain 
however despite its size, it is densely packed with nuclei which are responsible for the 
homeostasis of several processes, such as endocrine regulation and reproduction 
(Mancall and Brock, 2011). The arcuate nucleus of the hypothalamus is where the 
production of gonadotropin releasing hormone (GnRH) takes place. GnRH is released 
in pulses into the pituitary circulation and after reaching the anterior pituitary induces 
the biosynthesis of follicle stimulating hormone (FSH) and luteinizing hormone (LH) 
in the anterior lobe of the pituitary and their release into the circulation (Beshay and 
Carr, 2013). FSH and LH act as endocrine hormones binding to their individual, 
specific, receptors, the proteins of which can be located in different somatic cells in 
Figure 1-2 Schematic of hypothalamus-
pituitary-ovariy axis. 
Secretion of GnRH from the hypothalamus 
induces the production of LH and FSH 
hormones by the gonadotroph cells in the 
pituitary gland. LH and FSH are released 
into the circulation and signal to the theca 
and granulosa cells in the ovary to 
synthesise androgens, oestrogens and 
progesterone respectively.  
Retrieved from Molina (2013). 
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the ovary to stimulate steroidogenesis (detailed in section 1.1.2.2). The hypothalamus-
pituitary-ovary axis is regulated by both positive and negative feedback loops 
involving ovarian hormones, as illustrated in Figure 1-2 (Moore and Price, 1932, 
Krsmanovic et al., 2009). In women, the effect is menstrual cycle phase dependent 
reflecting fluctuations in ovarian hormones. Briefly, the increase in circulating 
concentrations of oestrogens during the late follicular phases, as a result of 
biosynthesis in antral follicles (Britt et al., 2004), stimulates the production of GnRH 
from the hypothalamus and LH from the pituitary. As follicles mature, the granulosa 
cells in the follicles synthetize the aromatase enzyme in response to FSH. Oestrogens 
further increase the responsiveness of granulosa cells to FSH, which leads to the 
progression of the dominant follicle and a further increase in the amount of oestrogens 
secreted into the circulation (follicular phase for the ovary and proliferative phase for 
the endometrium). Ovulation occurs in response to a surge in LH and the granulosa 
cells transform into corpora luteal cells that secrete progesterone, which negatively 
regulates the axis both at hypothalamus and pituitary levels. If pregnancy is not 
established the corpus luteum regresses, oestrogen and progesterone concentrations 
fall precipitously, the negative feedback is removed and the cycle starts again 
(reviewed by Stocco et al. (2007)).  
1.1.2.2 Ovarian steroid biosynthesis 
Oestrogen and progesterone play key roles in the growth and differentiation of the 
human endometrium. In women, the main sources of circulating sex hormones are the 
ovaries and the adrenal glands. Predominantly, sex steroid biosynthesis occurs in the 
ovary, which contains by two endocrine structures: the follicular complex with 
granulosa and theca cells and the corpus luteum (Figure 1-3, Yen (1977)). The crucial 
functions of the ovaries are the formation of the oocytes and production of sex steroid 
hormones. The somatic cells surrounding the growing follicles produce oestrogens that 
feed back to the hypothalamus-pituitary axis, as described above, and also drive local 
follicle maturation (Lunenfeld et al., 1975). The gonadotrophins LH and FSH 
influence the ovary and trigger the steroidogenesis of testosterone, oestradiol and 
progesterone. Steroids are synthesised de novo from free circulating cholesterol 
(reviewed by Payne and Hales (2004) and Hu et al. (2010)), which derives from the 
liver and arrives in the theca cells of the ovary. The biosynthesis of oestrogen and 
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progesterone requires an enzymatic cascade in both theca and granulosa cells, detailed 
in Figure 1-3 (Short, 1962, Hillier et al., 1994). This is often referred to as the “two-
cell, two gonadotrophin” mechanism, with LH binding to its cognate receptor (LHR) 
on the membrane of theca cells to trigger androgen synthesis, and FSH binding to the 
FHSR on the granulosa cells to stimulate the synthesis of the aromatase complex that 
converts testosterone into oestradiol.  
Briefly, LH by binding the membrane bound G protein coupled receptor (GPCR), 
LHR, stimulates a second message signalling involving cyclic adenosine 
monophosphate (cAMP) (Marsh, 1976), which then induces the transcription of the 
CYP11A gene in the theca cells. The CYP11a enzyme plays a key role as it catalyses 
the conversion of cholesterol to pregnenolone (Chung et al., 1986). Androstenedione, 
a testosterone precursor, is synthetized via multiple intermediates including the 
enzymes of CYP17 (also known as 17a hydroxylase) and 17βHSD (HSD17B) (Patel 
et al., 2010).  
FSH binds FSHR on granulosa cells, which is also a GPCR, and triggers a second 
messanger cascade involving production of cAMP to stimulate transcription of the 
CYP19 gene (aromatase) (Ryan et al., 1968). The aromatase enzyme complex converts 
androstenedione secreted from the theca cells, after cell membrane crossing, to 
oestrogens (oestrone and oestradiol), which are then released into the circulation and 
thereafter act in an endocrine manner on oestrogen-target tissues, including the 
endometrium.  
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The transformation of the follicles into corpora lutea changes the expression of 
steroidogenic enzymes so that progesterone, and not androgens, becomes the 
predominant hormone produced in the ovary during the secretory phase. This switch 
in steroid production is the result of the increased expression of CYP11A and 3bHSD 
favouring the conversion of cholesterol into pregnenolone and progesterone and a 
decrease in expression of CYP17 which reduces oestradiol production (Lachance et 
al., 1990). 
1.1.3 Histological features of endometrium during the 
menstrual cycle 
The human endometrium undergoes substantial transformation during every 
menstrual cycle with disintegration of the functional endometrium (menstrual phase), 
followed by its regeneration (proliferative phase) and differentiation of a new layer in 
preparation for an embryo implantation (secretory phase, Figure 1-4).  
Figure 1-3 “Two cell-two gonadotropin” model. 
Sex steroid hormones, oestrogen, progesterone and testosterone are synthesised in the somatic cells of 
the follicle, theca and granulosa cells. The synthesis is coordinated by the binding of LH and FSH to 
their GPCR receptors. Cholesterol is cleaved by CYP11A1 into pregnenolone, steroid dehydrogenase 
convert pregnenolone into progesterone (3βHSD) or into androstenediol (CYP17 and 17βHSD). 
Androstenediol can cross the basal membrane between the two cells, and is converted into oestrone and 
oestradiol, (CYP19 and 17βHSD) in the granulosa cells before being released into the blood stream. 
CYP11A1: cholesterol side chain cleavage cytochrome P450, CYP17: 17α hydroxylase/C17-20 lyase 
cytochrome P450, CYP19: aromatase, 17βHSD: 17β hydroxysteroid dehydrogenase, 3βHSD: 3β 
hydroxysteroid dehydrogenase, cAMP: adenosine 3’,5’-cyclic monophosphate, PKA: protein kinase A, 
FSH: follicle stimulating hormone, FSHR: follicle stimulating hormone receptor, LH: luteinising 
hormone, LHR: luteinising hormone receptor. Adapted from Beshay and Carr (2013) and Doshi and 
Agarwal (2013). 
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Based on the screening and histological staging of 8000 endometrial biopsies, 
Noyes et al. (1975) provided a classification of the different stages of the menstrual 
cycle which is a gold standard for histological staging. The length of the average 
menstrual cycle is 28 days, the convention numbers days of the cycle starting from 
menstruation (day 1) being followed by the proliferative phase (day 4 to 14) and after 
ovulation, the secretory phase (typically days 16 to 28). The secretory phase can be 
further subdivided into early (day 16-19), mid (day 20-24) and late secretory (day 25-
28) phases. For a better understanding of the sequence of events in the human 
endometrium, the phases of the menstrual cycle are described in detail in the following 
sections. 
1.1.3.1 The proliferative phase 
During the proliferative phase (also known as follicular phase based of the 
activity of the ovary) the endometrium undergoes intense cellular proliferation as 
reported by Ferenczy et al. (1979) and Johannisson et al. (1987). Evidence of DNA 
synthesis and mitoses of multiple cells in the epithelium, stroma and vascular network 
has been described in samples recovered towards the end of the proliferative phase, 
Figure 1-4 The human ovarian and functional endometrium during the menstrual cycle. 
The fluctuating concentrations of E2 and P4 (P, progesterone) in blood are shown schematically. During 
the latter half of the cycle the numbers of tissue resident uterine natural killer cells (uNKs) and 
macrophages (ϕ) are increased. Image courtesy of Professor Saunders, originally drawn by Mr Pinner 
for the MRC Human Reproductive Sciences Unit.  
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prior to ovulation (Talbi et al., 2006). The luminal epithelium initially appears thin 
after its regeneration post-menses but newly formed straight glands become more 
voluminous and tortuous as oestrogen concentrations rise (Figure 1-4). During the 
proliferative phase, the development of a glandular network occurs together with the 
formation of an elaborate vascular supply that is also accompanied by stromal cell 
proliferation (Gambino et al., 2002). Histologically, the endometrium thickens from 
about 2 mm recorded immediately after the menstrual phase, to 14 mm prior to 
ovulation on day 14, (see Figure 1-5, (Hess et al., 2006)). Notably, the presence of 
oestrogen receptor proteins in the endometrium are considered essential to facilitate 
normal proliferation and vascularisation. Specifically, studies using mouse models 
have shown that oestrogen regulates the proliferative phase through the oestrogen 
receptor isoform a, which induces stromal-epithelial interactions (Lubahn et al., 1993, 
Winuthayanon et al., 2010). The proliferative phase ensures the priming of the 
endometrium for the events necessary for hosting a pregnancy and it has been 
demonstrated that E2 induces both the upregulation of the expression of both its own 
receptor (ERa) and also progesterone receptors (PR) (Couse and Korach, 1999) 
enabling  to respond to progesterone released by the corpus luteum.  
1.1.3.2 The secretory phase 
After ovulation, the secretory phase begins (also called the luteal phase for the 
ovary, Figure 1-4). The transformation of the endometrium during the secretory phase 
is influenced by the high circulating concentrations of progesterone that are produced 
by the corpus luteum which induce both glandular and stromal cell differentiation. On 
days 15-16, the glandular epithelium starts to accumulate glycogen in its basal region, 
and the nuclei move towards the apical region of the cells (see Figure 1-5, (Hess et al., 
2006)). By day 17, well-organized vacuoles are present in the glycogen granules and 
mitochondria have an increased size an adaptation which is thought to overcome of 
high demand for energy in the highly tortuous glands (Verma, 1983). On days 19 and 
20, few vacuoles are left in the glandular epithelium as the glycoprotein-rich products 
are expelled by apocrine secretion into the glandular lumen. The uterine fluid found in 
the centre of the organ also contains plasma transudates derived from the endometrial 
vessels. The mid secretory changes become apparent after the day 20, with the stroma 
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become oedematous, due to an increase in vascular permeability (Okada et al., 2001). 
During the mid secretory phase there is also proliferation of epithelial cell and 
maturation/coiling of spiral arterioles in the functional layer.  
Decidualisation, a specific cellular transformation event of stromal fibroblasts is 
initiated co-incident with maximum oedema (day 22) and is first observed adjacent to 
the blood vessels but thereafter proceeds in a “wave” to occupy the entire stromal 
compartment of the functional layer (Raine-Fenning et al., 2004). Decidualisation 
results in the conversion of spindle-shape fibroblasts into rounded epithelial-like cells 
with an enlarged cell surface (Gellersen and Brosens, 2014). At day 23, the fibroblasts 
are surrounded by spiral arterioles and capillaries. Stromal differentiation continues 
with sub-epithelial pre-decidua establishment (day 25), and by day 27 this appears as 
a solid sheet of pre-decidualised cells (Tang et al., 1993).  
During days 24-25 of the menstrual cycle, there is a marked increase in 
lymphocyte infiltration into the endometrium (see section 1.2) which reaches its 
maximum by days 27-28 (late secretory phase) and persist after implantation in a 
Figure 1-5 Endometrial thickness during 
the menstrual cycle. 
A-B) Functional and basal compartments in 
full-thickness sections (endometrial-
myometrial junction to luminal epithelium) 
during the proliferative (A) and the mid-
secretory (B) phases. C) Mitotic events in 
glandular and stromal cells during 
proliferative phase (arrows). D) subnuclear 
vacuoles (arrowheads) and secretions in the 
lumen of glands (asterisk) during the mid-
secretory phase. Image adapted by Hess et al. 
(2006). G: gland, S: stromal compartment. 
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fertile cycle. If pregnancy occurs, the decidual cells will form the maternal component 
of the placenta, the basal decidua (Moffett and Loke, 2006). In the absence of the 
establishment of a pregnancy and consequent demise of the corpus luteum, levels of 
progesterone rapidly decline (progesterone withdrawal, Figure 1-4), which 
precipitously induces tissue breakdown with shedding that is experienced as 
menstruation (reviewed by Jabbour et al. (2009) and in Critchley and Saunders 
(2009)). 
1.1.3.3 The menstrual phase 
In absence of a developing blastocyst, the regression of the corpus luteum 
during the late secretory phase results in a rapid decrease in the circulating 
concentrations of ovarian-derived steroid hormones, and triggers a sequence of 
changes in endometrial tissue function that results in tissue breakdown and ultimately 
shedding of the functional layer of the tissue at menstruation.  
Morphological evaluation of the tissue recovered at the time of menstruation 
has shown that it is characterized by cell death in the epithelium, with the exception of 
glandular epithelial cells located in the basal compartment, as well as blood vessel 
necrosis; focal haemorrhage and tissue shedding (Owen, 1975).  
The cellular and molecular mechanisms that are initiated by progesterone 
withdrawal involve not only an impact on epithelial and stromal cells but also changes 
in the vascular compartment and the activity of immune cells (Maybin and Critchley, 
2011). Notably menstruation shares many characteristics with an inflammatory 
response, including an increase in the biosynthesis of prostanoids, cytokines and 
chemokines (Jabbour et al., 2006).  
It has been hypothesised that this inflammatory response can be considered as 
involving two phases: 1. An increase in the local concentrations of cytokines and 
prostaglandins in the endometrial tissue, induced in stromal cells in the response to the 
decreasing hormone concentrations (a progesterone receptor dependent event) (Jones 
et al., 2004, Catalano et al., 2007, Evans and Salamonsen, 2014); 2. An influx of 
immune cells in response to the local change in cytokines which is followed by 
immune cell activation (Kelly et al., 2001a, Kelly et al., 2001b).  
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1.1.3.4 Loss of vascular integrity 
Spiral arterioles are unique structures in the endometrium of menstruating 
species. The classic studies by Markee using human endometrial tissue explants 
demonstrated that steroid (oestrogen/progesterone) withdrawal induced a pronounced 
vasoconstriction of the endometrial spiral arterioles for up to 24h (Markee, 1940). This 
vasoconstriction was then followed by the opposite vascular process, vasodilatation of 
the vessels, initiating an increase in blood flow. Ischemic damage induced by 
vasoconstriction facilitates the release of blood from the vessels to the luminal surface. 
The combination of the interruption of blood supply and the acute tissue haemorrhage, 
has been reported to be transient and thus similar to an “ischaemia-reperfusion” injury.  
Several vasoactive mediators have been implicated in the response to steroid 
withdrawal. Prostaglandins (PGs) are locally produced and concentrations of 
vasoactive prostaglandin, PGE2 have been reported to be higher than those of the 
vasoconstrictor PGF2a at the time of menstruation (Baird et al., 1996b, Jabbour and 
Sales, 2004, Maybin et al., 2011). The vasodilator mediator nitric oxide (NO) is also 
locally synthesized in the endometrium and may have a role in regulating vascular tone 
(Cameron and Campbell, 1998), with vascular epithelial growth factor (VEGF) 
thought to have an effect on the induction of NO synthesis (Sharkey et al., 2000).  
The vasoconstriction of arterioles may also cause a transient hypoxia in the 
functional endometrium. Hypoxia has been demonstrated in mouse model of 
menstruation using pimonidazole, which stains hypoxic cells (Cousins et al., 2016). 
The results obtained suggested that endometrial oxygen levels were reduced to 10 
mmHg (110 mmHg is normal oxygen level) during menstrual phase (Fan et al., 2008, 
Cousins et al., 2016). Furthermore, the hypoxia-inducible factor 1 α (HIF-1α) protein, 
a transcription factor that is stabilised by low oxygen levels, was shown to be abundant 
in glandular and stromal cells in the functional endometrium during late secretory and 
menstrual phases, and absent during the proliferative phase (Punyadeera et al., 2006). 
HIF-1α activation has been shown to modulate the induction and/or repression of 
genes that regulate different cellular processes, such as angiogenesis, cell survival, 
proliferation and apoptosis (Piccoli et al., 2007) providing a link between hypoxia in 
the functional layer and processes required to restore tissue integrity.  
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1.1.3.5 Tissue breakdown 
The endometrial extracellular matrix (ECM) is composed of collagen, laminin, 
gelatin, fibronectin, proteoglycans, and hyaluronic acid structures (Nair and Taylor, 
2010). In addition to spiral arteriolar vasoconstriction, augmented ECM degradation 
is another principal mechanism that initiates menstruation. Metalloproteases (MMPs) 
control the degradation of the ECM (Gaide Chevronnay et al., 2012). Endometrial 
stroma expresses several MMPs (MMP-1, MMP-2, MMP-3, MMP-9, MMP-10), 
while the epithelium predominantly expresses MMP-7 (Salamonsen and Woolley, 
1999, Salamonsen et al., 2000). The immune cell populations produce many other 
MMPs following their activation (Evans and Salamonsen, 2012a).  
MMPs are generally secreted in an inactive form, as pro-MMPs. The synthesis 
of pro-MMPs increases just prior to menstruation in response to local signals (e.g. 
immune cell activation) as well as progesterone withdrawal. Withdrawal of 
progesterone leads to increased MMP production and activation of pro-MMPs 
triggering endometrial ECM degradation. The degradation of tissue matrix results in 
massive tissue destruction, loss of structural integrity, and vascular disruption. The 
endometrium is shed along with blood coming from the destroyed endometrial 
vasculature (Rogers and Abberton, 2003). Haemostasis is achieved after menstruation 
by coagulation in the basal endometrium (Davies and Kadir, 2012). Tissue breakdown 
induced by MMPs activates endometrial platelets and results in coagulation of the 
blood (Mastenbroek et al., 2015). 
1.1.3.6 Re-epithelialization and tissue repair  
The endometrium must rapidly repair to limit blood loss and prepare for arrival 
of a blastocyst in the following cycle. The processes implicated during an efficient 
endometrial repair share some features to classic wound healing, and these include 
inflammation, resolution, angiogenesis, tissue formation and tissue remodelling 
(Maybin and Critchley, 2015).  
A remarkable study using human endometrial tissues reported that the “repair” 
of the functional layer occurs within the 48h from start of menses; therefore it is 
considered a rapid process (Ferenczy, 1976a). Scanning electron microscopy (SEM) 
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of endometrial samples during the menstrual phase (day 2), has documented a ragged 
and irregular surface with secretory glands together with a complete lack of an intact 
epithelial luminal layer (Ludwig and Spornitz, 1991). The regrowth of the epithelium, 
both glandular and luminal, starts before stromal compartment expansion, with 
epithelial cells proliferating from the necks of the glands to meet migrating cells from 
other glands, forming a new luminal surface (Garry et al., 2010). The restoration of 
the luminal surface with a fully reconstructed epithelial cell layer, is achieved by day 
6 (Ferenczy, 1976a, Ferenczy, 1976b). A recent study employing SEM technology 
showed that the shedding of the functional endometrial layer appears to occur 
simultaneously with the repair process during menstruation, rather than in sequence as 
was once thought (Garry et al., 2009).  
Notably, the initial re-epithelialization of the endometrium and active bleeding 
occur during in steroid-depleted environment, after regression of the corpus luteum 
and prior to significant oestrogen secretion from the growing follicles. Animal studies 
investigating the repair process have demonstrated that oestrogen is not required in the 
initiation of, or during the process of endometrial repair (Kaitu'u-Lino et al., 2007, 
Matsuura-Sawada et al., 2005).  
1.1.4 Steroid hormones receptors 
Sex steroid hormones, such as oestrogen and progestagens, have a critical 
impact on several physiological functions and are essential regulators of reproductive 
function.  
Sex steroid hormones can alter cellular functions by binding to nuclear 
receptors, members of the nuclear receptor superfamily (Huang et al., 2010). The 
glucocorticoid receptor is also a member of the nuclear receptor superfamily (Rose et 
al., 2010). These steroid receptors all have a similar structure with a DNA-binding 
domain (DBD-C), which retains two zinc finger motifs, a hinge domain (D) and the 
receptor domain responsible for ligand binding (LBD-E) located towards the C 
terminus of the protein, as shown in Figure 1-6 (Griekspoor et al., 2007, Critchley and 
Saunders, 2009). 
A role of mast cells in women health and disorders of the endometrium 
Chapter 1 - Literature Review  14 
In humans, two isoforms of oestrogen receptor have been identified: ERa 
(NR3A1) and ERb (NR3A2), which are encoded by two separate genes, ESR1 and 
ESR2 respectively, located on the human chromosomes 6q25.1 (ESR1) and 14q23.3 
(ESR2) (Nilsson et al., 2001).  
The human progesterone receptor (PR, NR3C3) is the product of a single gene, 
which is located on chromosome 11q22 (Rousseau-Merck et al., 1987). PR can exist 
as two different isoforms PR-A and PR-B, which differ from each other by the 165 N-
terminal sequence of amino acids on the PR-B (Kastner et al., 1990) due to use of 
alternative start sites (Figure 1-6).  
The glucocorticoid receptor encoding gene (NR3C1) has been mapped onto 
human chromosome 5q31-32 (Francke and Foellmer, 1989). Two isoforms of GR have 
been described, GRa and GRb, which are identical until amino acid 727 but then differ 
due alternative splicing. GRa has an additional 50 amino acids (total of 777 amino 
acids, represented in Figure 1-6) and GRb an additional, non-homologous 15 amino 
acids (Oakley et al., 1996, Oakley et al., 1999). Only GRa appeared to be able to bind 
hormone and induce expression of a glucocorticoid-responsive reporters (Hollenberg 
et al., 1985, Taniguchi et al., 2010). 
1.1.4.1 Steroid receptor signalling 
According to the classical model of steroid hormone dependent gene 
activation, the receptors act as ligand activates transcription factors. In brief, steroids 
enter the cell, by either by passive diffusion through the lipid membrane or assisted by 
transporter proteins, and then bind to steroid receptors which are in the cytoplasm 
(Beato, 1989). Ligands bind in a “pocket” located in the LBD domain and this 
Figure 1-6 The steroid hormone 
receptor superfamily. 
Steroid hormone receptors have a 
conserved structure constituted by 
a variable N-terminal domain 
(A/B), a common DNA binding 
domain (DBD), a hinge domain 
(D) and ligand binding domain 
(LBD-E) located toward the C-
terminus. Adapted from Scally 
(2012). 
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provokes a conformational change in the receptor, which is accompanied by the 
dissociation of accessory proteins, exposing the DNA-binding domain (DBD) and sites 
for binding of cofactors typically in helix 12 at the C terminus of the proteins 
(McDonnell et al., 1993, Mangelsdorf et al., 1995, Losel and Wehling, 2003).  
The genomic actions of steroid hormones may be mediated through different 
pathways, categorised in two main mechanisms: “direct binding” where the ligand-
receptor complex directly binds to a specific DNA sequences in gene promoters or 
enhancers called steroid hormone response elements (oestrogen: ERE, progesterone: 
PRE and glucocorticoids: GRE), which are typically specific inverted palindromic 
sequences. Alternatively ligand-activated receptors use a “tethering” mechanism 
involving other DNA-bound transcription factors such as Jun, Fos and Sp1 and 
stabilises the DNA binding site of the specific factors (McDonnell et al., 1993) (Figure 
1-7).  
Figure 1-7 Different mechanisms of oestrogen receptor signalling. 
The effects of E2 can be mediated through four mechanisms: 1. Classical ligand-dependent, E2-ER 
complex binds to EREs in target promoters inducing an up- or downregulation of transcription and its 
consequent tissue responses. 2. ligand independent pathway, growth factors (GF) or cyclic adenosine 
monophosphate (not shown) stimulate intracellular kinase pathways, leading to phosphorylation event 
(P) and activation of ER at ERE-containing promoters. 3. ERE-independent, E2-ER complex modifies 
gene transcription containing alternative response elements such as AP-1 through association with other 
DNA-bound transcription factors (Fos/Jun), which tether the activated ER to DNA, resulting in an up-
regulation of gene expression. 4. Cell-surface (non-genomic) signalling, E2 activates a membrane 
associated binding site, that can be a form of ER linked to intracellular signal transduction pathways 
that generate rapid tissue responses (Hall et al., 2001). 
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In both cases, transcription depends upon recruitment of a cocktail of factors 
including polymerase II prior to activation or repression of transcription. The length 
of time between steroid entry and the accumulation of significant amounts of newly 
formed protein is in the order of hours, and the whole pathway is sensitive to particular 
inhibitors (Losel and Wehling, 2003).  
In addition to the direct effect on transcription, steroid hormones have been 
shown to influence the activity of many other signalling pathways in a non-nuclear 
manner, by the binding to cell membrane receptors. This mechanism is usually referred 
to “non-genomic” and secondary messenger mediated, involving protein kinase 
cascade (e.g. MAPK) (Migliaccio et al., 1996, Clark and Lasa, 2003, Treviño et al., 
2013). Furthermore, steroid hormones are also reported to act via members of the G 
protein coupled receptors superfamily (Kelly and Wagner, 1999) and exert rapid 
effects with increase of cAMP (Aronica et al., 1994), lipase or kinase pathways and/or 
with ion channel (Tesarik and Mendoza, 1995), inducing an alteration of intracellular 
Ca2+ (Figure 1-8).  
Figure 1-8 Simplified schemat of steroid hormone actions through the different pathways. 
This image represents the possible effects of steroid hormone-receptor mechanisms, via the “classical” 
genomic action (left part) or non-genomic ways: via conventional steroid hormone membrane receptors 
(middle part) or via non-classical receptors (right part). Image retrieved from Losel and Wehling (2003). 
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Oestradiol and oestrone are the classical endogenous ligands for both ERa and 
ERb, and both exhibit agonist activity at ERs (Gruber et al., 2002). Other molecules 
have been synthesised which show specific binding to ERs, for example two molecules 
have been widely used as specific agonists for studies in cell lines and mice, propyl-
pyrazole triol (PPT; ERa specific) and diarylpriopionitrile (DPN; ERb specific). 
Specific oestrogen receptor modulators (SERMs) are compounds capable of mixed 
agonist and antagonist actions on ERs, with their tissue specific actions dependent on 
the local availability of co-factors in different cells/tissues (Bryant, 2001, Sun et al., 
2002). Probably the most widely used SERM is tamoxifen, it is commonly employed 
as ER antagonist in breast cancer therapy, but it acts as an agonist in endometrial tissue 
(Dutertre and Smith, 2000, Katzenellenbogen et al., 2000). The compound ICI 182,780 
(fulvestrant) acts as full antagonist for both ER isoforms by inducing receptor turnover 
(Osborne et al., 2004).  
Progesterone receptors (PRs) may be activated, similar to ERs, by the 
endogenous steroid progesterone (P4), as well by the synthetic compounds with agonist 
or antagonist activity; medroxyprogesterone acetate is one of the most widely used PR 
agonists (Sitruk-Ware, 2004). Examples of SPRMs (selective progesterone receptor 
modulators) are ulipristal and asoprisnil, which exert different actions as agonist or 
antagonist in a tissue dependent manner (reviewed by Wagenfeld et al. (2016)).  
Glucocorticoid receptors (GRs) can be activated by both by cortisol from the 
circulation, cortisol generated locally within tissues by the actions of HSD enzymes 
(hydroxysteroid dehydrogenase) and by synthetic steroids such as prednisolone and 
RU 24858 (Vayssiere et al., 1997, McMaster and Rays, 2008), as well as by non-
steroidal molecules, as ZK 216348 which can act as selective glucocorticoid receptor 
modulators (SGRM) (McMaster and Rays, 2008). 
1.1.4.2 Steroid receptor expression in the human uterus 
The expression of steroid hormone receptors is tightly regulated both 
temporally and spatially in the uterus (reviewed in Critchley and Saunders (2009) and 
Gibson and Saunders (2012)).  
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Oestrogen receptors are present in cells within all the different uterine 
compartments including the myometrium and both the basal and functional 
endometrium. In the myometrium, mRNA concentrations of ERα are higher than ERb, 
but a switch in the ratio of mRNAs has been reported in the myometrium of 
postmenopausal women (Jakimiuk et al., 2004). In reproductive age women the ratio 
of ERa to ERb in the endometrium varies accordingly to the levels of circulating 
hormone during the menstrual cycle. During the oestrogen dominated proliferative 
phase expression of ERa is reported to be high in the epithelial glands and in the 
stroma but has not been detected in endothelial cells lining the blood vessels (Critchley 
et al., 2001). The protein decreases in the glands and stromal cells after the rise of 
progesterone levels during the progesterone dominant secretory phase (Critchley et al., 
2002). ERb is predominantly present during the secretory phase, and is notably 
expressed by stromal, epithelial and endothelial cells in the functional layer of the 
endometrium (Critchley et al., 2001). Furthermore, the action of oestrogen on 
endometrial endothelial cells (HEECs) has been reported to be ERb-dependent 
(Greaves et al., 2013). Notably most studies on endometrial leukocyte populations, 
including those focusing on natural killer cells (uNKs) and macrophages has reported 
they do not express ERa and are immunopositive for ERb (Hunt et al., 1998, 
Henderson et al., 2003, Thiruchelvam et al., 2013). 
Progesterone receptor expression varies throughout the phases of the menstrual 
cycle (Ingamells et al., 1996) and is reported to be oestrogen regulated with an increase 
in PR protein expression being detected in the endometrium during the proliferative 
phase (Mote et al., 2000). PR-A is the predominant type in the stromal compartment 
during the secretory phase and early pregnancy (Wang et al., 1998). While the 
expression of both isoforms PR-A and PR-B is drastically reduced in the glandular 
epithelium during the secretory phase, it has been shown that PR-A expression is 
persistent in the stroma and in particular in stromal cells associated with blood vessels, 
but that PR is no detectable in the endothelium (Perrot-Applanat et al., 1994, Critchley 
et al., 2001). The expression of PR in the basal endometrium is not affected by the 
hormonal changes, and stromal and epithelial cells are both immunopositive for PR 
throughout the cycle (Snijders et al., 1992).  
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Glucocorticoid receptor can be detected in the nuclei of endometrial stromal 
cells in all phases of the menstrual cycle, while epithelial cells are negative (Bamberger 
et al., 2001, Henderson et al., 2003). The impact of glucocorticoids is regulated not 
only by its receptor expression, but also by the presence of steroid-metabolizing 
enzymes (which are responsible for ligand bioavailability). The 11b-HSD family 
converts cortisone (inactive glucocorticoid form) into cortisol (active form) by the 
11b-HSD1 enzyme and inactivates cortisol into cortisone by 11b-HSD2 (Jabbour et 
al., 2006). It has been demonstrated that higher concentrations of 11b-HSD2 are 
present in the endometrial stroma throughout the phases of the cycle, compared to 11b-
HSD1 and 11b-HSD2 expression rises during the secretory phase in epithelial cells 
(McDonald and Henderson, 2006). It was also confirmed by Kuroda et al. (2013) that 
the increase of mRNA expression of 11b-HSD1 is driven by progesterone in 
decidualizing human endometrial stromal cells (HESCs). Notably, GR expression was 
also detected in some of the endometrial leukocytes, including the uNKs (Henderson 
et al., 2003) and macrophages (Thiruchelvam et al., 2013).  
1.2 Leukocytes in endometrium 
The immune cell complement of the human endometrium is dynamic, and varies 
almost every day in response to the hormonal changes occurring during the normal 
menstrual cycle and throughout pregnancy (Jabbour et al., 2006). Inflammatory cells 
constitute a substantial proportion of the total cell population within the endometrial 
stroma with CD45 (leukocyte common antigen) positive cells being located 
throughout the endometrium in both basal and functional layers (Kammerer et al., 
2004).  
It has been reported that immune cell numbers change over the different phases 
of the cycle, representing 10-15% of cells in the proliferative phase, 20-25% of cells 
in the late secretory phase, and up to 40% of cells in the menstrual phase, detailed in 
Figure 1-9 (Kamat and Isaacson, 1987, Salamonsen and Woolley, 1999, Maybin and 
Critchley, 2015). This population mainly consists of uterine natural killers (uNKs), 
macrophages, neutrophils, eosinophils and mast cells (Salamonsen and Lathbury, 
2000). Temporally, the proportion of different immune cell subtypes in the 
endometrium varies. For example, following the transition from the proliferative to 
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secretory phase, high numbers of uNKs and macrophages are detected (Kammerer et 
al., 2004). Whilst neutrophils and eosinophils are absent during most of the menstrual 
cycle, immediately before menstruation there is a stricking increase in their numbers 
in the functional endometrium (Jeziorska et al., 1995, Salamonsen and Woolley, 1999). 
In contrast some immune cells do not appear to fluctuate during the cycle, and this 
includes mast cells. Uterine leukocytes are described in detail in the sections below 
and as mast cells are the main focus of this thesis, they are reviewed in greatest detailed 
in section 1.3.  
1.2.1 Uterine natural killer cells 
The most abundant subtype of CD45+ cells in the endometrium are uterine NK 
cells (uNKs). Although they are all but absent during the early stages of the menstrual 
cycle, uNKs comprise over 70% of the endometrial leukocytes during receptive phase 
when implantation in favoured, a time in the cycle that is coincident with elevated 
circulating progesterone levels and decidualisation of stromal fibroblasts (Bulmer et 
al., 1991).  
A) 
B) 
Figure 1-9 The human leukocytes during the menstrual cycle. 
A) Sex steroid oscillations during the luteo-follicular transition. B) Overview of the uterine leukocyte 
population during the menstrual cycle. The size in panel B reflects the abundance in the endometrium. 
Image adapted from Maybin and Critchley (2015). 
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The increase in uNK cell number has been attributated both to local NK cell 
proliferation within the endometrium and also to an additional influx of circulating NK 
cells (Jones et al., 1997, Chantakru et al., 2002). NKs specific to the endometrium, 
defined as uterine NKs (uNKs), are phenotypically different from the peripheral blood 
NK population (pbNKs). Up to 90% of pbNKs are phenotyped as CD56dim-CD16pos 
while the minority is CD56bright-CD16neg (Koopman et al., 2003). uNKs appear to be 
exclusively CD56bright-CD16neg and are relatively granular, a feature not shared with 
the small percentage of CD56bright-CD16neg pbNKs. There are also important 
functional differences between endometrial and peripheral NK cells, for example 
uNKs show a relatively weak cytotoxicity and increased cytokine secretion compared 
to pbNKs (Cooper et al., 2001). 
During the late secretory phase and coincident with decidualisation, numbers 
of uNKs greatly increase (Bulmer et al., 1991). Unlike pbNKs, uNKs can secrete an 
array of factors with angiogenic actions, such as vascular endothelial growth factor 
(VEGF), placental growth factor (PLGF) and angiopoetin 2 (Li et al., 2001, Hanna et 
al., 2006, Lash et al., 2006). Notably, uNKs are often located near the spiral arterioles 
and accumulate in perivascular regions to exert their angiogenic action.  
It has been postulated that the function of uNKs could be influenced by sex 
hormones, due to their phase specific influx. Studies in our group have demonstrated 
that uNK cells immunonegative for ERa and PR (Henderson et al., 2003) and 
immunopositive for ERb and GR (Henderson et al., 2003, Bombail et al., 2008). 
1.2.2 Macrophages 
Monocytes develop from a common myeloid progenitors found in the bone 
marrow or the splenic reservoir (Hettinger et al., 2013). Progenitors are released into 
the circulation and subsequentially recruited into tissues, where differentiation into 
mature macrophages takes place. Tissue-resident macrophages show phenotypical 
differences based on their specific tissue environment (Radzun, 2015). Macrophages 
exert precise roles in the immune response through phagocytosis of apoptotic bodies, 
or modulation of other immune cells through the secretion of inflammatory factors in 
the tissue (Wynn and Barron, 2010, Thiruchelvam et al., 2013, Zhou et al., 2016). 
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Macrophages are important members of the immune cells in the endometrium 
and their number is tightly regulated temporally and spatially during the menstrual 
cycle. Macrophages make up 1-2% of the stromal endometrial compartment during the 
proliferative phase, their number increasing to 3-5% after the surge of progesterone in 
the secretory phase, and reaching their peak after progesterone withdrawal (late 
secretory) and menses, accounting for approximately 6-15% of the total stromal cells 
in the tissue (Kamat and Isaacson, 1987, Salamonsen and Woolley, 1999, Salamonsen 
et al., 2002, Thiruchelvam et al., 2013).  
It has been demonstrated that endometrial macrophages are able to release 
MMP-9, MMP-12, MMP-14 and plasminogen activator, which are all molecules 
implicated in the breakdown of the functional layer of the endometrium (Jeziorska et 
al., 1996, Salamonsen and Woolley, 1999, Curry and Osteen, 2003). 
Similar to uNKs, endometrial macrophages appear to express ERb and GR, but 
not PR (Hunt et al., 1998). There is also evidence to suggest that oestrogen can 
influence macrophages; the administration of exogenous oestrogen to women 
undergoing “in vitro fertilization” treatments induced a significant increase of 
macrophages in the functional endometrium (DeLoia et al., 2002). In vitro culture 
systems have been used to show macrophages also can respond to cortisol, promoting 
release of factors that promote angiogenesis (Thiruchelvam et al., 2016). 
1.2.3 Neutrophils 
Neutrophils are the most abundant leukocyte in the human immune system; in 
normal tissues they have a short lifespan but in inflamed tissues their lifespan can 
increased, as their rate of apoptosis is reduced by pro-inflammatory mediators and 
hypoxia (Ward et al., 1999, Cross et al., 2006). Neutrophils are released in the blood 
stream as mature or nearly mature immune cells (Mary, 1985, Galli et al., 2011). 
Neutrophils contain specific secretory granules, which store a diverse range of 
molecules that differ with the stage of neutrophil maturation.  
Neutrophils are closely associated with tissue damage in several immune 
disorders (Leitch et al., 2008, Wright et al., 2010, Robb et al., 2016). Neutrophils have 
been localized in the human endometrium, by staining for neutrophil elastase. 
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Endometrial neutrophils have also been phenotyped as CD11bpos, CD66bpos and 
CD16pos (Yeaman et al., 1998). Once activated they can release an array of pro-
inflammatory cytokines such neutrophil-elastase, interleukin 8 (IL-8) and tumour 
necrosis factor a (TNFa) (Li and Verma, 2002).  
Endometrial neutrophils are almost undetectable during most of the menstrual 
cycle, however their number drastically increases on days 27-28 of the late secretory 
phase, when they can account for up to 6-15% of the total number of endometrial 
stromal cells (Salamonsen and Woolley, 1999). Furthermore, studies on neutrophils in 
a mouse model of menstruation suggested that they were involved in the resolution of 
the endometrial wound as their depletion with antibody against Ly6G induces a delay 
in endometrial repair (Kaitu'u-Lino et al., 2007).   
Neutrophils store high levels of MMPs in their granules and have the ability to 
activate resident MMPs of the endometrium to then initiate tissue breakdown (Gaide 
Chevronnay et al., 2012, Maybin and Critchley, 2015). There is evidence that 
neutrophils may respond to hormonal changes, as they are reported to express both 
isoforms of ER (a and b), PR and GR (Strickland et al., 2001, Molero et al., 2002, 
Bhattacharjee et al., 2012, Bhattacharjee et al., 2014).  
1.2.4 Eosinophils 
Eosinophils are members of the leukocyte population resident in mucosal 
tissues; they are considered multifunctional immune cells that contribute to various 
physiological and pathological mechanisms. Eosinophils derive from a common 
progenitor, which is capable of generating colonies of either eosinophils or basophils 
(Kita, 2011); mature eosinophils are present in the peripheral circulation. Eosinophils 
are a source of both regulatory and pro-inflammatory cytokines and chemokines 
(Hogan et al., 2008). Immunolocalization of the eosinophil specific cationic proteins 
(ECP1 and ECP2) has identified eosinophils in the human endometrium. Like 
neutrophils, eosinophils have been reported to be absent in the endometrium during 
day 5-26 of the menstrual cycle (proliferative and secretory phases), and there was an 
influx at day 26, which last until day 28 (Jeziorska et al., 1995). Extracellular staining 
for ECPs shows that eosinophils in the endometrium appear to be activated (Jeziorska 
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et al., 1995). Eosinophils also contain VEGF and MMPs in their granules (Okada et 
al., 1997, Puxeddu et al., 2005), suggesting they might complement other immune cells 
playing a role in tissue remodelling. 
There is evidence that eosinophils respond to oestrogenic stimuli (Douin-
Echinard et al., 2011). Steroid hormone receptor expression has been investigated in 
human uterine eosinophils and immunopositivity for both isoforms of ER and GR has 
been reported (Tchernitchin et al., 1974, Tchernitchin et al., 1976, Peterson et al., 
1981), but they appear immunonegative for PR (Aerts et al., 2002).  
1.3 Mast cells 
MCs have long fascinated the scientific and medical communities due to their 
because of their association with the pathophysiology of common conditions such as 
asthma, dermatitis and allergic reactions. MCs were first identified by Ehrlich in the 
late XIX century (Ehrlich, 1878). They exhibit an array of adhesion molecules and 
immune response receptors that confer an advanced capability to react to multiple 
specific and nonspecific stimuli (Metcalfe et al., 1997). MCs are often detected in body 
sites that are in contact with the external environment and are play a role in host 
defence. The extensive tissue distribution of MCs supports their potential not only to 
act as first responders during host defence, but also to react to environmental 
alterations and communicate to other cells. Evidence that MCs are involved in tissue 
repair, wound healing and angiogenesis also support the crucial role they play in 
adaptive immunity (da Silva et al., 2014). MCs can rapidly interact with, and respond 
to, their surrounding environment and when activated they release a whole array of 
biologically active mediators and therefore even a small perturbation of the delicate 
balance between MC and their environment may result in devastating effects to the 
organism (Moon et al., 2010, Galli et al., 2011). 
1.3.1 Growth, development and survival 
MCs develop from CD34+/CD117+ pluripotent progenitors originating from the 
bone marrow (Kirshenbaum et al., 1999). The progression of progenitors cells to fully 
mature MCs is mainly dependent on c-kit receptor activation (CD117), which occurs 
as a consequence of the action of stem cell factor (SCF) which stimulates in receptor 
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dimerization and auto-phosphorylation (Gilfillan and Tkaczyk, 2006). Modifications 
of the c-kit receptor found on progenitors, as in the KitW-sh/W-sh “sash” mouse, leads to 
a reduced number of MCs (Tsai et al., 2011).  
Committed CD34+ progenitors are released into the circulation, from where they 
can migrate into tissues throughout the body. The progenitors become terminally 
differentiated into mature MCs with tissue-specific phenotypes due to the influence of 
cytokines present in the tissue microenvironment (Metcalfe et al., 1997). The 
migration of MC progenitors appears to be controlled in a tissue specific manner and 
it has been reported to differ between tissue such as the intestine and the lungs (Fox et 
al., 1988). The signals that might influence the uterine specific trafficking of MC 
progenitors are not yet known. Generally, specific membrane proteins are required to 
facilitate MC progenitor trafficking including integrin a4b7 and CXCR2 found on 
their surface, and VCAM-1 which is present on the endothelial cells (Gilfillan et al., 
2011). Evidence for the importance of these factors has been obtained from studies in 
integrin b7 null mice and studies using an antibody that blocks VCAM-1. Both 
strategies resulting in a profound deficit in the population of both MC progenitors and 
mature MCs (Artis et al., 2000, Gurish et al., 2001, Abonia et al., 2002). A similar 
effect has also been reported in a CXCR2 deficient mouse (Abonia et al., 2005). These 
studies highlight the importance of the IL-8-CXR2 pathways in MC recruitment. 
Trafficking from the capillaries to the peripheral tissues is maintained during 
homeostasis, but is drastically increased during inflammatory states (Haberstroh et al., 
2002, Rose et al., 2003, Deshmane et al., 2009), providing a mechanism to explain the 
increased number of MCs at the sites on inflammation (Halova et al., 2012) 
Fully differentiated tissue resident MCs are long-lived cells, but their lifespan is 
dependent on the maintenance of concentrations of SCF in the surrounding tissue. 
Accordingly, a reduction of SCF induces human mast cells to undergo apoptosis 
(Jensen et al., 2008). Moreover, SCF induced MC survival has been shown by Ekoff 
and Nilsson (2011) to be related to inactivation of FOXO3a, followed by the 
downregulation of the pro-apoptotic BH3-only protein.  
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1.3.2 Human and murine MC subtypes 
MC maturation has been demonstrated to be environment specific, and the 
concentrations of different growth factors and cytokines can influence the progenitor-
MC differentiation and the final mature MC phenotype (Jamur and Oliver, 2011). 
Accordingly, the MC populations within an individual may exhibit a high degree of 
heterogeneity due to their widespread tissue distribution.  
Enerback (1966a, 1966b) was the first scientist to demonstrate the existence of 
two rodent MC subtypes: the mucosal MC (MMCs) and the connective MC (CTMCs). 
In the mouse the MMCs have been identified in the mucosal epithelium of the lung 
and gastrointestinal tract (Irani and Schwartz, 1989). MMC specific protease content 
is characterized by mast cell protease 1 and 2, mMCP-1 and mMPC-2, both of which 
are chymases. CTMCs are identified in the intestinal submucosa, peritoneum and skin, 
and contain granules that have mMCP-4 (chymase) as well as mMCP-6 and mMCP-
7, both of which are tryptases and carboxypeptidase A (mCPA). Notably, the 
appearance of murine MCs as revealed by toluidine staining differs depending on this 
subtype-specific granule structure (Irani and Schwartz, 1989) (see Figure 1-10).  
The chymase-like (chymase) protease family expressed in rodents differs from 
that in humans in terms of function. For example, MCP-5 presents a catalytic domain 
mutation that fundamentally changes its specificity, from chymotryptic to elastolytic 
Figure 1-10 Murine and human MC subtypes. 
A) Murine MCs can be categorized into two 
subtypes based on their anatomical location, as 
being either connective or mucosal. The murine 
MC types differ in their granule structure and its 
components. B) Human MC subtypes are 
predominantly of two types: MCT and MCTC based 
on their protease granule content (Galli et al., 
2011). A third rare subtype MCC is not illustrated 
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(Kunori et al., 2002, Karlson et al., 2003).. MCP-4 instead is the most similar to human 
chymase in terms of target preferences and expression pattern (Caughey, 2007a).  
MMC granules are constituted by chondroitin sulfate chains of serglycin 
proteoglycans, whereas CTMC granules are formed by heparin chains of serglycin 
proteoglycans, as detailed in Figure 1-12 (Yurt et al., 1977, Enerback et al., 1986, 
Metcalfe et al., 1997). Therefore, they present with a different metachromatic staining 
with toluidine blue. As reported by Enerback (1966a), CTMCs appeared intensively 
purple stained whereas MMCs are only weakly stained, as illustrated in Figure 1-10-
A. Another difference between the two murine MC subtypes is the content of histamine 
and lipid mediators, as only CTMCs are able secrete histamine and prostaglandin 2 
upon stimulation (Heavey et al., 1988). 
Human MCs are classified based on the expression of the proteases in their 
granules (Figure 1-10), the most common subtype are MCT containing 
tryptase/heparin. There are also MCTC which contain both tryptase and chymase, and 
a rare and less studied subtype MCC, which is reported to be immunopositive for 
chymase but not tryptase (Irani et al., 1986, Irani and Schwartz, 1989, Weidner and 
Austen, 1993). MCT are predominant in the intestinal and pulmonary mucosa, similar 
to MMCs, and MCTC are located in the skin, lung and gastrointestinal mucosa, 
paralleling the locations of CTMCs (Irani et al., 1986). MCC have been described in 
bronchi and gastrointestinal submucosa and mucosa (Weidner and Austen, 1993). 
Human MC granule structure does not changes between the three subtypes, as they all 
rely on a structure of heparin and chondroitin sulphate proteoglycans, at a 2:1 ratio 
(Metcalfe et al., 1979, Thompson et al., 1988). 
The tissue specificity mast cell subsets and their protease content, brings into 
consideration the presence of specific inhibitors and target substrates for the 
proteinases, which also may vary from tissue to tissue. Thereby, it has been shown that 
proteinases released by MMC within gut epithelium during nematode infection (Tuohy 
et al., 1990) are initially likely to encounter lower concentrations of plasma-derived 
proteinase inhibitors such serpins (Irvine et al., 1990), when compared with CTMC, 
which are often located in the proximity of small blood vessels. Thus, the plasma 
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extravasation, rich in inhibitors, would promptly interfere with the chymases, released 
by CTMC, but this effect would be retarded in the epithelium, where the inhibitors 
need to diffuse into the tissue to act on MMCs. Therefore it has been postulated that 
the in vivo extracellular functions of mast cell specific proteinases is driven by: the 
specificity of the proteinase; the efficacy of inhibition and the ratio of 
proteinase/inhibitor; the solubility and stability of the proteinase itself; and the 
accessibility of target substrates and their susceptibility to proteolysis (Miller and 
Pemberton, 2002). 
MCs represent a small percentage of the endometrial leukocyte population, 
which is reported to be relatively constant through the menstrual cycle. MCs have been 
identified in all layers of the uterus (Sivridis et al., 2001). Both MCTC and MCT 
subtypes have been identified in the human uterus (Jeziorska et al., 1995). MCs in the 
functional layer are reported to have a low granule content during the premenstrual 
stages which may suggest they are activated (Jeziorska et al., 1995). 
MCs have been implicated in the active biochemical process of extracellular 
matrix (ECM) degradation that occurs during menstruation and because they are able 
to release both precursors of metalloproteinases (MMP-2, MMP-9) and collagenase 
(Lees et al., 1994, Milne et al., 2001). Moreover, MCs may be involved in implantation 
due to their ability to secrete histamine, which alters vascular permeability and induces 
stromal decidualisation (Wordinger et al., 1986, Menzies et al., 2011). Some mediators 
released by MCs such as histamine and serotonin have been shown to be associated 
with myometrial contractions, as they act as oxytocic agents (Menzies et al., 2012, 
Cruz et al., 1989).  
Due to the activation of uterine MCs throughout the different phases of the 
menstrual cycle, it has been hypothesised that hormones might be involved in inducing 
MC degranulation. In non-reproductive tissues and the HMC-1 cell line, MCs are 
reported to express ERa and PR, but appear to be immunonegative for ERb (Pang et 
al., 1995, Zhao et al., 2001, Nicovani and Rudolph, 2002, Zaitsu et al., 2007, Jensen 
et al., 2010). Investigations on GR expression using rat-derived MC lines, showed the 
expression of GR, both isoforms, on MC membranes (Oppong et al., 2013, Oppong et 
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al., 2014). To date there is no detailed phenotypic information related to steroid 
hormone receptors in MCs resident in the endometrium. 
1.3.3 MC granules 
The most distinguishing morphological characteristic of MCs is their high 
content of electron-dense lysosome-like secretory granules that represent the major 
component of their cytoplasm (as shown in Figure 1-11). In fact, it was the presence 
of multiple secretory granules that drew the attention of Paul Ehrlich, resulting in their 
naming as “mastung” cells, that in German means “well fed” (Ehrlich, 1878). 
Identification of MCs has usually been achieved by employing various cationic dyes, 
such toluidine blue. 
The serglycin proteoglycans are formed by a core protein to which chains of 
polysaccharide are covalently attached through glycosidic bonds to the serine residues 
of the core site (Wernersson and Pejler, 2014). The glycosidic part can be composed 
of heparin or chondroitin sulphate, both assembled in disaccharide chains (Figure 
1-12). They provide a mesh structure that enables the storage of molecules in the 
granules (Ronnberg et al., 2012).  
In addition to the storage, it has been shown that MC proteoglycans may have 
an effect on the activities of MC proteases. For examples, it has been demonstrated 
that tryptase’s stability is highly dependent on the presence of heparin that acts by 
Figure 1-11 MC granule morphology  
A) Mature granules contain electron-
dense material, which are equally 
distributed in the cytoplasm. B) 
Degranulating MC, with “degranulation 
channels” (long arrows), Figure adapted 
from Wernesson and Pejler (2014). 
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crosslinking the individual tryptase monomers and stabilizes the active tetramer of the 
protease (Hallgren and Pejler, 2006). On the contrary, the association of chymase with 
heparin chains has been shown to induce an inactivation of chymase substrates (Pejler 
et al., 2007). Therefore, heparin GAGs are present and they are required for protecting 
tryptase activity in CTMCs, where tryptase is the most abundant protease, and not in 
MMCs. 
MCs produce and store three main classes of molecules: pre-formed granule-
associated mediators, newly generated lipid mediators, and a variety of cytokines and 
chemokines, which are listed in detail in Table 1-1. Among these preformed/prepacked 
compounds, histamine, together with serotonin are the most prominent biogenic 
amines found in the MC granules. In line with the lysosome-like proprieties of granules 
(Arvan and Castle, 1998), MC granules also contain several lysosomal hydrolases as 
well as cytokines, such as TNFa and factors that regulate angiogenesis such as VEGF 
(Wernersson and Pejler, 2014). But notably, the major constituents of granules are the 
MC specific serine proteases: tryptase and chymase (Pejler et al., 2007). Other 
proteases such as carboxypeptidase A3 and MMP-9 are also present in the granules 
(Baram et al., 2001). 
Figure 1-12 MC proteoglycan types and structure. 
A) Proteoglycans are comprised of a “core protein” on which the glycosamiglycan (GAG) chains are 
covalently bound to serine residues (purple segment). B) Two different types of GAGs, heparin with 
chains of iduronic/glucuronic acid–glucosamine disaccharide (top), or chondroitin sulphate, are formed 
from glucuronic acid–N-acetyl-galactosamine disaccharide repeats (Wernersson and Pejler, 2014). 
 
A) B) 
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Activated MCs can also initiate the de novo synthesis of several lipid-derived 
molecules. Of significance are the arachidonic acid products, which have well-
established inflammatory activities. One of the main lipoxygenase products is 
leukotriene C4 (LTC4) (Dahinden et al., 1985, Sjostrom et al., 2002). The 
cyclooxygenase products of MCs include prostaglandin D2 and E2 (PGD2 and PGE2) 
(Metcalfe, 2008). 
Class Potential function 
GRANULE-ASSOCIATED  
Histamine and serotonin Alteration of the vascular permeability 
Heparin and/or chondroitin sulphate 
proteoglycans Enhancement of chemokine/cytokine function and angiogenesis 
Tryptase. Chymase and other proteases Tissue remodelling and recruitment of effector cells 
TNF and VEGF Recruitment of effector cells and increase of angiogenesis 
LIPID-DERIVED  
LTC4, PGD2 and PGE2 
Recruitment effector cells, regulation of immune response, 
promotion of angiogenesis and oedema, bronchoconstriction 
Platet-activating factor (PAF) Activation of effector cells, enhancement of angiogenesis 
CYTOKINES  
TNF, IL-1a, IL-1b, IL-6, IL-18, GM-
CSF, LIF, INFA and INFb Inflammation 
IL-10, TGFb and bFGF Regulation of inflammation and angiogenesis 
CHEMOKINES  
CCL-2, CCL-3, CCL-4, CCL-5, CCL-
11 and CCL-20 
Recruitment of effector cells, including dendritic cells and 
regulation of immune responses 
CXCL1, CXCL2, CXCL8, CXCL9, 
CXCL10 and CXCL11 Recruitment of effector cells and regulation of immune responses 
Table 1-1 Predominant components of MC granules: preformed and de novo synthetized molecules.  
(Metcalfe, 2008). 
 
1.3.4 MC activation 
The activation of MCs is often referred to as degranulation, due to the physical 
release of mediators from MC granules by exocytosis into surrounding extracellular 
sites. The release may be induced by: 1. chemical substances, such as proteases; 2. 
endogenous mediators, tissue proteases or cationic proteins generated by other 
immune cells; 3. immune mechanisms which may be IgE dependent or independent, 
as illustrated in Figure 1-13, (Galli et al., 2011, Kawa, 2012). MC degranulation is 
preceded by an increase of extracellular Ca2+ influx, which is an essential step as the 
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inhibition of changes in the intracellular Ca2+ suppresses degranulation (Rice et al., 
2013).  
Activation/degranulation occurs in two waves (Figure 1-14), first there is a 
rapid response that begins within seconds to minutes following stimulation, which is 
characterised by the release of the pre-formed mediators and the synthesis of lipid-
derived eicosinoids which is transcription independent. In the second phase of 
activation, MCs initiate de novo synthesis of mediators, including a large number of 
cytokines, that are transcribed and translated in response to activation (Figure 1-14) 
(Abraham and St. John, 2010). MCs are known to be long lived cells (Padawer, 1974, 
Kiernan, 1979), and once degranulation is complete their granules are replenished and, 
the MCs re-enter their resting phase (Figure 1-14). 
There is growing evidence that MCs have the capability to respond and 
degranulate in response to several types of stimuli, not only after IgE-antigen 
crosslinking. Various inflammatory products can induce MC activation, and these 
Figure 1-13 Patterns of functional 
MC activation may be IgE dependent 
or independent. 
A) MC represented at its resting phase, 
where little or no release occurs. B) IgE 
association occurs during allergic 
reactions and interaction to parasites. 
IgE binds to the FceRIa receptors on 
MC membrane and induces 
degranulation in the presence of an 
antigen (C). D-E) Degranulation can 
be induced by signals not dependent on 
IgE, like neuropeptides such substance 
P, NGF and histamine, or C3a C5a of 
the complement system or toll-ligands. 
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include complement factors, toll-like receptor ligands (TRLs), cytokines, hormones 
and neuropeptides (Yu et al., 2016).  
 Maximal release happens within a few minutes while recycling of the 
membrane and granule replenishment occurs within the scale of a few hours to 
days.(Blank et al., 2014, Balseiro-Gomez et al., 2016). The mechanisms of granule 
retrieval, such as endocytic processes which induce retention of the intragranular 
matrix after degranulation, guarantee the maintenance of granule shape and 
proteoglycan matrix. They also ensure rapid granule recycling which maintains the 
secretory response during repeated stimulation. 
1.3.4.1 Tryptase and histamine receptors 
MCs express receptors that enable them to modulate the immune response in 
both an activating and inhibiting fashion. Examples include the protease-activated 
receptor 2 (PAR-2), which can be activated by tryptase and the histamine receptor 1 
(HR1), which is activated by histamine. Both PAR-2 and HR1 belong to the G protein-
coupled receptor family (GPCRs) which regulate availability of functions via 
downstream mediators including Ca2+ (for ion channels), cAMP and cGMP (for 
adenylyl and guanlyl cyclases), inositol-1, 4,5-triphosphate (IP3), diacyl glycerol 
(DAG) and arachidonic acid (for phospholipases) (Tuteja, 2009). In the case of PAR-
2 and HR1 following their activation there is an increase in inositol triphosphate which 
leads to an increase of intracellular Ca2+ (Ossovskaya and Bunnett, 2004, Hill, 1990). 
Figure 1-14 Time frame of MC degranulation and granule replenishment after stimulation. 
MCs release pre-formed mediators within seconds after stimulation, within minutes the release of lipid-
derived molecules occurs (without transcription and protein translation). A second wave of 
degranulation consists with the release of de novo synthetized molecules, which require translation and 
transcription, and therefore this happens within hours after MC activation. Granules are replenished 
within days after activation. Image adapted from Abraham and St John (2010). 
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PAR-2 and HR1 other than being expressed by MCs, are also present in a wide variety 
of other cell types, including fibroblasts, endothelial cells, smooth muscle cells, 
immune cells and sensory neurons (Coughlin, 2000, Parsons and Ganellin, 2006). 
PAR-2 receptor is uniquely activated by irreversible proteolysis. Unlike other 
GPCRs, the endogenous PAR ligands are resident in the extracellular matrix, near the 
N-terminus of the receptor (Figure 1-15). The cleavage of the receptor in the N-
terminal domain by tryptase reveals the tethered ligands, which after being exposed, 
bind the second extracellular loops of the receptor structure (Soh et al., 2010, Zhao et 
al., 2014) initiating the signalling cascade. 
Antagonism to PAR-2 and HR1 receptors has been shown to block MC 
activation (Levi-Schaffer and Eliashar, 2009), reduce tissue oedema and pain 
perception (Mobarakeh et al., 2000, Ferrell et al., 2003, Sevigny et al., 2011, Poole et 
al., 2013).  
1.3.5 Tools for studying MCs 
1.3.5.1 MC cell lines and MC primary cells 
In 1988, the first human MC line was established from the peripheral blood of 
a patient with MC leukaemia, and named HMC-1 (Butterfield et al., 1988). HMC-1 
Figure 1-15 Two possible activation 
mechanisms of PAR-2 receptor: 
enzymatic and non-enzymatic way. 
A) Serine proteases such as tryptase can 
enzymatically cleave the N-terminal 
peptide of PAR-2, B) which induce the 
release a peptidic chain, and new N-
terminal end formation C), which can bind 
to the second transmembrane loop of the 
receptor. D) The formation of tethered 
ligand induce an intracellular G-protein-
coupled pathway that results in 
intracellular Ca2+ increase and activation 
of protein kinase C. The non-enzymatic 
was involves a synthetic SLIGRL peptide 
(E-F) directly binds to the body of PAR-2 
without the cleavage of the N-terminal 
peptide, therefore G) it mimics the effect 
of the PAR-2-activating proteases. 
(Kawabata, 2002) 
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cells share features with immature MCs, and they are independent of SCF for their 
growth, due to a point mutation in the CD117 (c-kit) receptor, which results in 
constitutive phosphorylation and activation of the receptor without the ligand. HMC-
1 cells lack the well-formed granules seen in mature MCs, and not all the classic MC 
components are present e.g. chymase is almost absent. The proteoglycan structure of 
the few granules that are present is similar to that of primary MCs, and contain both 
heparin and chondroitin sulphate. Furthermore, HMC-1 cells have other critical 
limitations, for example they lack a functional IgE receptor (Nilsson et al., 1994a). 
The development of other MC lines, such as LAD2, which was prepared from 
bone marrow aspirates of a patient with MC sarcoma/leukaemia, have improved the 
range of in vitro tools available to study MCs. LAD2 cells have numerous granules, 
degranulate in response to IgE-mediated activation, and are SCF dependent for their 
growth and survival and therefore share more features than HMC-1 with mature MCs 
(Kirshenbaum et al., 2003). 
MCs have also been cultured from foetal liver, umbilical cord blood and 
peripheral blood (Metcalfe, 2008). Unfortunately, the micro-environmental conditions 
that influence full MC maturation in vivo are very difficult to repeat in vitro. Thus the 
cultured MCs that have been studied to date are imperfect representatives of mature 
MCs (Moon et al., 2010). 
Although it is possible to isolate MCs from tissues that might provide important 
tissue specific information, this method also has associated limitations. Rodent 
peritoneal MCs (PMCs) can be easily collected in a relatively high number (Karimi et 
al., 1999), however, the human peritoneal cavity has few MCs and extrapolation of 
results from rodent PMCs to human MCs requires caution (Bischoff, 2007). Further 
limitations to the usage of peripheral tissue-derived MCs include: the labour-intensive 
nature of the isolation protocols; change of tissue-resident MC phenotype; and low 
yields of MCs. To date there have been reports that human MCs have been isolated 
from skin, intestine, lung and uterus (Massey et al., 1991, Gibbs and Ennis, 2001, 
Kulka and Metcalfe, 2001a, Sellge and Bischoff, 2006). Unfortunately, the effects of 
the isolation and enrichment procedures on MC functions has not yet been evaluated. 
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1.3.5.2 Animal models of MC deficiency 
The in vivo relevance of in vitro observations have been tested using MC-
deficient animal models, as this allows the study of MC function in complex in vivo 
settings that cannot be carried out in humans.  
The use of MC-deficient mice and their reconstitution with bone marrow 
derived MCs (BMMCs knock-in model) has been a powerful tool to study MC 
function in vivo. For example, the importance of MCs in pregnancy establishment and 
labour initiation has been demonstrated using the knock-in system in the KitW-sh/W-sh 
“sash” animals (Menzies et al., 2012, Woidacki et al., 2013b).  
Animals with spontaneous loss-of-function mutations at both alleles of the 
dominant white spotting (W) locus, for example c-kit gene, present an evident 
impairment in the c-kit tyrosine kinase-dependent signalling, which results into altered 
mast cell development and survival (Grimbaldeston et al., 2005).  
 
However, the interpretation of results obtained using MC-deficient animals 
should be treated with caution because they present with profound phenotypic 
abnormalities in both the hematopoietic and immune systems (Nocka et al., 1989).  
1.4 Biological effects of MC granule components 
MCs are implicated in the pathology of diverse conditions such as allergy, 
asthma, rheumatoid arthritis, interstitial cystitis, and inflammatory bowel syndrome 
(Theoharides et al., 2012). The mediators released by MCs can independently, and in 
synergy of other immune cell type cytokines (e.g. macrophages and T-cells derived), 
orchestrate a complex immune response.  
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The key events of MC degranulation and their putative impacts are summarized 
in Figure 1-16. 
In brief, histamine released by MCs exerts many effects following binding to 
receptors such as HR1 including the stimulation of afferent sensory nerves (Kim et al., 
2011), induction of smooth muscle contraction (Suzuki and Kou, 1983), increases in 
vascular permeability and vasodilation (Sorbo et al., 1994, Lu et al., 2013).  
It has been demonstrated that MCs can actually store preformed cytokines 
within secretory granules, initially reported as tumour necrosis factor a (TNFa), which 
contributes significantly to the pro-inflammatory response (Wernersson and Pejler, 
2014). MCs also produce and secrete a large number of other cytokines, growth factors 
and chemokines (Galli et al., 2005). These factors are mostly released as a result of do 
novo synthesis as opposed to preformed pools (Lundequist and Pejler, 2011). 
However, there are a number of factors/cytokines that may actually be stored in MC 
granules including vascular endothelial growth factor (VEGF) (Grutzkau et al., 1998), 
transforming growth factor-b (TGFb) (Lindstedt et al., 2001). 
The MC-specific proteases which are abundant in MC granules, have a 
significant impact both through the activation of protease-activated receptor 2 (PAR-
Figure 1-16 An overview of the possible biological effects of MCs. 
Image adapted from Wernersson and Pejler (2014). 
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2) and other structural components. For example, the cleavage of PAR-2 by tryptase 
results in the activation of afferent nerves, leading to an increase in pain perception 
(Hoogerwerf et al., 2001), and in activation of fibroblasts to stimulate consequent 
extracellular matrix (ECM) deposition and fibrosis (Akers et al., 2000). Moreover, 
chymase can also promote tissue remodelling either directly by degrading the ECM 
fibronectin (Okumura et al., 2004), or indirectly by activation of the pro-MMPs into 
proteolytic MMPs (Tchougounova et al., 2005, Magarinos et al., 2013) 
1.4.1 MCs in tissue remodelling and fibrosis 
Direct action of MC proteases on ECM components includes the degradation 
of fibronectin by chymase (Okumura et al., 2004). As an important example of an 
indirect role, chymase has been reported to have pro-collagenase activity (Saarinen et 
al., 1994) and is essential for transforming the pro-enzymes for matrix metallo-
proteinase 9 (pro-MMP-9) and pro-MMP-2 into active enzymes (Tchougounova et al., 
2005). Similarly, tryptase has been demonstrated to activate MMP-3 and MMP-13 
(Magarinos et al., 2013).  
There is also evidence that MC proteases can stimulate pro-fibrotic activity by 
inducing fibroblast proliferation via PAR-2 receptor cleavage (Akers et al., 2000, 
Duchesne et al., 2011) and that chymase can activate transforming growth factor-β 
(TGFb) (Lindstedt et al., 2001), therefore facilitating pro-fibrotic activity. It is also 
likely that protease-mediated effects on the ECM could further support angiogenesis, 
as this could be augmented by the release of VEGF from preformed stores in granules 
(Grützkau et al., 1998). 
1.4.2 MCs and angiogenesis 
MC are often associated with blood vessels and their numbers increase during 
angiogenesis-dependent events like ovulation and wound healing (Norrby, 2002).  
The stimulatory action of MC mediators can affect different stages of 
angiogenesis such as degradation of the ECM, migration and proliferation of 
endothelial cells, formation and distribution of new vessels, synthesis of ECM, and 
pericyte mobilization (de Souza Junior et al., 2015). 
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Therefore, the biological consequence of MC activation on the vasculature has 
been extensively studied. It is known that the micro-vascular responds to granule-
derived mediators such as histamine, lipid-derived PGD2, LTB4, LTC4, and cytokines 
like VEGF and PAF (platelet activation factor), all present or sequentially synthetized 
and stored in MC granules. All these agents are able to augment micro-vasculature 
permeability, which has pro-angiogenic effects (Dvorak et al., 1999). Moreover, PAF 
is also a powerful chemotactic agent for eosinophils and neutrophils and causes platelet 
aggregation (Norrby, 2002).  
Furthermore, it has been demonstrated that tryptase and chymase can also exert 
angiogenic effects. For example, it has been shown that tryptase acts as a mitogen on 
micro-vascular endothelial cells enhancing capillary growth, an effect that can be 
suppressed by tryptase inhibitors (Caughey et al., 1993, Blair et al., 1997). For 
chymase, it has been shown that its angiogenic action is indirectly related to the role 
of angiotensin II (Ang II) (Muramatsu et al., 2000b). Chymase, like the angiotensin 
converting enzyme (ACE), can cleave angiotensin I into angiotensin II isoform, which 
has been reported to be a potent inductor of neovascularization via VEGF (Muramatsu 
et al., 2000a). Notably, chymase is more efficient that ACE in producing this 
conversion. It has been also demonstrated that Ang II can increase blood flow by 
ischemia-induced angiogenesis (Sasaki et al., 2002) highlighting the diverse impact of 
chymase on the vasculature.  
Interestingly, Ang II has been shown to positively influence the proliferation 
of endothelial cells and vascular smooth muscle cells in vitro (Tamarat et al., 2002). 
Moreover, Ang II is a potent stimulus for VEGF-induced proliferation and tube 
formation in retinal microvascular endothelial cells, through the induction of the 
VEGF receptor (Otani et al., 1998).  
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1.4.3 MCs and nerve interaction, pain perception 
MCs are critical cellular regulators of physiological and pathological pain 
pathways. Pain can be classified as either a protective or a maladaptive process. 
Protective pain includes nociceptive pain which triggers nerve signals to ensure rapid 
removal from an intense stimulus (Figure 1-17-A). Protective pain also includes the 
inflammatory-induced pain that is associated with tissue damage (Figure 1-17-B), 
which promotes immune cell influx and hypersensitivity until the tissue has been 
repaired (Woolf, 2010). Pathological pain, which is a result of a maladaptive pain, is 
of a chronic nature, it doesn’t resolve rapidly and is often associated with long term 
symptoms (Figure 1-17-C). The intimate interaction between sensory nerves and the 
immune system plays a key role in pain processing, and in the fine balance between 
protective and pathological pain (Ren and Dubner, 2010).  
Figure 1-17 Three classes of 
pain. 
A) Nociceptive pain responds 
to a detection of potential 
tissue-damaging stimuli and is 
considered a protective type of 
pain, B) Inflammatory pain 
occurs after tissue damage, 
with the influx of several 
immune cells. Hypersensity 
may occur until full resolution. 
It is a protective type of pain, 
C) Pathological pain occurs in 
the case of damage to the 
nervous system (neuropathic 
type, top right) or in response of 
the abnormal fuction 
(dysfunctional type, bottom 
right) (Woolf, 2010). 
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MCs are frequently associated with nociceptive neurons and may reside in close 
proximity to unmyelinated nerve fibres, such as nociceptive C-fibres (Forsythe and 
Bienenstock, 2012). MCs can release an array of mediators with neuro-inflammatory 
proprieties including histamine, serotonin, IL-1b, TNFa and IL-6 which have been 
demonstrated to induce hyperalgesia in either an independent manner or in association 
with chemical or allergen stimulation (Cunha et al., 1992, Lavich et al., 2006, Verri et 
al., 2006). It has been postulated that there is a positive feedback loop between 
nociceptive neurons and MCs during neuro-inflammation (Rosa and Fantozzi, 2013), 
where neuronal fibres activate proximal MCs by releasing neuromodulators and 
subsequently MCs release algogenic molecules that then amplify vasodilation and 
sensitization of nociceptors (Figure 1-18) (Koda and Mizumura, 2002). This 
relationship between sensory nerves and MCs has also been supported by the use of 
MC stabilizers which were shown to inhibit nociception (Le Filliatre et al., 2001).  
Figure 1-18 Potential interactions between sensory nerves and MCs. 
Both neurons and MCs have the potential to produce and then secrete an array of neuro-inflammatory 
mediators, such as NGF, substance P (SP), which can bind their receptors (trkA and NK-1, respectively). 
NGF and SP can also take part in nociceptive signalling. MC specific tryptase may bind PAR-2 receptor 
on neurons and initiate inflammatory cascades, which include the release of CGRP (calcitonin gene 
related peptide). CGRP receptors are expressed on MCs, and their stimulation leads to histamine release 
from the granules. Image adapted from Chatterjea and Martinov (2015).  
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Another key signalling molecule between nerves and MCs is substance P. This 
factor can be released by both neurons and MCs and leads to a sequential production 
of histamine and prostaglandins (Janiszewski et al., 1994, Theoharides et al., 2012). 
Histamine is also released from MCs and directly excites nociceptors. Several studies 
have demonstrated that histamine H1 receptors have a critical role in physiological and 
pathological pain perception (Foreman et al., 1983, Mobarakeh et al., 2000).  
The release of the MC-specific protease tryptase can also cause hyperalgesia 
upon binding to PAR-2 expressed on the nociceptors (Amadesi et al., 2006). PAR-2-
mediated hyperalgesia has been shown to depend on TRPV4, a member of the transient 
receptor potential cation channel subfamily V, in a model of colorectal distension (Sipe 
et al., 2008). Moreover, tryptase-induced PAR-2 activation can also trigger the release 
of calcitonin gene-related peptide (CGRP) by neurons, which in turn stimulates 
histamine from MCs (Ottosson and Edvinsson, 1997). MCs in women health 
 Substantial differences in the inflammatory responses of women compared with 
those of men have been identified (Grossman, 1989, Schuurs and Verheul, 1990). It 
has also been reported that the incidence and the severity of immune disorders are 
generally higher in women than in men and included in this observation were MC-
related painful conditions such as asthma, irritable bowel syndrome (IBS) and 
interstitial cystitis (IC). 
For example, the prevalence of asthma is higher in boys than girls during puberty 
(Bonds and Midoro-Horiuti, 2013) but switches during adulthood so that women then 
have a greater incidence of asthma exacerbations which are also much more severe 
than in men (Leynaert et al., 2012). Highlighting a link to steroid hormones are reports 
that asthma worsens in women during the perimenstrual phase of their cycle, and that 
an alleviation of asthmatic attacks occurs after menopause (Romieu et al., 2010).  
Adult premenopausal women suffering from IBS present with a higher 
prevalence of symptoms and a lower quality of life compared to men, and have worse 
symptoms perimenstrually (Canavan et al., 2014, Heitkemper and Chang, 2009). It is 
reported that the total count of immune cells is increased in intestinal tissue biopsies 
from women compared to men (Barbara et al., 2004, Cremon et al., 2009). 
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Similar characteristics are reported for women with IC, with 90% of IC patients 
being female, and they report a worsening of IC pain symptoms during the 
postovulatory phase (Bjorling, 2001). 
An association between the actions of female sex hormones, oestrogen and 
progesterone, and symptoms of MC-associated disorders has been extensively studied.  
1.4.4 MC oestrogen receptor expression  
The first evidence of the expression of oestrogen receptor (ER) in human MCs 
was reported by Pang et al. (1995). He and his colleagues reported that MCs appeared 
both numerous and immunopositive for ER (ER isoform not specified) in bladder 
biopsies from patients with interstitial cystitis (IC). This finding was the first to support 
the hypothesis that oestrogen could have direct receptor mediated effects in a MC-
related condition. 
Following this observation, other scientists have evaluated the presence of ER 
positive MCs in other tissues considered to be MC targets. These include nasal polyps 
(Zhao et al., 2001), a condition that often coexists with asthma, and the examination 
of aortic wall, as site of vascular MCs (Nicovani and Rudolph, 2002). Once again, 
MCs were found to be immunopositive for ERs in both of these tissues.  
Once the presence of ER in the nuclei of mature MCs was confirmed, it was 
shown that MCs can respond to oestrogen (E2) and sequentially degranulate and 
release the granule-derived compounds, including cytokines, such as TNFa and IL-6 
(Theoharides et al., 1993, Kim et al., 2001). The activating action of oestrogen has also 
been implicated in studies on environmental compounds with oestrogenic activities 
(Narita et al., 2006), which have been implicated in the rise in prevalence and 
morbidity associated with allergic disease, including asthma, in industrial countries 
(Burr et al., 2006). 
The mechanism by which E2 induces MC activation was defined as being 
dependent on ERa not ERb, using bone marrow-derived MCs from ERa knockout 
animals and the HMC-1 line (Narita et al., 2006, Zaitsu et al., 2007, Jensen et al., 
2010). 
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1.4.5 MC progesterone receptor expression 
Fewer studies have investigated the expression of progesterone receptor (PR) in 
MCs. A small percentage of MCs in IC biopsies were reported to be immunopositive 
for PR, which was low when compared to the 100% that were reported to be ER-
positive (Theoharides et al., 1993, Pang et al., 1995, Letourneau et al., 1996), 
suggesting some heterogeneity may exist between MCs in the bladder. Zhao et al. 
(2001), investigated PR expression together with ER expression in MCs in the upper 
airways, reporting MCs were immunopositive for both. Studies employing HMC-1 
cells have also demonstrated the nuclear expression of PR (Letourneau et al., 1996, 
Jensen et al., 2010).  
Interestingly, there is contradictory evidence on the impact of progesterone on 
MC activation. Anti-inflammatory effects were illustrated by Vasiadi et al. (2006), 
where progesterone was shown to inhibit histamine release after MC stimulation with 
substance P and c48/80, both MC secretogue compounds. In contrast, pro-
inflammatory effects were demonstrated by Jensen et al. (2010), in combination with 
oestradiol. 
1.5 Endometriosis: an incurable gynaecological 
condition 
Endometriosis is a benign, oestrogen-dependent, chronic gynaecological 
disorder associated with pelvic pain and infertility (Giudice and Kao, 2004). It is 
defined as the presence of endometrial tissue outside (ectopic lesion) of the normal 
uterine location (eutopic endometrium). The majority of lesions are found on the pelvic 
peritoneum, but also may be detected on the ovaries (endometriomas) and in the 
rectovaginal septum and in the pouch of Douglas (as illustrated in Figure 1-19). 
Classification of endometriosis is based on criterion established by the American 
Society for Reproductive Medicine (ASRM) ranging from mild endometriosis (grade 
I) to severe (IV) (Canis et al., 1997).  
The prevalence of pelvic endometriosis is estimated to be approximately 6–10% 
of the total population of women of reproductive age (Eskenazi and Warner, 1997). In 
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women suffering from pain, infertility, or both, the frequency of endometriosis is up 
to 35–50% (Cramer and Missmer, 2002, Janssen et al., 2013).  
The most widely accepted theory explaining the establishment of endometriotic 
lesions was proposed by Sampson (1927) as the theory of “retrograde menstruation”. 
He proposed that the shed endometrium which is fluxed back via the Fallopian tubes 
into the peritoneal cavity during menstruation becomes implanted in extra uterine sites. 
Other theories also exist and a full understanding of the aetiology and pathogenesis 
remains uncertain (Young et al., 2013). 
Endometriosis is frequently under-diagnosed and menstruation occurs as 
retrograde in up to 90% of healthy women (Halme et al., 1984) and this, together with 
its complex presentation is believed to account the average of 6.7 years from the onset 
of symptoms before a definitive diagnosis following surgical investigation. 
Endometriosis is a debilitating condition which can dramatically affect the patient’s 
quality of life (Oehmke et al., 2009, Facchin et al., 2015). It is further considered to 
have a significant societal impact; a European multi-centre study has estimated that 
the direct cost per endometriosis patient is up to 3113€ per annum, similar to other 
chronic diseases such as diabetes (2858€/year) (Simoens et al., 2012). In addition, the 
indirect costs of endometriosis-associated symptoms on loss of productivity are twice 
Figure 1-19 Representation of possible sites of endometriotic lesions and their morphology during 
laparoscopic investigation. 
A) The most common endometriotic lesion sites are on the pelvic peritoneum (bottom left), in the 
pouch of Douglas and on the ovaries, image retrieved from the Institute for Quality and Efficiency 
in Healthcare (IQWiG) B-A) Endometriotic lesion (red type), adhesions, and hyperemia in the 
peritoneum. B-B) Two types of peritoneal lesions, including red and blue–black lesions and 
adhesions. B-C) General adhesions distorting the normal pelvic anatomy. B-D) Ovarian 
endometriotic lesion (endometrioma), (Giudice, 2010). 
A) B) 
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as large as the direct health care costs mentioned above, being comparable with those 
associated with rheumatoid arthritis. 
No definite cure exists for endometriosis, and the current treatment options 
include either the surgical removal of endometriotic lesions by laparoscopy, and 
medical therapies that aim to the relieve pain and ameliorate infertility, or both, 
detailed in section 1.5.5 (Giudice and Kao, 2004).  
1.5.1 Evidence that lesions have an altered hormonal 
environment 
Steroid hormones may have an effect on the proliferation of endometrial cells, 
their capacity to attach onto the peritoneal mesothelium and their evasion of immune 
mediated clearance. The  hypothesis that endometriosis is an oestrogen dependent 
condition has supported by a number of studies (Kitawaki et al., 2002). The striking 
finding in endometriotic lesions compared to the eutopic endometrium is the elevated 
expression of the aromatase enzyme and reduced expression of 17β-hydroxysteroid 
dehydrogenase (17β-HSD) type 2 (Zeitoun et al., 1998, Zeitoun and Bulun, 1999). The 
consequence of this enzymatic disparity is an increase in the local bioavailability of 
E2. The available E2 may also stimulate the production of eicosanoids within the 
lesions including prostaglandin E2 that can further stimulate aromatase enzyme 
activity (Noble et al., 1997). These pioneering findings have been recently 
complemented by use of chromatography mass spectrometry and evaluation of mRNA 
concentrations highlighting the importance of local “intracrine” metabolism of 
oestrogens in detecting the steroid environment of the lesions (Huhtinen et al., 2012). 
Furthermore, studies have highlighted that oestrogen may influence mature MC 
behaviour for example E2 induces recruitment/movement and triggers degranulation 
in vitro (Jensen et al., 2010). Therefore, locally produced E2 in endometriotic lesions 
may act as an enhancer of MC activities in the peritoneal cavity of women suffering 
from endometriosis, contributing to aberrant inflammatory processes. 
There is also evidence that “progesterone resistance” is also important in the 
pathophysiology of endometriosis (Bulun et al., 2006). For example, endometriotic 
lesions display a significant reduction in progesterone receptor (PR) expression 
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compared to the eutopic endometrium, and a complete ablation of the isoform B of PR 
(Attia et al., 2000). Furthermore, the gene profiling of the eutopic endometrium has 
revealed a dysregulation of progesterone responsive genes during the luteal phase 
(Burney et al., 2007) of women with endometriosis. An imperfect proliferation to 
secretory phase transition of the endometrium may result into molecular implications 
that might support the survival and implantation of shed endometrium but this requires 
further investigation.  
1.5.2 Peritoneal endometriosis 
1.5.2.1 Physiology of the peritoneum 
The human peritoneum is the largest serous membrane with the body 
(approximately 1.8 m2) (Michailova, 2006). It consists of a layer of loose connective 
tissue covered by the mesothelium over the basal lamina (Figure 1-20). The 
mesothelium is an epithelial-like monolayer that covers the surface of the peritoneal 
membrane. The mesothelium protects organs from movement friction and a small 
volume of peritoneal fluid is present to further enhance this frictionless environment 
(Blackburn and Stanton, 2014). 
The mesothelial cells are responsible for the physiological homeostasis of the 
peritoneal cavity. The peritoneum, sometimes referred to as the peritoneal 
“membrane”, is also important for the transport of solutes and fluids to blood vessels, 
and participates in host defence. The tight junctions between the mesothelial cells 
Figure 1-20 Histological appearance of the human peritoneum and schematic structure of peritoneal 
cellular compartments.  
(Young et al., 2013) 
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control the transport of ions, water and other solutes ensuring the unique 
microenvironment of the peritoneal fluid is maintained.  
The peritoneal membrane can also contribute to host defence by secreting 
inflammatory cytokines which subsequently recruit immune cells such as neutrophils 
and macrophages (Jonjic et al., 1992, Lanfrancone et al., 1992). In the sub-mesothelial 
layer within the collagen mesh, there are networks of capillaries surrounded by a 
variety of cell types including fibroblasts, macrophages and mast cells, which can also 
interact with the underlying adipose tissue in a paracrine manner (Shimotsuma et al., 
1993, Michailova, 2006). The peritoneum includes afferent nerves, many of which 
appear to be of the sensory type (Bentley et al., 1981, Tanaka et al., 2002).  
1.5.2.2 Peritoneal fluid 
The peritoneal fluid derives from plasma transudate and ovarian exudate in 
women (Koninckx et al., 1980) and its volume varies throughout the menstrual cycle, 
typically being between 5 and 20 ml with the largest volume during the secretory phase 
(Oral et al., 1996a). In women peritoneal fluid is considered to be a sex steroid 
reservoir (Kim-Bjorklund et al., 1991, D'Hooghe et al., 1995). The fluid contains a 
variety of immune cell types including natural killer cells (NKs), macrophages and 
mast cells (Hill et al., 1988, Weil et al., 1997, Xu et al., 2002). The physiological 
characteristics and any pathological changes in the peritoneal fluid are important 
contributors to the health and/or disease of the peritoneum (Young et al., 2013).  
1.5.2.3 Lesion formation and cell invasion 
Although, endometriosis is considered a benign disorder, the processes of 
attachment and invasion of the endometrial cells shares some features with those of 
malignant cells.  
Once attached, ectopic endometrial cells must invade the peritoneal layer to 
form endometriotic lesions which are sustained by development of a blood supply. It 
is not clear yet whether the ectopic endometrium requires the mesothelium to be 
damaged in order to establish a lesion or if it can adhere directly to an intact 
mesothelial cell layer (Young et al., 2013).  
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Notably, studies using endometrial and peritoneal biopsies from patients with 
and without endometriosis revealed there was an increase in the invasiveness of the 
endometrial stromal cells in the endometriosis group (Shi et al., 2011). This 
endometrial cell invasion may be facilitated by MMPs, which are able to digest and 
remodel the ECM. MMPs are present in the normal functional endometrium at the time 
of menses and it has been shown that they are expressed in endometriotic lesions and 
also in the peritoneal fluid (Gilabert-Estelles et al., 2007, Itoh et al., 2012, Chen et al., 
2013). Studies using primary mesothelial cells from women with endometriosis have 
shown that they have an altered metabolic profile (Young et al., 2014), which may also 
encourage formation of lesions. The role of the mesothelium in establishment of 
lesions is an active area of research with a number of studies identifying altered 
expression of regulatory molecules including TGF-β (Young et al., 2015, Young et al., 
2016). 
1.5.3 Endometriosis associated inflammation 
Endometriosis is considered to be a neuroinflammatory disorder and cells of 
the immune system are believed to play an important role in the pathogenesis of the 
disorder (Lebovic et al., 2001) with inadequate immune cell surveillance within the 
peritoneum proposed as a factor in its aetiology. For example, peritoneal NKs from 
women suffering from endometriosis show a reduced cytotoxicity when compared 
with those from healthy controls which may allow ectopic endometrial cells to avoid 
detection (Oosterlynck et al., 1991, Quaranta et al., 2006). These findings complement 
those showing that a decrease in peritoneal NK cytotoxicity was correlated with a more 
severe endometriosis stage (Funamizu et al., 2014). 
Macrophages are the most abundant immune cell type in the peritoneal fluid 
and many studies have investigated whether they may play a role in the pathogenesis 
of endometriosis (Ho et al., 1997, Bacci et al., 2009, Capobianco and Rovere-Querini, 
2013). Peritoneal macrophages have been recorded as more numerous in 
endometriosis patients, and they appear to be activated (Oral et al., 1996a, Tran et al., 
2009). High concentrations of macrophages are also reported to be associated with the 
endometriotic lesions themselves, especially with the highly inflamed “red” 
endometriotic lesions (Zeller et al., 1987, Khan et al., 2004). These findings were also 
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recapitulated in a mouse model of endometriosis using transgenic mice in which cells 
of the monocytes lineage were labelled with GFP. GFP positive cells were readily 
detected in the induced endometriotic lesions and shown to be derived from 
endometrium or peritoneum (Greaves et al., 2014b).  
Increasing evidence has also supported the possible role of mast cells (MCs) in 
the altered inflammatory environment of endometriosis. High numbers of 
degranulating MCs have been observed in association with endometriotic lesions 
(Matsuzaki et al., 1998b, Sugamata et al., 2005). Furthermore, stem cell factor (SCF), 
which is important for MC number, has been reported to be elevated in the peritoneal 
fluid of endometriosis patients (Osuga et al., 2000). 
An increase in the number of immune cells might lead to sustained 
inflammation with an increasing production of inflammatory cytokines that would not 
only affect the endometriotic lesions but also the surrounding area. Indeed, the 
peritoneal fluid from women affected by endometriosis showed elevated 
concentrations of cytokines, growth and angiogenic factors, (Gazvani and Templeton, 
2002), which may be produced directly by the lesions, or released by immune cells. 
After endometriotic lesions become established they are thought to secrete pro-
inflammatory molecules into the peritoneal environment. It has been proposed that 
cytokines including IL-1, IL-8, TNFa and interferon g present in the peritoneal fluid 
may act as chemotactic agents to increase the recruitment of macrophages and T 
lymphocytes to the peritoneum (Giudice and Kao, 2004) but further studies are 
required to confirm this.  
It has been hypothesised that endometriosis shares features with autoimmune 
disorders, with reports of an increase in polyclonal B-cell activity, alterations in the 
function and number of B and T cells, and evidence of familial inheritance (Badawy 
et al., 1987, Lebovic et al., 2001, Nothnick, 2001). Additionally, high concentrations 
of IgG, IgA, and IgM autoantibodies have been revealed in serum and peritoneal fluid 
from patients with endometriosis (Badawy et al., 1987, Gleicher et al., 1987). Studies 
in patients have also revealed that there is a tendency for autoimmune diseases such as 
lupus erythematous, rheumatoid arthritis; and atopic conditions like asthma and 
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eczema to overrepresented in women with endometriosis (Sinaii et al., 2002, Caserta 
et al., 2016). Translation of these findings for patient benefit is awaited. 
1.5.4 Endometriosis-associated pain and neuro-inflammation 
Many of the most distressing symptoms among women suffering from 
endometriosis are pain-related, and these include dysmenorrhea (pain at menstruation), 
dyspareunia (pain during sexual intercourse) and chronic pelvic pain (CPP) 
(Kobayashi et al., 2014). Pain is often more severe during and before menstruation 
with a recent review proposing the shed menstrual tissue and the lesions themselves as 
the “trigger” for inflammatory pain in endometriosis (Laux-Biehlmann et al., 2015). 
It has been postulated that endometriosis-associated CPP may be generated 
through a number of different pathways including one suggestion that endometriotic 
lesion establishment could provoke a compression or infiltration of nerves (Anaf et al., 
2000). Alternatively it has been postulated that increasing concentrations of nerve 
growth factor (NGF), together with other neuro-inflammatory molecules such as 
TNFa, found in the endometriotic lesion and surrounding tissue area results in 
hyperalgesia. Finally, the altered inflammatory microenvironment may also promote 
increased “neural sprouting” stimulating the growth of new neuronal afferents within 
the lesion and additional interaction with nervous system (Arnold et al., 2012). The 
cocktail of neuro-inflammatory mediators found in the lesions and peritoneum of 
women with endometriosis may also exacerbate the CPP (Cheng and Ji, 2008).  
The nerve fibres detected in endometriotic lesions are a mixture of Ad and C 
sensory, cholinergic and adrenergic nerve fibres which have often been found to 
colocalize (Tokushige et al., 2006). Interestingly, both mature nerve endings and 
newly grown nerve fibres have been detected in endometriotic lesions, with the latter 
being associated with immature blood vessels (Tulandi et al., 2001). This close 
association between nerves and blood vessels has led to the proposal that 
neuroangionesis should be considered both important to the aetiology of the disorder 
and also a therapeutic target (Asante and Taylor, 2011). 
There is also cumulative evidence that these new sensory fibres innervating 
endometriotic implants release pro-inflammatory compounds which in turn support 
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the heightened inflammatory state in the lesion. Conversely, nerve fibres themselves 
may become sensitized through the pro-inflammatory environment (Stratton and 
Berkley, 2011).  
The secretion of potent neuroactive molecules by the endometriotic lesions or 
nerves may also promote a pro-inflammatory environment by recruiting immune cells, 
such macrophages, and by activating tissue resident leukocytes, such as MCs 
(Horigome et al., 1994). It is notable that MCs have been reported in close association 
with nerves in both peritoneal endometriosis (Kempuraj et al., 2004) and deep 
infiltrating endometriosis (Anaf et al., 2006) (recto-vaginal infiltrative lesions that 
affect vital structures such as bowel, ureters, and bladder (Vercellini et al., 2004)). 
These findings have led to the suggestion that MCs play a role in pain perception in 
women affected by endometriosis (Kirchhoff et al., 2012). 
1.5.5 Current treatments for endometriosis 
Three types of treatment have been used to alleviate pain and regress the lesions 
in women with endometriosis: non-steroidal anti-inflammatory drugs (NSAID) and 
other analgesics, hormonal agents, and the surgical removal of the endometriotic 
lesions. The choice of treatment may depend on the severity of the disease (Brown et 
al., 2014).  
Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently used to relieve 
dysmenorrhea (pain at menstruation). One randomized, controlled trial presented no 
significant reduction in endometriosis-associated pain with the use of NSAIDs as 
compared with placebo, and furthermore no difference between different NSAID 
drugs (Allen et al., 2005).  
Hormonal therapy aims to suppress ovarian function thereby reducing 
circulating oestrogens and is employed to reduce proliferation/growth of lesions and 
associated pain. Hormonal therapy includes progestins, androgens, GnRH agonists, 
and contraceptive steroids (combination of oestrogens and progestins) (Vercellini et 
al., 1997, Practice Committee of American Society for Reproductive Medicine, 2008, 
Abou-Setta et al., 2013). 
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Surgical approaches to relieve endometriosis-related pain are often used as first-
line therapy or initiated after failed medical therapies (Duffy et al., 2014). Surgical 
procedures include excision, laser fulguration, or laser ablation of endometriotic 
implants on the peritoneum (Giudice, 2010). 
While most patients have improvement in symptoms with medical or 
conservative surgical interventions, >50% will experience recurrence of pain after 
medical treatment is discontinued and within 5 years after surgery (Falcone and 
Lebovic, 2011). Moreover, long-term efficacy of medical treatment, both analgesic 
and hormonal, is frequently limited by cost and adverse side effects (Lindsay et al., 
2015). Therefore, the development of new treatment options that may overcome these 
obstacles remains a lay focus of the academic and pharmaceutical communities 
(Rogers et al., 2016).  
1.6 General conclusions and aims of the study 
The human endometrium, located in the centre of the uterus is a dynamic tissue, 
which cyclically experiences extensive tissue remodelling driven by the fluctuations 
in ovarian-derived hormones, most notably oestrogens and progesterone originating 
by the follicles and corpus luteum respectively. The endometrium is a multi-cellular 
tissue, which comprises of stromal and epithelial compartments and is usually 
classified into functional and basal regions with the former shed at the time of menses. 
The endometrial stroma is predominately formed by fibroblasts, a well-developed 
vasculature and hosts a diverse leukocyte population.  
MCs are long-lived tissue resident immune cells characterised by the presence 
of granules containing proteases. Their phenotype is determined by the surrounding 
tissue environment, and in humans they are generally classified as being MCT or MCTC 
subtypes, depending on their expression of the MC specific proteases, tryptase and 
chymase. Mast cells have been detected in the human uterus, both in the myometrium 
and in the endometrium, but little is known about their regulation or the impact of 
steroids on their differentiation status in this organ. Studies on non-reproductive 
tissues have reported an impact of sex steroid hormones on MC behaviour.  
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Recently MCs have been associated with the physiology and pathology of 
different pain pathways but their role in endometrial pathologies has not been 
investigated. Endometriosis is an oestrogen-dependent, neuroinflammatory, incurable, 
gynaecological disorder characterized by the presence of endometrial tissue outside 
the uterine cavity, mainly on the pelvic peritoneum.  
Women affected by endometriosis can experience debilitating symptoms, 
including chronic pain. Endometriosis symptoms are thought to be the result of an 
excessive inflammatory environment within the pelvis. Aberrant inflammation is not 
only present in the endometriotic lesions but also in the eutopic endometrium of 
patients with endometriosis.  
Although the aetiology of endometriosis is uncertain, reports of close 
proximity between activated MCs and sensory nerves in endometriotic lesions, has 
suggested the MCs may contribute to endometriosis-related chronic and neuropathic 
pain. 
Since there is evidence of MCs in the human endometrium that can degranulate 
in response to sex steroids the overarching hypothesis  is that MCs could be involved 
in the establishment and maintenance of endometriosis.In the current study had the 
following aims: 
1. To determine the spatial and temporal location of uterine MCs and to explore 
their phenotype including expression of steroid receptors, 
2. To investigate the presence and activation status of MCs in women with 
endometriosis and/or pain,  
3. To explore the use of primary cells, well-established cell lines, and mice as 
models to study the impact of sex steroids on MC phenotype and influence of 
their behaviours. 
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Chapter 2 Materials and Methods 
2.1 Human tissues biopsies 
 Tissue collection  
Human tissue was obtained from women undergoing surgery for non-
malignant gynaecological conditions or sterilisation procedures. All patients were 
within the 25-50 year age range, had regular menstrual cycles, between 25-35 days, 
and had not taken exogenous hormones within three months prior to surgery.  
Local ethical committee approval was granted and written informed patient 
consent was obtained prior to tissue collection. Ethical approvals were held by 
Professor H.O.D. Critchley (Number LREC 10/S1402/59 and 16/ES/0007) and 
Professor A.W. Horne (Number 11/AL/0376). 
Blood samples obtained at the time of surgery were used to evaluated 
peripheral sex steroid hormone levels by Dr Forbes Howie (Specialist Assay Service, 
Surf Facility, University of Edinburgh). Endometrial cycle stage was confirmed by 
examination of tissue sections by an expert pathologist, Professor A.R.W. Williams 
(NHS, Royal Infirmary, Edinburgh). 
 Tissue processing 
Tissue samples were either placed into 4% neutral buffered formalin (NBF) for 
future tissue processing and paraffin embedding (Section 2.5.1) or into RNAlater 
(Ambion, ThermoScientific, Paisley, UK) for subsequent RNA extraction (Section 
2.2.1).  
2.2 RNA extraction 
RNA extraction was performed using the RNeasy mini kit (Qiagen, UK) for 
tissue samples and cell lines and the PureLink RNA Micro kit for RNA isolation from 
primary cell culture (Section 0, Invitrogen, UK). After tissue lysis, samples were 
homogenized and centrifuged. Total messenger RNA (mRNA) was eluted in RNA-
free water following the manufacturer’s protocol. mRNA enrichment was ensured by 
appropriate tRNA and rRNA size exclusion during this extraction protocol. 
Every RNA extraction was carried out in RNA free conditions using RNase zap 
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(ThermoFisher Scientific, UK), sterile, filtered tips and dedicated pipettes were used 
to reduce contamination and avoid RNA degradation. 
 RNA extraction from human tissue biopsies 
RNA was obtained from frozen biopsies immersed in RNAlater® (Ambion, 
Life Technologies, UK). Tissue biopsies were weighed and 20mg of tissue were cut 
into smaller pieces with sterile scalpels, to avoid saturating the RNeasy columns. 
Selected tissue pieces were minced and 1ml of TriReagent (Sigma-Aldrich, UK) was 
added in a 2ml Eppendorf tube containing a stainless steel bead (5mm, Qiagen, UK) 
to ensure efficient tissue lysis. Samples were lysed using a TissueLyser (Qiagen, UK) 
at a frequency of 25Hz for 2x3 minutes, followed by a 5-minute incubation at room 
temperature (RT), centrifugation for 15 minutes at 14,000g at 4°C for removal of tissue 
debris. The lysate was transferred into a pre-centrifuged 2ml PhaseLock “Heavy Gel” 
tube (5Prime, UK) with 200µl of chloroform (Sigma Aldrich, UK), forming 2 phases: 
aqueous and phenolic phase. The two phases were mixed thoroughly for 15 seconds 
and incubated for 5 minutes at RT, ensuring formation of an emulsion and subsequent 
RNA/protein separation. The mixture was centrifuged at 14,000g for 15 minutes at 
4°C to complete the RNA/protein separation. The RNA containing phase (aqueous 
fraction) was then pipetted off into a new tube.  
Samples were desalted and concentrated by adding 550µl of 70% ethanol, 
before column extraction. Phenolic phase locked under the gel of 2ml “PhaseLock” 
Heavy Gel tube, was discarded into special chloroform-containing waste. The 
aqueous/alcohol mixture was carefully transferred onto an RNeasy spin column and 
the tube was centrifuged and washed according to the manufacturer’s instructions 
(details protocols provided in the RNeasy mini kit). An intermediate DNA digestion 
was carried out using a DNAase kit to reverse DNA (Qiagen, UK). The total RNA was 
eluted in 30µl of RNA-free water and stored at -80°C until further use. 
 RNA quantification and quality assessment  
Total RNA concentration and quality were measured by absorbance of eluted 
RNA, using a Nanodropâ ND-1000 spectrophotometer (Nanodrop Technologies, 
ThermoFisher Scientific, UK). Concentration and purity of RNA was established by 
measurement of absorbance at 260/280nm and 260/230nm. All RNA samples were 
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standardised to 100ng/µl, the RNA concentration required for reverse transcription as 
optimal in our laboratory. 
2.3 Reverse transcription: complementary DNA 
synthesis 
Synthesis of complementary DNA (cDNA) from RNA samples was performed 
using the Superscriptâ VILOä synthesis kit (Invitrogen, Paisley, UK). The reaction 
was made to a final 1x VILO reaction mix with a total volume of 20µl, containing: 
primers, deoxynucleotide nucleoside triphosphates (dNTPs), MgCl2 and ribonuclease 
inhibitors, 0.125x Superscript Enzyme Mix (reverse transcriptase enzyme) and 100ng 
RNA (Table 2-1). Samples were incubated at 25°C for 10 minutes (primer annealing 
phase), 42°C for 60 minutes (primer extension phase) and 85°C for 5 minutes 
(inactivation of reverse transcription phase) in a thermal cycler (MJ Research PTC 200 
Thermal Cycler, BC-MJPC200, USA).  
Before undertaking PCR analysis a cDNA standard curve was created to 
determine primer efficiency; standards were created using a 10-fold serial dilution 
from pooled concentrated RNAs. Controls included a human positive control (Applied 
Biosystems, UK) and 2 technical negative controls. A “NO RT” control, where the 
reverse transcriptase enzyme was omitted and replaced by 0.25µl of RNA free water, 
for identifying possible DNA contamination. A second “NEGATIVE” control, where 
the RNA was omitted and instead replaced by 1µl of RNA free water, allowing 
detection of contamination of reagents and/or primer dimer formation during PCR 
reactions. A “POSITIVE” control was also included, using a RNA sample that was 
known to contain cDNA encoding the gene of interest. 
Reagent Final concentration Volume 
5x VILO Reaction mix 1x 4µl 
10x Superscript Enzyme Mix 0.125x 0.25µl 
RNA (100ng/ml) 100ng 1µl 
RNA free H2O  14.75µl 
Total Volume  20µl 
Table 2-1 Protocol used for a single reaction for Reverse Transcription 
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2.4 Quantitative Real-Time (Taqmanâ PCR) 
For this study the Taqmanâ Real-Time PCR technique was used. This method 
relies on the ability of Taq polymerase to cleave fluorescently labelled probes bound 
on a template cDNA sequence. In brief, Taqmanâ probes are oligonucleotides 
containing a fluorophore at one end and a quencher at the other end, the latter 
suppresses the fluorophore’s fluorescence as long the quencher and fluorophore are in 
close proximity to each other (Figure 2-1-A). Following binding of the forward primer, 
elongation by Taq polymerase (polymerisation step, Figure 2-1-B) the polymerase 
reaches the binding site of the labelled probe, the 5’-3’ exonuclease enzyme activity 
of Taq cleaves the probe from the DNA template Figure 2-1-C). Removing from the 
proximity of the quencher molecule resulting in fluorescent detection by the PCR 
machine (Figure 2-1-D). As each cycle results in release of fluorophore, the amount of 
fluorescence is proportional to the amount of cDNA in the initial reaction mix.  
 Universal Probe Library (UPLä) and Taqmanâ 
Mastermix 
The Universal Probe Library (UPLä, Roche, UK) contains 165 short 
hydrolysis probes labelled with FAM tag (6-carboxyfluorescein) on their 5’-end and 
with a dark quencher on their 3’-end. These probes consist of 8-9 nucleotides chosen 
because their sequences are present in the transcriptome of several species. The UPLä 
Figure 2-1 Taqman probe mechanism 
during quantitative PCR. 
Single step described in Section 2.4. Image 
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probes have locked nucleic acids (LNAs), which have a protected ribose ring with a 
methylene bridge with the 2’-O atom connected to the 4’-C atom. LNAs are able to 
bind to their target sequences regardless of their short size, because they contain the 
common nucleobases (T, C, G, A, U and mC) that RNA and DNA contain. 
In this study, primers were specifically designed by using the “Universal 
ProbeLibray Assay Design Center” (Table 2.2), and were purchased from Eurofins 
Genomics, Billingham, UK).  
Gene name Forward primer Reverse primer UPL probe number 
Homo Sapiens tryptase 
alpha/beta (TPSAB1) cctgcctcagagaccttcc acctgcttcagaggaaatgg 20 
Homo Sapiens chymase 1 
(CMA1, set 1) ttcacccgaatctcccatta tcaggatccaggattaatttgc 81 
Homo Sapiens chymase 1 
(CMA1, set 2) acggaactttgtgctgacg ggctccaagggtgactgtta 4 
Human Sapiens proteinase-
activated receptor-2 (PAR-2) gagccatgtctatgccctgt cgatgcagctgttaagggtag 13 
Homo Sapiens Histamine 
receptor H1 (HR1) agaatcagacctgggtggaa aatgagtctgaggctcccatag 68 
Homo Sapiens Nuclear 
receptor subfamily 3, group 
C, member 1: glucocorticoid 
receptor (GR or NR3C1) 
tccctggtcgaacagttttt gctggatggaggagagctta 45 
Human Sapiens 
Prostaglandin E receptor 2 
(subtype EP2, PTGER2) 
tggctatcatgaccatcacc gtttcattcatatatgcaaaaatcgt 68 
Homo Sapiens Oestrogen 
Receptor 1 (ESR1 or ERa) aaccagtgcaccattgataaaa cctcttcggtcttttcgtatc 69 
Human Sapiens Oestrogen 
Receptor 2 (ESR2 or ERb) 
gctcctgtcccacgtcag tgggcattcagcatctcc 62 
Table 2-2 Table of oligonucleotide sequences and UPL probes used in RT-PCR analysis. 
Reactions contained the qPCR Supermix with Premixed ROX kit (Invitrogen, 
UK). Taqmanâ mastermix (Table 2-3) and was plated in a 96-well MicroAmp Fast 
Optical reaction plate (Applied Biosystem, UK) with 14µl final volume in each well. 
Thereafter 1µl cDNA from the standard curve, controls and samples were added in 
duplicate to the individual wells. The qPCR reaction was carried out using Applied 
Biosystems 7900HT Fast real-time PCR system machine (Applied Biosystems, UK), 
with the following programme: 95°C for 10 minutes, 40 cycles at 95°C for 15 seconds, 
60°C for 1 minute.  
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Reagent Company Final Concentration Volume 
Express Supermix (2x) Invitrogen 1x 7.5µl 
Forward Primer (20µM) Eurofins 200nM 0.15µl 
Reverse Primer (20µM) Eurofins 200nM 0.15µl 
Probe (10µM) Roche 100nM 0.15µl 
GAPDH or CYC (primers-probe 
mix, 20x) 
ThermoFisher 
Scientific 1x 0.75µl 
cDNA ---  1µl 
RNA free H2O Qiagen  
5.75µl for GOI 
6.05µl for 
GAPDH or CYC 
Total Volume   15µl 
Table 2-3 Real-time PCR Taqman reaction mix.  
 
 qRT-PCR analysis 
Amplification graphs were plotted using the detection of fluorescence and the 
cycle threshold (Ct) value, which was defined as the amplification cycle where the 
signal of detection was higher than the background noise levels. Notably Ct values are 
inversely proportional to the amount of targeted nucleic acid in the sample; a change 
of 1-fold in Ct values corresponds to a 2-fold change in the initial cDNA concentration 
and therefore gives indication of gene expression at mRNA level. 
2.4.2.1 Primer amplification efficiency 
In an ideal PCR amplification reaction duplication of the amount of RNA 
occurs every cycle, but contamination and a sub-optimal primer design can also 
interfere with the efficiency of the PCR reaction. Together with the R2 value for the 
standard curve, efficiency (E) of all the primer sets was calculated by the formula E = 
(10(-1/slope)-1) x100 10-fold dilutions. E is expressed in percentage value, and in this 
study, DDCt analysis was performed only for primer sets with an efficiency range of 
95-105%. Otherwise, relative standard curve method of analysis was used.  
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2.4.2.2 Relative standard curve analysis 
The relative standard curve (rSC, Figure 2-2) method determines the quantity 
of cDNA in each experimental sample using a standard curve equation and then 
comparing it to a calibrator sample. The standard curve is employed to deduce relative 
expression information for mRNA encoded by gene(s) of interest in samples. The 
values (x) of the standard curve are expressed a log10 of the mRNA concentration, then 
expressed to the power of 10 (10x). The obtained values are normalized to the 
endogenous controls, such as GAPDH or CYC (ThermoFisher Scientific, UK). These 
absolute results are then converted into relative values expressed as ratio of sample x 
to the selected control sample.  
2.4.2.3 Statistical analysis 
Statistical analysis was accomplished using GraphPad Prism 6.0 (GraphPad 
Software Inc., USA), using statistical tests as described in corresponding result 
chapters.  
 Separation of DNA in polyacrylamide gels  
Electrophoresis with polyacrylamide gels is one of the most widely used tools 
in molecular biology. This technique is suitable for the separation of small pieces of 
DNA (from 1-1000 base pairs) because of the smaller pore size in a polyacrylamide 
matrix compared to those made of agarose. Double stranded real-time PCR products 
were run on Tri-borate-EDTA (TBE) gels (Novex pre-cast gel cassettes composition 
in Table 2-4, LifeTechnology, ThermoFisher, UK) in native (non-denaturing) 
conditions, using 1x TBE running buffer in a XCell SureLock™ Mini-Cell 
Figure 2-2 Example of standard 
curves and primer sets efficiency 
calculation.  
The Ct value of each standard is 
graphed against the log10 of mRNA 
concentration both CYC 
(endogenous control) and gene of 
interest (GOI). The line formula is 
used for relative standard curve 
method analysis as explained in 
2.4.2.2. 
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(ThermoFisher Scientific, UK). DNA samples and ladder were prepared with Novex® 
Hi-Density TBE sample buffer (5x, Novex, Life UK) as described in Table 2-4. 
Reagent Volume 
DNA sample 15 µl 
Novex® Hi-Density TBE sample buffer (5x) 4 µl 
Deionized water 1 µl 
Total volume 20 µl 
100bp DNA ladder (Invitrogen, Paisley, UK) 1µl 
Novex® Hi-Density TBE sample buffer (5x) 2 µl 
Deionized water 7 µl 
Total volume 10 µl 
Table 2-4 DNA samples and ladder preparation mix before electrophoresis. 
 
Samples and a molecular size ladder (100bp DNA ladder, Invitrogen, Paisley, 
UK) were loaded onto the gel and the tank was filled with 200ml of 1x TBE buffer in 
the upper buffer chamber and 600ml in the lower buffer chamber. Gels were 
electrophoresed at 200V for 60 minutes with an expected current of between 10-18mA 
at the start and 4-6mA at the end of the run.  
Once electrophoresis was complete, TBE gels were stained with 1x Sybr® Safe 
DNA gel stain for 30 minutes on a rotating platform (1:10000 dilution in 1x TBE 
running buffer; ThermoFisher Scientific, UK) before visualising the DNA band using 
a UV-transluminator (U:Genius, Syngene, UK).  
2.5 Immunohistochemistry 
Immunohistochemistry is a scientific method that visualises proteins in cells or 
tissue sections by employing an antibody that has specificity for specific antigenic 
epitopes within the target proteins.  
 Tissue fixation and processing  
Due to the use of tissue from different species and diverse detection methods 
in this study, two main fixatives were used;  human samples used for 
immunofluorescence staining where fixed in 4% neutral buffered formalin (Sigma 
Aldrich, UK) at 4°C for 16h and mouse samples used for toluidine blue staining 
(Section 5.4.5) were fixed in Carnoys’ fixative (with 60% absolute alcohol – VWR 
Chemicals, UK, plus 30% chloroform and 10% acetic acid – Sigma Aldrich, UK) for 
6h at room temperature (RT). After fixation, tissues were transferred into 70% ethanol 
for storage prior to paraffin embedding (performed by the SURF Histology facility in 
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the MRC Centre for Reproductive Health, the University of Edinburgh). 5µm sections 
were cut using a microtome (Leica Biosystems, RM2135, UK) and flattened in a 37°C 
water bath to allow the paraffin to stretch and remove folds (ThermoFisher Scientific, 
UK). The sections were then mounted on charged glass slides (Leica Biosystem 
Surgipath X-tra Adhesive, pink labelled for human tissues and white labelled for 
animal tissues, UK) and dried at 50oC overnight.  
  Dewaxing and tissue rehydration 
To improve the antibody-antigen interaction within fixed tissue, sections were 
first deparaffinised (or dewaxed) and rehydrated. Dewaxing is accomplished by 
immersing the slides in xylene (VWR Prolabo, UK) for 10 minutes. Rehydration is 
characterized by immersing the slides in solutions of decreasing alcohol concentration 
(2 washes in 100% ethanol for 20 seconds each, then one wash each of 95% ethanol 
for 20 seconds, 70% ethanol for 20 seconds and tap water). 
 Antigen retrieval 
Aldehyde-containing fixatives, such as 4% NBF, result in cross-linking of 
amino acids which may mask epitopes recognised by antigen formations. Therefore 
antigen retrieval was used to unmask the antigenic epitopes of interest (Figure 2-3). 
In this study, heat-induced epitope retrieval (HIER) that relies on both heat and 
high pressure was used. Briefly, after rehydration, the slides were placed in 1x pH 6 
citrate retrieval buffer (1mM citric acid (mono hydrate)) in a decloaking chamber 
(BioCare Medical, Concord, USA). Maximum temperature reached during antigen 
retrieval step was 110°C.  
Fixation Heating 
Figure 2-3 Schematic of heat-induced antigen 
retrieval.  
After heating, methylene bridges produced by 
formalin fixation, are cleaved and the protein 
chains expose their hydrophobic sites. Image 
adapted from Emoto et al. (2005) 
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 Methanol-Peroxidase block 
Slides were blocked with 3% hydrogen peroxide (H2O2; VWR Prolabo, UK) 
in methanol (VWR Prolabo, UK) on the rocking platform (at 3g/min, Heidolph 
Polymax 2040, Germany) for 30 minutes to prevent endogenous tissue peroxidases 
reacting with the chromogen substrate. Slides were then rinsed in tap water and washed 
twice with Tris Buffered Saline (TBS: 0.05M Tris-HCl, pH 7.4, 0.85% NaCl, Sigma 
Aldrich, UK) for 5 minutes. 
 Serum block 
In order to prevent non-specific binding of the secondary antibody to the tissue 
sections, a blocking step with serum from the species that the secondary antibody was 
raised in is required. The serum reduces non-specific binding during the assay because 
it contains antibodies that bind to reactive sites on the tissue. 
In this study, tissue sections were incubated with normal goat serum (NGS) 
buffer containing 20% NGS (Sigma Aldrich, UK) and 0.05% bovine serum albumin 
(BSA; Sigma-Aldrich, UK) in TBS for 30 minutes at room temperature.  
 Avidin-Biotin block 
Chromogenic immunohistochemistry relies on the strong affinity between 
biotin and avidin molecules. To prevent avidin-peroxidase complexes reacting with 
endogenous biotin present in the tissue, instead of binding target protein-biotinylated 
secondary antibody complexes, an avidin-biotin block is required. Slides were blocked 
for 15 minutes with avidin, washed twice with TBS and incubated for 15 minutes with 
biotin (Avidin-Biotin Kit, Vector Laboratories, UK). Slides were again washed twice 
with TBS before adding the primary antibodies. 
 Primary antibody staining 
Primary antibodies were diluted in NGS at optimized concentrations and left 
at 4°C for 16h in a humidity chamber. Appropriate controls were also included, such 
as negative control (primary antibody omission) and positive controls (tissues that 
strongly express the antigen of interest). The list of antibodies and dilutions used is 
shown in Table 2-5.  
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Source Clone Concentration Dilution Secondary 
Antibody 
Use 
Tryptase Rabbit Abcam 
(ab134932) 




Chymase Mouse AbSerotec 
(MCA1930T) 




Tryptase (1) Rabbit Abcam 
(ab134932) 








Chymase Mouse AbSerotec 
(MCA1930T) 


















































Table 2-5 Primary antibodies, secondary antibodies and dilutions used in immunohistochemistry and 
immunofluorescence. 
 
 Secondary antibody incubation  
Slides were washed for 5 minutes in 0.05% Tween in TBS (TBS-Tween, 
Tween: VWR Prolabo, UK) and then twice in TBS only before the secondary antibody 
blocking step. The secondary antibodies selected for immunofluorescence antigen 
detection were streptavidin-HRP for DAB immunohistochemistry or directly 
horseradish peroxidase conjugated (HRP) for immunofluorescence. 
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 Antigen detection methods 
2.5.9.1 DAB immunohistochemistry 
Target antigen detection can be achieved by using 3,3’-diaminobenzidine 
(DAB), a chromogenic method. This method relies on the oxidation of DAB by antigen 
bound-antibody HRP complexes and generates a brown deposit at the site of antibody 
binding (Figure 2-4).  
Streptavidin-HRP conjugated secondary antibodies (Vector Laboratories, UK) 
were diluted at 1:500 in TBS, and incubated on a section for 30 minutes. Slides were 
washed twice in TBS for 5 minutes and the DAB chromogenic substrate was applied 
to the tissue sections following the manufacturer’s instructions. The chromogenic 
reaction was monitored microscopically and then stopped by immersing the slides in 
tap water. The tissues were counterstained for 2 minutes in Harris’ haematoxylin 
(Leica Biosystems, UK), which turns the acidic substances, such as nucleic acids in 
the cell nuclei, blue. Slides were washed with tap water to remove any excess 
haematoxylin, and then immersed in 1% acid alcohol (CellPath, UK) for 20 seconds 
and in Scott’s tap water (CellPath, UK) for 30 seconds. The tissue sections were 
dehydrated using increasing concentrations of ethanol (70%, 80%, 95% and absolute 
ethanol, 20 seconds each) before immersion in xylene (2x 5 minutes immersion steps; 
VWR Collection, UK). The slides were mounted using Pertex (Cell Path, UK) and a 
coverslip (VWR Collection, UK). 
Figure 2-4 Schematic of DAB immunohistochemistry principle.  
HRP-secondary antibody interacts with the DAB substrate and generates a brown precipitate in positive 
cells. Image adapted from the Human Protein Atlas (2016). 
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 Immunofluorescence: tyramide signal amplification 
fluorescence system. 
Immunofluorescence enables the detection of multiple target proteins in the 
same tissue section using a tyramide signal amplification (TSA™) system that allows 
the user to employ up to 1000-fold less concentrated primary antibodies as compared 
to chromogen immunohistochemistry.  
The TSA reagent is a phenolic molecule that once activated by the horseradish 
peroxidase (HRP) (Figure 2-5-A) is transformed into a short-life compound (Figure 
2-5-B). This is exceptionally reactive to free radical intermediates. These intermediate 
molecules can quickly react and bind to electron-rich-regions of proteins. HRP is 
conjugated to the secondary antibody, bound to the primary-target antigen complex 
(Figure 2-5-C).  
The covalent binding between tyramide and an antigen of interest releases 
fluorescence and it can be detected by using confocal microscopy. There are different 
fluorochromes with distinct wavelengths of excitation and emissions and minimal 
spectra overlap, that allows concurrent detection of different antigens. For this study 
fluorescein (green) 494nm/517nm (excitation/emission wavelengths) and cyanine 3 
(red) 550nm/570nm were used. 
Figure 2-5 Tyramide signal amplification by covalent binding with electron-rich regions of protein 
of interest.  
Chemical reaction explained in Section 2.5.10. Image taken from PerkinElmer (2015). 
A) B) C) 
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Following the HRP-secondary antibody incubation, slides were washed in 
TBS-Tween and then TBS for 5 minutes each. The TSA system was used at 1:50 
dilution following the manufacturer’s instructions (TSA™, PerkinElmer, USA). TSA 
incubation was for 10 minutes in the dark, and was followed by two washes with TBS. 
Because TSA is light sensitive, the slides were then kept in the dark during all the 
following steps in the protocol to prevent photo-bleaching of the fluorochromes. 
 Double fluorescence 
During the study, dual antigen detection was performed by 
immunofluorescence. After the first TSA fluorochrome incubation, usually 
fluorescein, tissue sections were incubated in TBS+3% H2O2 if the second primary 
antibody did not require any antigen retrieval, for example chymase antibody. Citrate 
antigen retrieval was performed for other second primary antibodies (PAR-2, ERα, 
ERβ, PR and GR) that required antigen retrieval. 
Slides were washed twice in TBS and blocked with NGS for 30 minutes before 
incubating in the second primary antibody at 4°C for 16h. The subsequent steps in 
double IF protocol are as the aforementioned in Sections 2.5.8 - 2.5.10. The second 
TSA fluorochrome used was Cyanin 3. 
 Fluorescent nuclear counterstain 
4’,6’-diamidino-2-phenylindole (Dapi) was used as nuclear counterstaining on 
tissue sections. Dapi is a fluorescent dye that has high affinity for A-T-rich regions of 
DNA. Dapi is excited by UV light. Its excitation wavelength is 358nm; and it emits at 
461nm in the blue/cyan spectrum. 
Slides were incubated with Dapi (Sigma Aldrich, UK) at 1:500 dilution in 
1xTBS for 10 minutes. Two 5 minute TBS washes were performed before mounting 
the slides with Permafluor™ (ThermoFisher Scientific, UK). 
 Imaging and analysis 
Slides stained with DAB were scanned on an Axioscan Z1 (Zeiss, UK) for 
quantitative analysis with Zen Blue software (Zeiss, Germany). 
A role for mast cells in women’s health and disorders of the endometrium 
Chapter 2 – Materials and methods  69 
Fluorescence slides (tissues and cells) were visualized on a Zeiss 710 confocal 
microscope (Zeiss, UK) and scanned for further full size image analysis, and both Zen 
Black and Zen Blue software were used for analysis.  
2.6 Enzyme-linked Immunosorbent Assay 
Enzyme-linked immunosorbent assays (ELISA) are quantitative immunoassays 
that detect target proteins in biological liquids/fluids. As with immunohistochemistry 
(Section 2.5) and Western blotting (Section 5.3.13), this method relies on the specific 
binding of antibodies to epitopes on target proteins. There are several different types 
of ELISA, but only two have been used in this study. These are: non-competitive two-
site “sandwich” ELISA (Figure 2-6-A) and competitive ELISA (Figure 2-6-B). 
 Non-competitive two-site “sandwich” ELISA 
In the “sandwich” ELISA, the wells of a flat-bottomed 96-well microtiter plate 
are pre-coated with a capture antibody, which binds specifically to epitopes in the 
protein interest (Figure 2-6-A). Samples together with standard curve and blank are 
then added to the plate, and incubated for 1-2 hours. This incubation allows the first 
step of “sandwich” binding, between in the capture antibody and protein of interest 
present in the samples. A detection antibody is then added, which recognises a 
different epitope on the protein of interest. It forms the second part of “sandwich” with 
capture-protein complex. The detection antibody is conjugated with the HRP enzyme, 
or biotinylated, so that by the addition of streptavidin-HRP the amplification of a 
chromogenic change can take place. In these ELISAs the 3,3’-5,5’-
tetramethylbenzidine (TMB) substrate is added to the wells and the chromogenic 
reaction starts by forming a blue product in the presence of the peroxidase enzymes. 
Figure 2-6 Illustration of 
Sandwich (A) and Competitive 
(B) ELISA methodologies.  
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The colour reaction is stopped by addition of an acid (usually, 2N sulphuric acid), it 
changes the TMB from blue into yellow. The optical density of each well is then 
measured using a microplate reader spectrophotometer set to the appropriate 
wavelength. The recorded signal is quantified using a standard curve. The amount of 
the protein of interest is proportional to the optical density of the TMB substrate.  
2.6.1.1 Human tryptase and chymase “sandwich” ELISAs 
In this study, the two-site “sandwich” ELISA was used for detection of human 
tryptase and chymase in peritoneal fluid (PF) from women with/without 
endometriosis. PF were stored at -80°C to preserve protein integrity and thawed 
immediately prior to the assay. Concentrations of tryptase and chymase were 
calculated using the pre-coated ELISA kits: SEB070Hu for tryptase (Cloud-Clone 
Corp., USA) and MBS2021042 for chymase (MyBioSource.com, USA), according to 
the manufacturers’ instructions. Details of the protocol are reported in Section 4.3.9. 
 Competitive ELISA 
Competitive ELISA relies on the principle that an unlabelled protein of interest 
present in the biological samples will compete for binding with enzyme-labelled 
antigen (HRP-conjugated) for a limited number of target antibody binding sites in the 
wells of the assay plate such that the HRP-conjugated antigen will bind to the target 
antibody only where the binding sites are not occupied by unlabelled protein of interest 
(Figure 2-6-B). As unbound reagents are removed by washing the amount of bound 
HRP in competitive ELISA is inversely proportional to the concentration of the levels 
of protein of interest in the sample. Two kits were used for investigating the levels of 
histamine in human peritoneal fluid: ENZ-KIT140 (Enzo Life Sciences, Switzerland) 
and CEA927Ge (Cloud-Clone Corp., USA). Details in Section 4.3.9. 
 ELISA data analysis 
Data analysis was conducted by using GraphPad Prism 6.0 software to generate 
a four-parameter logistic (4-PL) curve fitting, the OD values of samples against the 
standards reads allowing calculation of the “unknown” value versus the “known” 
values of the standards. The data were statistically evaluated with GraphPad Prism 6.0 
as explained in detailed in results Chapters 4 and 5.  
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2.7 Flow cytometry and fluorescence-activated cell 
sorting (FACS) 
Flow cytometry is a technique that simultaneously evaluates multiple physical 
and chemical characteristics of single cells within a heterogeneous cell mixture, as 
they flow in a fluid stream through a beam of light.  
This technology is based on three main systems: fluidics, optics and electronics. 
The first system carries particles to the laser beam for cellular interrogation, the second 
involves of a panel of lasers that illuminate the particles in the sample stream and of 
optical filters to direct the resulting light signals to the appropriate detectors. The third, 
system converts the detected light signals into electronic signals that can then be 
processed by a computer. 
The main features measured include a particle’s relative size, internal 
complexity, relative granularity and relative fluorescence intensity (Neuhoff, 1973). 
Cell size is determined by the forward scatter area (FSC-A), which is a parameter 
roughly proportional to the cell size. The internal complexity, such as nuclear structure 
and the presence of granules is discerned from the side scatter (SSC) (Figure 2-7).  
Another important physical characteristic to consider is the pulse geometry, 
FSC-H (forward scatter height) versus FSC-A (Figure 2-8-C) but this can only be 
included in the analysis signals emitted by single cells. When cell clumps pass through 
the laser intercept (Figure 2-8-A), they take longer time compared to a single cell 
suspension (example 3µs for doublets vs 1µs single cell) and this affects the area of 
the signal as shown in Figure 2-8-B.  
Figure 2-7 Light-scattering characteristics of cells going through the flow cytometer (A), FSC and 
SSC events collected by the detector and converted into a plot by the computer (B). 
Figure 2-7-A adapted from BD Bioscience (2000). 
 
A) B) 
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Relative fluorescence intensity can be used to describe cell populations by 
detection of different spectral emissions of cells going through the lasers following 
prior incubation with fluorescence-conjugated antibodies for the proteins of interests. 
In this study, flow cytometry and FACS were used to identify mast cells and other 
immune cell population isolated from human peritoneal fluids and mouse peritoneal 
lavages. 
A) B) C) Figure 2-8 Differences in signal detection between 
single cells and cell 
aggregated going through a 
flow cytometer.  
Image taken from Excyte 
Expert Cytometry (Excyte 
Expert Cytometry, 2012). 
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 Sample compensation for multi-colour flow panel 
Flow cytometry has continuously advanced over the last years. This has 
included an increasing number of colours that can be detected, up to 18 colours at the 
same time. This has allowed a more precise investigation of many cell types in samples 
with a mixed population and has also expanded the number parameters gathered 
simultaneously for each sample. 
The most critical factor of a multi-coloured flow cytometry experiment is the 
spill over of emission spectra. This is often due to a large variability of intrinsic 
brightness among the fluorochromes frequently used, for example when spectra from 
one dye optically interfering with signals from another (Figure 2-9). 
For examples, BV650 fluorochrome (detected in the blue laser) has an emission 





Figure 2-9 Fluorochromes 
excitation and emission 
spectra and possible spillovers.  
Knowledge of the spectra from 
the different lasers (A, blue; B, 
green/yellow; C, red laser) 
enables the operator to prevent 
possible overlaps between some 
of the antibodies included in the 
detection panel (Table 2-7). 
Some of the fluorochromes 
(BV650, PE, PE/CY7 and APC, 
dot circles) can influence each 
other’s spectra and cause artefact 
the results. For example, BV650 
has a spectrum range of 600-780 
nm (excitation-emission) and it 
can interfere with PE (500-700 
nm) due to their emission 
wavelengths that are very close 
to each other. Image adapted 
from BD Bioscience (2015). 
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Therefore, in a complex multi-parameter flow cytometry is crucial to perform 
both studies using unstained cells controls and compensation with beads. Using beads 
allows to the investigator save experimental cells, which are precious and are in limited 
number. Compensation beads are micro-particles, typically polystyrene, that are pre-
coated with antibodies recognizing species-specific antibody light chains, IgG, κ light 
chain of mouse, rat and/or hamster (Figure 2-10). 
Beads are supplied with individual fluorochrome-conjugated antibodies for use 
as single-colour compensation controls. Each drop of beads contains two populations: 
a negative population that will not react with antibody and a positive population that 
will capture any mouse, rat or hamster antibody. When a fluorochrome-conjugated 
antibody is added to the beads, both positive and negative populations result. 
The fluorescence minus one (FMO) control is another essential control that 
must be used to enable correct interpretation of flow cytometry data. It allows for 
detection and gating of cells in the context of a spread of data by a multiple 
fluorochromes. A FMO control consists in all the fluorochromes minus the one that is 
going to be measured. In this study, the human FMOs performed are shown in Table 
2-6.  
Figure 2-10 Compensation beads: their function and IgGs components used for flow cytometry. 
A) Compensation particle covered with anti-light chain antibody after binding with fluorochrome-
conjugated detection antibody. Image adapted from UWCCC (2015). B) OneComp eBeads, light 
chain IgGs coated on the polystyrene micro-particles. Image adapted from Affymetrix (2016). 
 
A) B) 
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Fluorochrome 
PE PE-CY7 BV650 APC 
Antigen 
FceRIa - c-kit HLADR CD163 
c-kit FceRIa - HLADR CD163 
HLADR FceRIa c-kit - CD163 
CD163 FceRIa c-kit HLADR - 
Table 2-6 FMOs used for flow cytometry analysis in the human study. 
FceRIa: high affinity IgE receptor I a, c-kit: stem cell factor receptor; HLADR: human leukocyte 
antigen – antigen D related; CD163: cluster of differentiation 16.  
 
The FMOs ensured that any spread of the fluorochromes into the channel of 
interest was properly identified before running the cell samples, as illustrated in Figure 
2-9. 
 Sample preparation 
Following isolation of peritoneal fluid (PF) cells from human peritoneal fluids 
(Chapter 4, Section 4.3.3) and from mouse peritoneal lavages (Chapter 5, Section 
5.4.6.1), samples stored -80°C were thawed at 37°C in a water bath, transferred into 
polystyrene flow cytometry tubes (BD Falcon, Oxford, UK) and washed with 3ml of 
filtered FACS buffer (phosphate-buffered saline without calcium and magnesium, 
PBS, ThermoFisher Scientific, Paisley, UK; 2% BSA, Sigma Aldrich, Dorset, UK). 
Samples were centrifuged for 5 minutes at 1000g at 4°C then cells were re-suspended 
in 1ml of FACS buffer and filtered to remove cell clumps, using filter polystyrene 
FACS tubes (BD Falcon, UK). Cell suspensions were counted and viability assessed 
using Countess II (as mentioned in Section 5.3.1).  
 Conjugated antibody staining 
Samples were stained in 100µl of FACS buffer with the panel of anti-human 
antibodies, epitopes, concentrations and fluorochromes as illustrated in Table 2-7, anti-
mouse antibodies are showed in Table 2-8. Single staining beads (eBioscience, 
Altrincham, UK) and FMOs were performed for compensation settings at the same 
time. Cell suspensions were kept in the dark, for 30 minutes (mouse cells) or for 1 hour 
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(human cells) on ice. Following incubation, samples were washed with 3 ml of FACS 





raised Source Clone Fluorochrome Cat. N° Concentration Dilution 
CD45 Mouse Invitrogen HI30 PE-TexasRed MHCD4517 69 µg/ml 1:100 
CD3 Mouse BioLegend OKT3 BV711 317327 40-60 µg/ml 1:50 
CD19 Mouse BioLegend HIB19 BV711 302245 40-50 µg/ml 1:50 
CD56 Mouse BioLegend HCD56 BV711 318335 80-100 µg/ml 1:50 
CD14 Mouse BioLegend M5E2 BV510 301841 150 µg/ml 1:50 
CD11β Mouse BioLegend ICRF44 BV605 301331 200 µg/ml 1:50 
HLADR Mouse BioLegend L243 BV650 307649 100 µg/ml 1:50 
CD163 Mouse BioLegend GHI/61 APC 333610 80-100 µg/ml 1:50 
c-kit Mouse BioLegend AER-37 (CRA-1) PE-Cy7 313211 200-400 µg/ml 1:50 
FcεRIα Mouse BioLegend 104D2 PE 334609 25-100 µg/ml 1:50 






Source Clone Fluorochrome Cat. N° Concentration Dilution 
CD45 Rat BD Horizon 30-F11 BV650 563410 0.2 mg/ml 1:200 
CD3 Armenian 
Hamster 
eBioscience 145-C11 PerCP-Cy5.5 45-0031-80 0.2 mg/ml 1:200 
B220 Rat BioLegend RA3-
6B2 
FITC 103205 0.5 mg/ml 1:100 
CD335 Rat BioLegend 29A1.4 PE-Cy7 137617 0.2 mg/ml 1:200 
CD11β Rat BioLegend M1/70 APC-Cy7 101226 0.2 mg/ml 1:100 





PE-Dazzle 108451 0.2 mg/ml 1:100 
c-kit Rat BD 
Biosciences 
2B8 BV421 562609 0.2 mg/ml 1:200 
FcεRIa Armenian 
Hamster 
BioLegend Mar-1 PE 134308 0.2 mg/ml 1:200 
Table 2-8 Anti-mouse conjugated antibodies used for flow cytometry studies. 
 
 Viability staining 
To assess cell viability and to analyse live cells, the ability of cells to integrate 
the fluorescent DNA-binding probe Dapi was quantified. Dapi can be incorporated 
only if the cellular membrane has become porous, when the cells are non-viable. Dapi 
(D9542, Sigma Aldrich, UK) was added at 1:500 dilution to the cell suspension, 5 
minutes before running the sample through the flow cytometer or sorter. 
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 Equipment used for flow cytometry and FACS 
Flow cytometry was achieved using a 6 laser BD Fortessa flow cytometer (BD, 
UK). FACS was performed by Centre for Inflammation Research Flow Cytometry 
facility team, using the BD Aria Fusion sorter (BD, UK). 
 Flow cytometry data analysis 
Data gathered from flow cytometry and FACS were analysed using the software 
FlowJo 8.7 (Flowjo, LLC, USA). Statistical analysis was conducted using GrapPad 
Prism 6.0. 
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Chapter 3 Characterization of the phenotype 
of human uterine mast cells. 
3.1 Introduction 
Mast cells are derived from CD34+/c-kit+ pluripotent progenitors which reside 
in the bone marrow (Kirshenbaum et al., 1999). MC progenitors leave the bone marrow 
and enter the circulation, (Gurish and Austen, 2012), where they are recruited into 
peripheral tissues by chemokines secreted by stromal cells. Together with stem cell 
factor (SCF), a complex array of cytokines and a range of micro-environmental factors 
control the local development of progenitors into mature MCs (Valent et al., 1992). 
Expansion of tissue resident populations can also occur as MCs can be long-lived and 
may re-enter the cell cycle to undergo proliferation locally (Metcalfe et al., 1997). 
Mature mast cells are classified according to the proteases identified in granules; these 
are tryptase and chymase, which both are serine proteases. When secreted, these 
proteases contribute to host defence by promoting inflammation and tissue 
remodelling.  
MCs are described as being MCTC, which contain both tryptase and chymase 
and MCT, which contain only tryptase (Collington et al., 2011, Wernersson and Pejler, 
2014). MCs maturing in different tissue microenvironments vary widely in type and 
the amount of tryptase and chymase they contain (Caughey, 2007b). When MCs are 
activated they degranulate and the aforementioned proteases, together with other 
inflammatory meditators, stored in the cell’s granules, are released into the 
extracellular environment by exocytosis (Tiwari et al., 2008, Lorentz et al., 2012). MC 
degranulation can occur in response to various stimuli in an IgE dependent or 
independent manner, as described by Galli et al (2011). 
However, in addition to provoking the release of preformed granule 
components, MC activation also induces the de novo synthesis of many bioactive 
molecules, including leukotriens, prostaglandins and cytokines (Abraham and St. 
John, 2010). 
The human endometrium undergoes cycles of cellular proliferation, 
differentiation, and secretory activity during each menstrual cycle (Johannisson et al., 
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1987). In the absence of embryo implantation, the upper functional layer of the 
endometrium breaks down and is shed at menstruation (Jabbour et al., 2006). This 
monthly tissue remodelling process is regulated by changes in cyclical ovarian steroid 
hormones (Salamonsen and Lathbury, 2000, Kelly et al., 2001b, Maybin and Critchley, 
2015). Endometrial tissue contains stromal, epithelial, and endothelial cells, as well as 
a diverse population of immune cells, such as T cells, neutrophils, macrophages and 
mast cells (MCs) (Evans and Salamonsen, 2012a, Thiruchelvam et al., 2013). 
Inflammatory cells represent a significant percentage of the total cell population within 
the endometrial stroma and their numbers fluctuate representing 10-15% of cells in the 
proliferative phase, 20-25% of cells in the late secretory phase, and up to 40% of cells 
immediately before menstruation (Kamat and Isaacson, 1987, Salamonsen and 
Woolley, 1999). Leukocyte recruitment (uterine natural killer cells (uNKs) and 
macrophages) is most striking during the final stages of the menstrual cycle, with 
numbers rising rapidly during the late secretory phase to support the maturation of the 
tissue during decidualization. Notably, the majority of neutrophils influx immediately 
prior to menses (Salamonsen and Lathbury, 2000, Evans and Salamonsen, 2012a).  
There is evidence that mast cells are part of the inflammatory cell population 
in the uterine environment. Uterine MCs are predominantly present in the basal layer 
and myometrium, they are reported not to change in number across the menstrual cycle 
and they are considered to be tissue resident cells (Mori et al., 1997b). Few studies 
have reported that uterine MCs fit the common phenotypic classification: they may be 
both MCT and MCTC, with the tryptase only phenotype reported to be predominant in 
the functional layer (Jeziorska et al., 1995). MCs are usually considered as being in a 
quiescent state and only reported to be highly activated, in an IgE-independent manner, 
during the mid secretory phase (oedematous state) and immediately before and during 
menstruation (Jeziorska et al., 1995, Sivridis et al., 2001). MCs with low granule 
content, suggesting prior activation, have been observed within the endometrium at 
the premenstrual stages (Sivridis et al., 2001). MCs have been implicated in the active 
biochemical process of extracellular matrix (ECM) degradation during menstruation 
and implantation because they are able to release precursors of metalloproteinases 
(MMP-2, MMP-9) and precursors of collagenase (Lees et al., 1994).  
A role for mast cells in women’s health and disorders of the endometrium 
Chapter 3 - Characterization of the phenotype of human uterine mast 
cells.  80 
Tryptase, a mast cell specific protease, is able to cleave substrates including its 
receptor PAR-2 (protease-activated receptor 2), which is expressed on several cell 
types including immune cells, fibroblasts and endothelial cells (Fiorucci and Ascoli, 
2004, Ossovskaya and Bunnett, 2004). There is evidence of PAR-2 expression in the 
human endometrium throughout all phases of the menstrual cycle and after the 
establishment of pregnancy (Hirota et al., 2005). It has been reported that PAR-2 
activation leads to in vitro proliferation of endometrial stromal cells and interleukin-8 
release from both cultured endometrial stromal and epithelial cells (Hirota et al., 2005). 
These findings suggest that MCs are involved in both endometrial tissue remodelling 
and leukocyte recruitment in the final stages of the menstrual cycle.  
Moreover, other studies have shown that MCs are critical during blastocyst 
implantation due to their ability to secrete histamine: a mediator that alters vascular 
permeability and also induces stromal decidualization via histamine receptor 1 (HR1) 
(Liu et al., 2004, Szewczyk et al., 2006). Blockage of MC degranulation or ablation of 
mast cells from the maternal interface resulted in impaired implantation and delayed 
development of the implants, altering trophoblast invasion in rodent models 
(Salamonsen et al., 1996, Woidacki et al., 2013b). Furthermore, the release of 
histamine and serotonin has been linked to uterine contractility, linked to the location 
of MCs within smooth muscle fibres in the myometrium (Rudolph et al., 1993, 
Bytautiene et al., 2004, Bytautiene et al., 2008). Smooth muscle cells are a source of 
stem cell factor (SCF), essential for MC progenitor maturation and MC survival 
(Nilsson et al., 1994b, Metcalfe et al., 1997). 
Female sex hormones, such as oestradiol and progesterone, have long been 
suspected to have an effect on MC behaviour, due to the fact that many MC-related 
pathophysiological conditions have a higher prevalence in females rather than males 
(Narita et al., 2006). Studies in non-reproductive tissue systems and using the HMC-1 
cell line (human mast cell line, (Butterfield et al., 1988)) reported that MCs express 
the oestrogen receptor a isoform (ERa) and the progesterone receptor (Nicovani and 
Rudolph, 2002, Zaitsu et al., 2007, Jensen et al., 2010). Alongside mRNA expression, 
authors showed that MCs can be rapidly stimulated to degranulate by oestradiol via 
ERa (Zaitsu et al., 2007).  
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3.1.1 Summary 
Mast cells have been documented to be part of the leukocyte population in the 
human uterus, in both the endometrial and myometrial compartments. Only Jeziorska 
et al (1995) have investigated the tryptase/chymase phenotype of uterine MCs across 
the different phases of the menstrual cycle. In their studies they used single colour 
staining for endometrial proteases by staining serial sections.  
Another important aspect to take into consideration is that MC development is 
specifically influenced by the microenvironment into which the cell progenitors 
migrate. The human endometrium is a specialised tissue environment, not comparable 
with others, which may have a unique impact on MC maturation and behaviour. 
With these observations in mind, this study was designed to elucidate the phenotype 
of mast cells in the unique microenvironment of the human uterus by investigating the 
expression of serine proteases and sex hormone receptors throughout the menstrual 
cycle. 
3.2 Aims of the Chapter 
1. To investigate the spatial and temporal localization of uterine mast cells. 
2. To investigate the phenotype of the uterine mast cell subtypes and their 
environmental specific expression of steroid hormone receptors. 
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3.3 Material and methods 
3.3.1 Human tissue resources 
Uterine samples were obtained from women undergoing total abdominal 
hysterectomy for non-malignant gynaecological conditions. Endometrium from the 
functional layer was collected by using a suction “pipelle” endometrial sampling 
device, and “full thickness” samples were collected after the hysterectomy was 
performed. The “full thickness” uterine sample includes the endometrium from the 
endometrial-myometrial junction to the uterine lumen (Figure 3-1). 
Patients were aged between 25-50 years (average of 39.8 years), had regular 
menstrual cycles and had not taken any exogenous hormones in the three months prior 
to surgery. Stage of the menstrual cycle was confirmed by histo-pathology and 
oestradiol and progesterone blood levels at the time of biopsy. Critical inclusion 
criteria were the absence of pelvic pain, such as dysmenorrhea, absence of fibroids or 
presence of small fibroids only (<3 cm). Decidual samples were collected during 
selective termination of pregnancy between 9-12 weeks of gestations. Local ethics 
committee approval was granted and written patient consent was obtained prior to 
Figure 3-1 Endometrial-myometrial junction in uterine full-thickness biopsies.  
The insert represents a haematolyxylin staining of a representative sample of full thickness biopsy, 
with the myometrial layer (left), endometrial layer facing the uterine cavity lumen. Image adapted from 
the original made by Mr Grant, graphic designer, MRC Centre for Reproductive Health, University of 
Edinburgh.  
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tissue collection by dedicated research nurses (Ethical approval was held by Professor 
H.O.D. Critchley: 10/S1402/59 and 16/ES/0007). 
















procedure UF Polyps HMB Endo Pain Use 
7108 805 2.89 P 42 25 TAH 	 	 	 	 IHC 
5433 103.57 2.47 P 39 29 TAH 	 	 	 IF 
7815 3.3 <1 P 42 n.a. Endometrial sampling 	 	 	 	 RNA 
5323 107 0.94 P 45 30 TAH 	 	 	 	 IHC IF 
5491 185 9.42 P 40 22 TAH 	 	 	 	 	 RNA 
7680 215 <3 P 36 28 TAH 	 	 	 	 IF 
7151 245 2.7 P 36 n.a. Insert LNG-IUS 
n.a
. 	 	 	 	 RNA 
7541 295 4.02 P 33 31.5 LapSter 	 	 	 	 	 RNA 
5342 318 2.6 P 45 21 VagHyst 	 	 	 	 IHC IF 
5144 357 1.8 P 41 30 LapSterRev n.a. 	 	 	 	 RNA 
5021 428 6.4 P 42 30 LapSter n.a. 	 	 	 	 RNA 
7728 444 <3 P 42 30 Hysteroscopy 	 	 	 	 	 RNA 
5612 472 2.33 P 37 28 LapSter n.a. 	 	 	 	 RNA 
5312 565 5.49 P 42 21 TAH 	 	 	 	 IHC IF 
5007 570 3.7 P 44 27 TAH 	 	 	 	 IHC IF 
7854 571 10.2 P 47 21 TAH 	 	 	 	 IF 
7903 628 3.2 P 40 23.5 TAH 	 	 	 	 IF 
7283 679.57 4.46 P 40 28 LapSter n.a. 	 	 	 	 RNA 
7115 921 7.89 P 44 28 TAH 	 	 	 	 IF 
5201 943 3.24 P 39 26.5 LapSter n.a. 	 	 	 	 RNA 
5616 1178 2.2 P 44 26.5 LapSter 	 	 	 	 	 RNA 
5074 988 34.1 ES 35 28 LapSter 	 	 	 	 	 RNA 
5158 604 42.5 ES 39 26 LapSter 	 	 	 	 	 RNA 
5037 592 46.1 ES 32 30.5 LapSter 	 	 	 	 	 RNA 
5067 514 22.8 ES 44 28 Polypectomy 	 	 	 	 RNA 
7294 504.29 72 ES 40 28 LAVH 	 	 	 	 IHC 
5541 244 51.75 ES 38 28 TAH 	 	 	 	 IHC 
5014 407 44.4 ES 36 28 LapSter 	 	 	 	 	 RNA 
7210 289.28 89.93 ES 33 28 VagHyst &PFR 	 	 	 	 	
IHC 
IF 
7882 338 28.5 ES 43 28 VagHyst &PFR 	 	 	 	 	
IHC 
IF 
5300 398 63 ES 35 30 Labial Cyst 	 	 	 	 	 RNA 
7248 549.91 88 ES to MS 32 28 TAH 	 	 	 	 	
IHC 
IF 
5211 502 43.2 ES to MS 43 24.5 STAH 	 	 	 	 IF 
3155 351 23.1 ES to MS 32 28 TAH 	 	 	 IF 
6412 460 32.5 MS 39 30 Ovarian Cystectomy 	 	 	 	 	 RNA 
5624 457 25.83 MS 30 28 Polypectomy 	 	 	 	 RNA 
7384 331 83.5 MS 42 24.5 TAH 	 	 	 	 IHC IF 
5690 323 38.6 MS 39 27.5 TAH 	 	 	 	 RNA 
7730 312 43.2 MS 39 29 Polypectomy 	 	 	 	 	 RNA 
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41 28 TAH 	 	 	 IHC 
7941 271 33.4 MS 46 28 TAH 	 	 	 	 RNA 
6359 203.3 16.63 MS 42 28 LapSter n.a. 	 	 	 	 RNA 
5607 38.2 7.09 MS to LS 38 25 TAH 	 	 	 	 IF 
5743 132 6.4 LS 47 28 TAHBSO 	 	 	 IF 
5135 602 14.7 LS 44 28 TAHBSO 	 	 	 IF 
7817 8.4 2.3 M 42 29.5 Endometrial sampling 	 	 	 	 RNA 
5316 371 7.54 M 40 28 LAVH 	 	 	 	 	 RNA 
7229 175.87 2.55 M 40 28 TAH 	 	 	 	 IF 
7909 242 <3 M 35 24.5 STAH 	 	 	 	 IF 
5609 196 8.21 M 38 30 Ovarian Cystectomy 	 	 	 	 	 RNA 
Table 3-1 Sample information and experimental application of tissue resources used in Chapter 3. 
Tissues were collected under Ethical approval 10/S1402/59 and 16/ES/0007. UF: uterine fibroids, 
HMB: heavy menstrual bleeding, Endo: endometriosis, n.a.: not applicable, TAH: total abdominal 
hysterectomy, STAH: subtotal abdominal hysterectomy, VagHyst: vaginal hysterectomy, PFR: pelvic 
floor repair, LAVH: laparoscopically assisted vaginal hysterectomy, LNG-IUS: levonorgestrel-
releasing intrauterine system, LapSterRev: laparoscopic sterilization reversal. IHC: 
immunohistochemistry, IF: double immunofluorescence.  
 
3.3.2 Tissue processing 
Tissue samples were either placed into 4% neutral buffered formalin (NBF) for 
future tissue processing and paraffin embedding (Section 2.5.1) or into RNAlater for 
subsequent RNA extraction (Section 2.2).  
3.3.3 RNA extraction from endometrial biopsies 
Total RNA was extracted from homogenized endometrial tissue biopsies 
(20mg/sample) using TriReagent (Sigma Aldrich, UK) and the RNA fraction separated 
from tissue proteins using chloroform (Sigma Aldrich, UK). The RNA solution was 
transferred into an RNeasy spin column and manufacturer’s instructions were followed 
(Qiagen RNA extraction kit, UK). DNA was digested using a DNase kit (Qiagen, UK) 
and total RNA was eluted in 30µl of RNA-free water. Samples were stored at -80°C 
for a minimum of 16h before measuring RNA concentration and quality with the 
Nanodropâ ND-1000 spectrophotometer (Nanodrop Technologies, UK). RNA 
concentration was standardised to 100ng/µl in RNAse-free water prior to cDNA 
preparation. 
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3.3.4 Preparation of cDNA 
Reverse transcription of RNA samples was accomplished by using the 
SuperScriptâ VILOä cDNA synthesis kit (Invitrogen, UK) in an adaptation of the 
manufacturer’s protocol. In brief, each reaction included a final concentration of 1x 
VILO mastermix, 0.125x SuperScript enzyme and 100ng RNA in a total volume of 
20µl. Sample were run at 25°C for 10 minutes, 42°C for 60 minutes and at 85°C for 5 
minutes. 
3.3.5 Quantitative Real Time PCR (Taqmanâ method) 
Quantitative PCR was used for this study; principles of the method are 
explained in Section 2.4. Each reaction mix was prepared using qPCR Supermix with 
premixed ROX kit (Invitrogen, UK). The qPCR amplification reaction was carried out 
using the Applied Biosystemsâ 7900HT Fast Real-time PCR system using the 
reaction mix illustrated in Section 2.4.1. Primer sets were designed using the Roche 
Universal Probe Library (UPL, sequences are described in Table 3-2). Primers were 
purchased from Eurofins (Eurofins Genomics, UK) and the probes from the Roche 
UPL Human set (Roche Applied Science, UK). Samples were assayed in duplicate and 
run at 95° for 10 minutes, 40 cycles of 95°C for 15 seconds and 60°C for a minute.  
Gene name Forward primer Reverse primer UPL probe number 
Homo Sapiens tryptase 
alpha/beta (TPSAB1) cctgcctcagagaccttcc acctgcttcagaggaaatgg 20 
Homo Sapiens chymase 1 
(CMA1) ttcacccgaatctcccatta tcaggatccaggattaatttgc 81 
Human Sapiens proteinase-
activated receptor-2 (PAR-2) gagccatgtctatgccctgt cgatgcagctgttaagggtag 13 
Homo Sapiens Histamine 
receptor H1, (HR1) agaatcagacctgggtggaa aatgagtctgaggctcccatag 68 
Table 3-2 Table of oligonucleotide sequences used in RT-PCR analysis. 
 
3.3.5.1 Relative mRNA expression and statistical analysis 
PCR analysis was conducted using the standard curve method (Section 2.4.2.2) 
and compared to tonsil control mRNA (ASD-0088, Applied StemCell, Menlo Park, 
USA), a positive control for mRNA expression of mast cells mediators.  
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Statistical analysis was carried out using GraphPad Prism 6.0 (GraphPad Software, 
USA). Data are presented as median. One-way ANOVA was used, and Kruskal-Wallis 
was performed as a secondary test with Dunn’s multiple comparisons test. Criterion 
for significance was p<0.05. 
3.3.6 Immunohistochemistry 
Immunohistochemistry was carried out on “full thickness” (uterine lumen to 
endometrial-myometrial junction) human uterine sections to establish the presence and 
localization of mast cells in the different tissue layers constituting the uterus: 
myometrium, basal endometrium and functional endometrium. Uterine biopsies were 
fixed in 4% NBF, embedded in paraffin wax and cut in 5µm sections. After dewaxing 
and tissue rehydration, sections were either exposed to antigen retrieval treatment 
using 1mM Citrate buffer (pH 6) when staining for tryptase, or were directly blocked 
in methanol peroxide for 30 minutes at RT when staining for chymase. All slides were 
then blocked in normal goat serum (NGS, 20% serum, 0.05% bovine serum albumin 
BSA in TBS, Sigma Aldrich, UK) for 30 minutes at RT, then an avidin-biotin block 
applied (Vector Laboratories, UK). Sections were incubated overnight at 4°C with the 
primary antibody (tryptase and chymase at the concentration of 1:500, details in Table 
3-3). After primary antibody incubation, slides were incubated with secondary 
antibodies at 1:200 dilution (Table 3-3) for 1h at RT. Streptavidin-HRP was added 
before performing antigen detection with the 3,3’-diaminobenzidine substrate (DAB, 
Vector laboratories, UK). Slides were counterstained with haematoxylin and mounted 






Source Clone Dilution Secondary Antibody 
Tryptase Rabbit Abcam 
(ab134932) 
EPR8476 1:300 1:500 - Goat anti-rabbit 
biotinylated (ab7055) 
Chymase Mouse AbSerotec 
(MCA1930T) 
CC1 1:500 1:500 - Goat anti-mouse 
biotinylated (ab6822) 
Table 3-3 Primary antibodies used for DAB immunohistochemistry. 
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3.3.7 Immunofluorescence 
Detection of colocalised target antigens was accomplished by using the 
tyramide signal amplification system (TSA™, details in Section 2.5.10). 
3.3.7.1 Image analysis and mast cell quantification using Fiji software. 
DAB single stained images were acquired on the Axioscan Z1 and converted 
to Tiff files before using Fiji image analysis software (Schneider et al., 2012). The 
region of interest (ROI) was manually drawn (illustrated in Figure 3-2-A), to 
distinguish endometrial and myometrial layers. The two different areas were 
established by examining nuclei shape and differences in cellular density between the 
endometrial and myometrial compartments. Due to sample variability, select fields of 
view were not chosen, instead the whole area of endometrial and myometrial tissue 
was taken into account. The total ROI’s area (was then cut from the original image and 
measured in pixels (Figure 3-2-B,C), converted into µm2 based on the characteristic of 
A) B) 
Figure 3-2 Region of interest establishment by manual selection. A) Example of manual selection of 
the endometrial compartment from the myometrium, based on nuclei density, in a uterine full thickness 
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the optical objective and camera installed on the slide scanner (information was 
available in the czi file, and accessed using Zen Blue software). 1µm corresponded to 
45.45 pixels.  
DAB positive cells (brown stained) were quantified using the “cell counter 
plug-in”, and manually selected throughout the ROI, as in the example shown in Figure 
3-3-A. Figure 3-3-B illustrates the Cell Counter plug-in window, where positive cells 
were counted. Values were expressed as the total number of positive cells (tryptase or 
chymase single staining) in the ROI.  
 
A) B) 
Figure 3-3 Mast cell quantification with Cell counter Fiji Plug-in.  
A) High magnification of region of interest (ROI) with counted cells, B) Cell counter window with 
accounted positive cells. Blue arrows indicate DAB positive mast cells. 
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 As a confirmation of quantification using DAB staining, images using double 
immunfluorescence images of representative samples were also quantified. A set area 
was drawn in myometrium and endometrium for each sample, fluorescent channels 





Figure 3-4 Immunofluorescence quantification after colour decovolution with Fiji software. 
A) Double immunofluorescent region of interest (ROI). B) Colour deconvoluted image, into green 
channel and red channel. C) Quantification of staining both in the green (tryptase) and in the red 
channel (chymase), using Fiji Cell Counter Plug-in. 
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3.4 Results 
3.4.1 Concentration of mRNAs of mast cell specific proteases 
and receptors in the human endometrium. 
Gene expression analysis was carried out on RNA extracted from tissue 
homogenates of human endometrium and decidua 9-11 week gestation to 
identify dynamic changes in the expression of genes encoding mast cell 
specific serine proteases, histamine receptor 1 (HR1) and protease-activated 
receptor 2 (PAR-2) (Figure 3-5). 
Concentrations of messenger RNA encoded by TPSAB1 (gene for 
tryptase α and β isoforms) remained unchanged throughout the different phases 
of the menstrual cycle; TPSAB1 mRNA was significantly downregulated in 
first trimester decidua when compared to expression levels at the menstrual 
stage. Similarly, CMA1 (chymase) mRNA concentrations did not change 
during the menstrual cycle, while lower levels were detected in first trimester 
decidua samples however this was not significant.  
The mast cell mediators: histamine, tryptase and chymase may act 
through different receptors. In the current study the pattern of expression of 
HR1 and PAR-2 were selected for further investigation. HR1 mRNA 
concentrations did not show any alteration during the phases of the menstrual 
cycle, whilst HR1 was significantly downregulated in the decidua samples 
compared to menstrual phase samples. Interestingly, PAR-2 mRNA 
concentrations were apparently higher during the early and mid-secretory 
phases when compared to proliferative and menstrual phase of the cycler and 
early pregnancy decidua, although they did not reach statistical significance. 
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Expression of PAR-2 was also confirmed at the protein level (Figure 3-6). 
Immunofluorescence showed that PAR-2 was expressed in the cytoplasm of both 
endometrial stromal and epithelial cells. More intense immuno-staining was detected 
in glandular epithelial cells during early and mid-secretory phases, which is at the time 
when it is reported that epithelial cell proliferation is occurring. 
  
Figure 3-5 Expression of mRNAs encoding mast cell specific proteases, histamine receptor 1 and 
protease-activated receptor 2 in human endometrial and decidual biopsies. 
A) TPSAB1 mRNA expression was not significantly changed across the menstrual cycle. Interestingly 
mRNA levels were apparently lower during mid secretory phase and significantly decreased in 
decidua samples when compared to menstrual phase tissue. B) CMA1 mRNA expression was not 
significantly changed across the menstrual cycle. mRNA levels during early secretory phase showed 
a trend of increase when compared to proliferative phase levels. C) HR1 receptor mRNA expression 
remain unchanged in endometrial biopsies and it was significantly downregulated in decidua samples. 
D) PAR-2 receptor mRNA expression was increased during early and secretory phases. Single dots 
represent different samples, and data are expressed as median. Statistical test used was One-way 
ANOVA, Kruskal-Wallis post-test, *p<0.05. Proliferative phase n=14, Early Secretory phase n=7, 




A role for mast cells in women’s health and disorders of the endometrium 
Chapter 3 - Characterization of the phenotype of human uterine mast 
cells.  92 
3.4.2 Localization of mast cells in “full thickness” sections of 
human uterus. 
Staining for individual proteases was performed using DAB detection on serial 
sections and cells were quantified following the methods as outlined by Jeziorska et al 
(1995). Results were generated using 10 “full thickness” uterine samples (endometrial-
myometrial junction to uterine lumen): 5 proliferative phase and 5 secretory phase 
(representative sample staining showed in Figure 3-7). Counting of DAB positive cells 
showed inconsistent results regarding numbers of MCs of each phenotype during the 
proliferative phase. Quantification revealed that 2/5 proliferative endometrial and 3/5 
Figure 3-6 PAR-2 protein immunolocalization in endometrial functional layer during the 
proliferative, early and mid secretory, and menstrual cycle stages.  
PAR-2 protein is present in the human endometrium; being located both in the epithelial and stromal 
cell compartments. Epithelial expression is apparently higher during both early and mid-secretory 
stages when compared to proliferative phase tissue. This finding confirms the significant PAR-2 
mRNA upregulation during secretory phases, see Figure 3-5. Proliferative n=3, Early Secretory n=2, 
and Mid Secretory n=3. Negative control: omission of primary antibody. 
Figure 3-7 Single DAB staining for tryptase and chymase on representative samples of human uterus 
from across the menstrual cycle.  
Brown triangles indicate DAB positive cells. 
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proliferative myometrial samples had a higher percentage of chymase positive cells 


















2001-1145 Proliferative 0 4 0:4 0% 100% 
2003-1213 Proliferative 33 66 33:66 33% 67% 
2003-1814 Proliferative 7 2 7:2 78% 22% 
2003-2326 Proliferative 42 4 42:4 95.5% 4.5% 
2008-2333 Proliferative 5 1 5:1 83% 17% 
2007-1323 Mid Secretory 23 15 23:15 60.5% 39.5% 
2007-1321 Early Secretory 1 1 1:1 50% 50% 
2012-1591 Early Secretory 141 188 141:188 43% 57% 
2005-1949 Early Secretory 7 2 7:2 78% 22% 
2005-1076 Mid Secretory 142 40 142:40 78% 22% 
Table 3-4 Quantification of tryptase and chymase single DAB staining in endometrial serial sections.  



















2001-1145 Proliferative 12 53 12:53 18% 82% 
2003-1213 Proliferative 713 1010 713:1010 41% 59% 
2003-1814 Proliferative 14 17 14:17 45% 55% 
2003-2326 Proliferative 119 67 119:67 64% 36% 
2008-2333 Proliferative 340 73 340:73 82% 18% 
2007-1323 Mid Secretory 235 133 235:133 64% 36% 
2007-1321 Early Secretory 166 84 166:84 66% 34% 
2012-1591 Early Secretory 463 225 463:225 67% 33% 
2005-1949 Early Secretory 233 65 233:65 78% 22% 
2005-1076 Mid Secretory 856 723 856:723 54% 46% 
Table 3-5 Quantification of tryptase and chymase single DAB staining in myometrial serial sections. 
Rows shaded in grey identify samples with abundant MCs used for further study. 
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To further quantify protease expression by immunohistochemistry, 
representative samples (grey rows in Table 3-4, Table 3-5) were used for dual 
immunofluorescence staining for tryptase and chymase. Data showed that uterine MCs 
were more likely to express tryptase in their granules (over 55% of the total number 
of mast cells, Table 3-6) than chymase. This finding confirms that both MCT and MCTC 
phenotype are present in the human uterus. Comparing results with those in tables 3-
5, 3-6 it is also apparent that double immunofluorescent staining using the tyramide 
system is a more reliable method than analysing single DAB stains on serial sections 






















Endometrium 59 48 59:48 55% 45% 
Myometrium 166 78 166:78 68% 32% 
2012-1591 
Mid Secretory 
Endometrium 213 68 213:68 76% 26% 
Myometrium 384 213 384:213 64% 36% 
Table 3-6 Quantification of double staining for mast cell tryptase and chymase 
 
3.4.3 Immuno-profiling of uterine mast cell subtypes based 
on the expression of proteases: tryptase and chymase 
The location and phenotype of uterine MCs in functional and basal 
endometrium, and in myometrium, were extensively investigated using double 
immunofluorescence staining for tryptase and chymase on “full thickness” biopsies 
obtained from normally cycling women (Figure 3-8).  
MCs were rare in the stroma of the functional endometrium, independent of 
the phase of the cycle. In the basal layer, MCs were mainly detected at the myometrial-
endometrial junction. Basal endometrial MCs were seen in the stromal compartment 
close to epithelial cells and endothelial cells. In some areas of the basal endometrium 
mast cells were observed in clusters. In the myometrium, mast cells were located in, 
and between, muscle bundles and closed associated with blood vessels. 
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The activation/degranulation state of uterine MCs appeared to be cycle stage 
specific. For example, during the proliferative phase, immunostaining of MCs showed 
a round phenotype with proteases with the cytoplasm suggesting they were not 
activated hence no extracellular release of tryptase or chymase was detected (Figure 
3-8-C). Evidence of MC activation within the human uterus was detected during the 
early secretory phase, a stage known to be associated with stromal oedema. This 
observation suggests that MCs undergo activation/degranulation at specific phases of 
the menstrual cycle and that they are intimately involved with cellular changes in the 
stromal compartment. 
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Figure 3-8 Identification of mast cell subtypes in full thickness uterine biopsies across the menstrual cycle by tryptase and chymase immunolocalization. 
A-B-C) Myometrium, basal and functional endometrium during proliferative phase (P); D-E-F) Early secretory phase (ES); G-H-I) Mid secretory phase (MS); J-K-L) 
Late Secretory phase (LS); M-N-O) Menstrual phase (M); P-Q-R) Negative control (omission of primary antibody). Double immunofluorescence has revealed the 
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3.4.3.1 Proliferative phase 
Uterine MC phenotype and activation profiles were further analysed in each 
phase of the menstrual cycle. Interestingly, the uterine MC phenotype differed between 
the three compartments of the “full-thickness” uterine tissue sections as revealed using 
confocal imaging (Figure 3-9). In the myometrial layer, MCs expressed tryptase and 
chymase with different intensities and multiple cell phenotypes were identified: MCT 
with high tryptase and no chymase; MCTC with high tryptase and low chymase, defined 
by intensity of the fluorescent signal; or MCTC with low tryptase and high chymase 
(Figure 3-9).  
Figure 3-9 Mast cell subtypes and activation state in the proliferative phase endometrium.   
Single fluorescence channels show the different mast cell subtypes in a uterine “full thickness” 
section during proliferative phase of the menstrual cycle. The myometrial compartment shows three 
different mast cell subtypes: tryptase single positive, chymase single positive and tryptase and 
chymase double positive. Basal endometrial mast cells are tryptase single positive and double 
positive, instead functional endometrium MCs are fewer in number and show a tryptase only 
phenotype. The MC activation profile during proliferative phase looks quiescent; proteases are 
retained in the cytoplasm. (n=4) (White triangles: MCTC cells; white Vs: MCT cells; white arrows: 
MCC cells). 
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In contrast, basal endometrial MCs expressed tryptase only or high 
tryptase/low chymase in their granules.  Endometrial MCs in the functional layer were 
only detected by immunostaining for tryptase, revealing the MCT phenotype (white Vs 
in Figure 3-9). 
3.4.3.2 Early secretory phase 
The MC activation profile changed during the early secretory phase (Figure 
3-10). MCs appeared activated in both basal endometrium and myometrial layers. In 
Figure 3-10 Mast cell subtypes and activation state during the early secretory phase.  
Single fluorescence channels show the different mast cell subtypes in a uterine full thickness section 
during the early secretory phase. Myometrial compartment shows three different mast cell subtypes: 
tryptase single positive, chymase single positive and tryptase and chymase double positive. Basal 
endometrial mast cells are tryptase single positive and double positive, instead functional endometrium 
MCs are fewer in number and show a chymase negative phenotype. MCs during the early secretory 
phase appeared to be activated, releasing both proteases from the cytoplasm. (n=4) (White triangles: 
MCTC cells; white Vs: MCT cells; white arrows: MCC cells). 
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the myometrium cells appeared to have released both tryptase and chymase, whereas 
in the basal endometrium chymase alone was released. Additionally, the uterine MC 
phenotype was either MCT or low tryptase/high chymase MCTC. 
3.4.3.3 Mid secretory phase 
During the mid-secretory phase, MCs appeared to degranulate in the 
myometrial compartment, with both tryptase and chymase released. In contrast, MCs 
in the endometrium were in a resting state with proteases retained in their cytoplasm. 
Figure 3-11 Mast cell subtypes and activation state during the mid secretory phase.  
Myometrial compartment shows three different mast cell subtypes: tryptase single positive, chymase 
single positive and tryptase and chymase double positive. Basal endometrial mast cells are tryptase 
single positive and double positive, instead functional endometrium MCs are fewer in number and 
show a chymase negative phenotype. MCs during the early secretory appeared to be activated in the 
myometrium and basal endometrium, releasing both proteases from the cytoplasm. (n=3) (White 
triangles: MCTC cells; white Vs: MCT cells; white arrows: MCC cells). 
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Regarding the phenotypic profile, a different subtype of MCs was also detected, 
together with the common MCTC, in basal endometrium and myometrium: MCC only 
(white arrows in Figure 3-11) were present. In accordance with other findings (Mori 
et al., 1997b), MCs found in the stroma of the functional endometrium, showed MCT 
phenotype (white triangle). 
3.4.3.4 Late secretory 
During the late secretory phase (Figure 3-12), activated MCs were detected 
only in the myometrium, with extra-cellular tryptase located outside the cytoplasmic 
Figure 3-12 Mast cell subtypes and activation state during the late secretory phase. 
During the late secretory phase, MCs are identified as tryptase single positive and weakly double 
positive (MCTC). In both the endometrial layers MCs showed a strong tryptase only phenotype. MCs 
during the late secretory phase appeared to be activated only in the myometrial compartment, 
releasing tryptase and retaining chymase in the cytoplasm. (n=3) (White triangles: MCTC cells; white 
Vs: MCT cells). 
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membrane. Moreover, the MC phenotype appeared to be different when compared to 
the previous phases of the cycle, showing a low chymase content in MCTC cells, no 
MCC in the myometrium, and MCT in the basal and functional compartments. 
3.4.3.5 Menstrual phase 
During the menstrual phase MCs in the basal endometrium had intense 
cytoplasmic staining for both tryptase and chymase (Figure 3-13). MCs were not 
detected in the shed functional layer of the endometrium. Interestingly, the numbers 
of MCs observed was higher when compared to the other phases of the cycle. The MC 
Figure 3-13 Mast cell subtypes and activation state during the menstrual phase.  
Uterine mast cells appear to be tryptase and chymase double positive, in both myometrial and basal 
endometrial layers. MCs during the menstrual phase appeared to be activated only in myometrial 
compartment, releasing both tryptase and chymase from the cytoplasm. In the basal endometrium, 
MCs showed a steady state instead. (n=2) (White triangles: MCTC cells; white Vs: MCT cells; white 
arrows: MCC cells). 
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phenotype within the different uterine layers during the menstrual phase, were MCTC 
with high tryptase/low chymase, and MCC only. 


























“resting” “activated” “activated” “resting” “activated” 
Table 3-7 Summary table of uterine MC phenotypes and activation profile during the menstrual cycle 
 
3.4.4 Immunolocalisation of oestrogen receptors shows ERb 
is present in human uterine mast cells. 
The available data on sex steroid hormone receptor expression in human MCs 
is based on a few studies in non-reproductive tissues (Zhao et al., 2001, Nicovani and 
Rudolph, 2002) and those using immortalized cell lines such as HMC-1 (Butterfield et 
al., 1988). These studies reported detection of progesterone receptor (PR), oestrogen 
receptor isoform α (ERα) but the oestrogen receptor isoform β (ERβ) was not identified 
(Zhao et al., 2001, Nicovani and Rudolph, 2002, Jensen et al., 2010) 
The current investigation of the pattern of sex steroid hormone receptor 
expression in human uterine MCs started with validation of ERα immunoexpression 
in control tissues reported to contain ERα positive MCs, including skin, nasal polyps 
and tonsil (Figure 3-14). In contrast to previous findings, none of the positive control 
tissues were immunopositive for the oestrogen receptor isoform α (ERα) positive MCs, 
including samples from nasal polyps, tissue used by Zhao et al (2001). In the present 
study, first trimester decidua samples were also included as a positive control for ERα 
immunoreactivity (red staining in Figure 3-14).  
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Figure 3-14 Mast cells and ERa expression in other human tissues.  
Mast cells were found to be immunonegative for ERa (red staining; positive in decidual cells) in 
human nasal polyps, tonsil, skin and prostate. (Nasal polyps n=1, Tonsil n=1, Skin n=2, Decidua 
n=2 and prostate n=2. 
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ERα immunoexpression was detected in the human uterine biopsies. However, 
MCs present in the myometrium and basal layer of the endometrium were 
immunonegative for ERα in both proliferative and secretory phases of the menstrual 
cycle (Figure 3-15). In line with expectations, expression of ERα was detected in the 
nuclei of stromal and epithelial cells of the endometrium and in smooth muscle fibres 
in the uterine wall (Critchley et al., 2001). 
In contrast to previous reports, the results presented in this study demonstrate 
that MCs in the human uterus are strongly immunopositive for ERβ (oestrogen 
receptor isoform β, Figure 3-16). Uterine MCs expressed ERβ independently of phase 
of the cycle and of location in the different compartments of the uterus. The expression 
pattern of ERβ in the stroma and epithelial compartments of the endometrium was 
consistent with our previous studies being higher during proliferative phase compared 
to the secretory phase (Critchley et al., 2002).  
Zhao et al (2001) reported the immunoexpression of progesterone receptor in 
human MCs resident in the upper airways. MCs resident in the uterine environment 
were immunonegative for PR. This result was the same in both basal endometrium and 
myometrium, and was independent of the stage of the cycle (Figure 3-17). 
Nuclear expression of ERβ in uterine leukocytes often parallels that of the 
glucocorticoid receptor (GR), uterine natural killer cells being one such example 
(Henderson et al., 2003). In the current study, nuclear GR was detected in MCs (Figure 
3-18). MCs were immunopositive for GR regardless of their location, being GR 
positive in functional and basal endometrium and myometrium. In uterine cells, GR 
protein was sharply immunopositive in the endometrial stroma and smooth muscle 
fibres during the proliferative phase, but its expression was reduced during the 
progesterone-dominant secretory phase (Bamberger et al., 2001, Henderson et al., 
2003). Figure 3-19 summarizes the unique steroid hormone receptor protein 
expression profile of uterine MCs. Notably, in this study double immunofluorescence 
demonstrated conclusively that mature uterine MCs do not contain ERα or PR as 
reported by Zhao et al (2001), but remarkably both ERβ and GR protein were localized 
to their nuclei. 
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Figure 3-15 Uterine mast cells are immunonegative for ERa.  
Double immunofluorescence showed no ERa expression (red staining) in the nuclei of uterine 
mast cells (green staining). Mast cells were noted to be immunonegative in all uterine layers 
and across the phases of the menstrual cycle. Myometrial, stromal and epithelial cells showed 
expression for ERa, as expected (Proliferative n=5, Secretory n=5). 
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Figure 3-16 Uterine mast cells are immunopositive for ERb.  
Immunohistochemistry showed co-localization of ERb in uterine mast cells. Nuclear 
expression of ERb receptor (red staining) was detected in mast cells across the tissue 
structures of uterus, myometrium, basal and functional endometrium, and during both the 
proliferative and secretory phases of the menstrual cycle. (Proliferative n=5, Secretory n=5) 
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Figure 3-17 Mast cells and progesterone receptor expression in the human uterus.  
Mast cells were demonstrated to be immunonegative for PR expression (red staining), across 
“full thickness” uterine sections and during both the proliferative and secretory phase. 
(Proliferative n=5, Secretory n=5). 
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Figure 3-18 Mast cells express the nuclear activated form of glucocortoid receptor in the 
human uterus.  
Uterine mast cells express the activated form of glucocorticoid receptor (GR; red staining) 
during the proliferative and secretory phase, throughout the myometrium, functional and 
basal endometrial and layers. (Proliferative n=5, Secretory n=5). 
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3.5 Discussion 
While other uterine leukocytes have been extensively studied, only a few studies 
have investigated the nature of the mature mast cells resident in the human uterus. This 
study investigates both the numbers of mast cells in the uterus (endometrium and 
myometrium) as well as their phenotype in the specific microenvironment of the 
human uterus. 
 The cellular and extracellular composition of human endometrium undergoes 
extensive remodelling during every phase of the menstrual cycle. This dynamic 
remodelling is orchestrated by the ovarian steroid hormones, oestrogen and 
progesterone, and their fluctuating serum levels. There is compelling evidence that the 
leukocyte population contributes to the tissue adaptation across the phases of the cycle 
(Evans and Salamonsen, 2012a). Notably, both the total number of immune cells and 
the relative numbers of each immune cell type varies according to the different stages 
of the menstrual cycle. The lympho-myeloid cell types in the endometrium include 
eosinophils, macrophages, neutrophils, uterine natural killer and mast cells. Whereas 
the influx of eosinophils and neutrophils is apparent during the pre-menstrual and late 
secretory phases, macrophages and natural killers increase in number immediately 
after ovulation and during the decidualization process (Kamat and Isaacson, 1987, 
Figure 3-19 Representative steroid receptor expression panel in human uterine mast cells 
Uterine MCs are immunopositive for ERβ and GR, and immunonegative foe ERα and PR. 
RED staining: ERα, ERβ, PR and GR, GREEN staining: tryptase. 
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Kammerer et al., 2004). Other cells like mast cells are reported to be consistent in 
number throughout the menstrual cycle (Salamonsen et al., 2002). 
The current investigation, undertaken 15 years after the last published study of 
uterine mast cells (Sivridis et al., 2001), confirmed with modern technologies that 
mature mast cells are resident in the human uterus. Firstly, confirmation of the uterine 
MCs was accomplished with analysis of the expression of mRNA’s encoded by 
proteases in endometrial tissue biopsies. This is the first time, mRNAs for mast cell 
specific proteases have been quantified in endometrial tissue homogenates. The 
concentrations of tryptase and chymase mRNAs remained unchanged in the 
endometrium during the different phases of the menstrual cycle. I speculate that these 
results may be influenced by the life span of tissue resident mast cells. For example, 
in vivo studies have reported that mast cells have a lifespan of weeks to months in 
tissues (Padawer, 1974, Kiernan, 1979). As tryptase and chymase are constitutively 
expressed proteases in mast cell granules (Pejler et al., 2007), it is not unexpected that 
expression of their mRNAs might remain unchanged during their long life span.  
Furthermore, the potential downstream effects of mast cell mediators released 
during activation were also investigated by measuring the concentration of mRNAs 
encoded by histamine receptor 1 (HR1) and protease-activated receptor 2 (PAR-2), 
which are activated by histamine and tryptase respectively. Histamine has often been 
reported to be part of the angiogenetic machinery (Lu et al., 2013). Angiogenesis is 
the formation of new blood vessels, and occurs in the endometrium during tissue 
remodelling in the proliferative phase and during formation of spiral arterioles in early 
stages of the secretory phase (Rogers, 1996, Demir et al., 2010). The pro-angiogenetic 
action of histamine has been reported to work through HR1 and HR2 receptor-
mediated synthesis of vascular endothelial growth factor (VEGF) (Sorbo et al., 1994, 
Rizzo and Defouw, 1996). Indeed, several studies have showed that VEGF is involved 
in regulation of endothelial cell growth, angiogenesis and permeability in the human 
endometrium (Sugino et al., 2002, Punyadeera et al., 2006). 
PAR receptors are G protein-coupled receptors (GPCRs) that are uniquely 
activated by proteolysis (Soh et al., 2010). The isoform 2 of PAR receptor is 
predominately cleaved by mast cell tryptase and trypsin (Compton et al., 2001). PAR-
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2 is mainly expressed in vascular, epithelial, fibroblastic and immune cells. Its 
activation has been reported to be important in the processes of haemostasis and 
inflammation (Coughlin, 2000). PAR-2 activation regulates ion transport in epithelial 
cells, by increasing levels of intracellular calcium (Kunzelmann et al., 2002). There is 
evidence that PAR-2 activation mediates a proliferative response in human endothelial 
cells (Mirza et al., 1996) and it influences prostaglandin synthesis by upregulating 
synthesis of the cyclooxygenase 2 enzyme (COX-2) in fibroblasts (Seymour et al., 
2005, Zhang et al., 2012). Furthermore, cleavage of the N-terminal domain of PAR-2 
can trigger an immune response indirectly by the release of the chemoattractant 
interleukin-8 from epithelial and endothelial cells (Asokananthan et al., 2002), and 
directly by enhancing motility of neutrophils (Shpacovitch et al., 2004) and activating 
eosinophils (Miike et al., 2001). 
mRNAs encoded by HR1 and PAR-2 were detected at very high concentrations 
in human endometrium when compared to control tissues, such as tonsil. HR1 mRNA 
remained constant throughout the different phases of the menstrual cycle, consistent 
with a possible role for histamine during tissue remodelling and angiogenesis in the 
human endometrium. PAR-2 appeared to be upregulated, in a non-significant manner, 
during the secretory phase compared to proliferative phase, a time that is characterized 
by epithelial growth, decidualization and immune cell influx. PAR-2 protein was also 
investigated, and it was demonstrated that this protease-activated receptor was present 
in the human endometrium, in both stromal and epithelial compartments. This finding 
would be consistent with potential activation of PAR-2 in endometrial and epithelial 
cells as described by Hirota et al. (2005).  
Quantification of mast cells conducted during this study has revealed new 
evidence that their phenotype in both the basal endometrium and myometrium was 
predominately one of co-expression of tryptase/chymase. Mast cells were rarely 
detected in the functional endometrium and in this compartment they not only 
appeared to be of the MCT phenotype but the tryptase was detected within the 
cytoplasmic granules and did not appear to be released in the surrounding tissue. Two 
methods were used, first DAB staining for tryptase and chymase was conducted 
separately on serial sections, repeating the study reported by Jeziorska et al. (1995) 
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and second, double immunofluorescent staining was undertaken allowing 
simultaneous detection of both proteases in the same cell section, which coupled with 
the tyramide amplification system is demonstrated to have 1000-fold signal 
amplification compared to DAB detection. 
Detailed analysis of the uterine MC’s phenotype in multiple samples for each 
phase of the cycle, has revealed the presence of a rare novel third subtype not 
previously described in the endometrium: the chymase-only positive mast cell (MCC). 
Traditionally, human mast cells were classified according to their proteolytic granules 
based on the expression of tryptase and/or chymase (Irani et al., 1986). Weidner et al. 
(1993) were the first scientists to report the existence of chymase positive/tryptase 
negative (MCC) mast cells. MCC were subsequently detected by immunofluorescence 
in the airway and gastrointestinal tract, reported as 12% in human bronchi and 16.8% 
bowel submucosa of total MC number. The presence of a MCC population was also 
investigated in cases of organ rejection, such as following a kidney transplant (Yamada 
et al., 2001). The current study provides further evidence for the presence of three 
different subtypes of mast cells. In this study the phenotype of uterine MCs was 
extensively studied and it was evident that the different phenotypes were both stage 
and tissue compartment specific. For example, MCC were detectable only in the 
myometrium and the basal endometrium during the mid secretory phase. This finding 
would appear to be consistent with the concept of phenotypical plasticity that has been 
advanced by Galli et al (2011). The current findings would suggest that uterine mast 
cells adopt a chymase-positive phenotype facilitating stage specific impacts which 
may include the formation of endometrial arterioles from arcuate arteries in the 
myometrium (Farrer-Brown et al., 1970).  
The activation state of uterine MCs was further explored during the present 
study. Generally, uterine MCs are reported to degranulate during the secretory phase 
at a time when the endometrial tissue is in an oedematous state. This observation was 
based on detection of extracellular tryptase during oedema and weak intracellular 
tryptase staining detectable during the proliferative phase (Jeziorska et al., 1995). In 
this study, endometrial activation and the degranulation of MCs was documented 
during the early and mid-secretory stages of normal uterine tissue with detection of 
A role for mast cells in women’s health and disorders of the endometrium 
Chapter 3 - Characterization of the phenotype of human uterine mast 
cells.  113 
tryptase and chymase in the extracellular matrix. A “recovery” state, characterised by 
weak immunostaining, was observed in tissue collected from patients during the 
proliferative, late secretory and menstrual stages. Within the myometrial compartment 
MCs were in a “resting” state only during the proliferative phase. Interestingly, in the 
myometrium MCs were activated during both secretory and menstrual phases, 
suggesting a potential role for MCs in regulation of arteriole sprouting at early/mid 
secretory phases and smooth muscle contraction during menses. These findings 
conclusively demonstrated that MC behaviour is cycle phase dependent and prompted, 
further investigation as to the possible impact of sex hormones on the degranulation 
process. 
Female sex hormones have long been suspected to affect the behaviour/action 
of mast cells, in part because many MC-related conditions have a higher prevalence in 
women than in men. For example, the incidence of asthma is greater in women during 
early to mid-adulthood, it worsens perimenstrually and during menopause it is 
aggravated by hormonal replacement therapies (Bonds and Midoro-Horiuti, 2013). 
Furthermore, there is also some evidence for the expression of sex steroid hormone 
receptors in human mast cells (Zhao et al., 2001, Nicovani and Rudolph, 2002). 
However, the current study is to my knowledge the first investigation to elucidate the 
steroid hormone receptor expression profile of mast cells in the human uterus. Based 
on current literature, the results obtained were unexpected as dual 
immunofluorescence revealed that uterine MC did not contain detectable oestrogen 
receptor α (ERα) or progesterone receptor (PR). Notably, the uterine MCs were 
immunopositive for oestrogen receptor β (ERβ) and this expression was independent 
of the phase of the menstrual cycle. Interestingly, we have previously documented that 
other uterine resident immune cells, such as uterine natural killer cells (uNKs) and 
macrophages have a similar expression pattern, being immunopositive for ERβ and 
immunonegative for ERα (Henderson et al., 2003, Thiruchelvam et al., 2016). 
Several studies have reported that glucocorticoids may have an indirect anti-
inflammatory impact on mast cells, with the postulated mechanism being a reduction 
of stem cell factor production by fibroblasts (Da Silva et al., 2002). Alternatively, they 
may also have direct impacts by reducing IgE binding to the FcεRI receptors thereby 
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downregulating the expression of these receptors on the cell membrane of the mast 
cells and inhibiting MC degranulation in vitro (Finotto et al., 1997, Yamaguchi et al., 
2001, Zhou et al., 2008). Prior to the current study, the only report of expression of 
glucocorticoid receptor (GR) expression in human mast cells was from Oppong et al. 
(2014). In their study, they localized GR to the plasma membrane in RBL-2H3 mast 
cells. The current study is the first to demonstrate that uterine mast cells are 
immunopositive for nuclear GR. A glucocorticoid rich environment would favour 
activation of GR, with shuttling of ligand activated receptor from the cytoplasm 
towards the nucleus (Phuc Le et al., 2005). This observation is due to high uterine 
endometrial levels of glucocorticoids. This finding is consistent with local biosynthesis 
of cortisol and expression 11-β hydroxysteroid dehydrogenase enzymes (11β-HSDs) 
within the uterus (McDonald and Henderson, 2006, Gibson et al., 2013). 
Although, other authors have demonstrated a direct effect of female sex 
hormones on mast cell behaviour, activation and migration, in those studies they cited 
activation of MCs via ERα and PR (Zaitsu et al., 2007, Jensen et al., 2010). In contrast, 
the current data suggests that the impact of oestrogens on uterine mast cells may be 
mediated via ERβ. This speculation is also supported by the activation of uterine mast 
cells during the secretory phase. This is a time in the menstrual cycle when intracrine 
biosynthesis of oestradiol has been shown to activate ERβ positive uNKs (Gibson et 
al., 2015). 
In summary, the studies described in this chapter confirm that mast cells are a 
component of the leukocyte population of the human uterus, and are most abundant in 
the myometrial and basal compartments. The data show that uterine MCs 
predominantly belong to the classic mast cell subtypes: tryptase positive/chymase 
negative (MCT) and tryptase/chymase positive (MCTC), but a rare third subtype was 
also identified in the uterine population: the tryptase negative/chymase positive uterine 
MCs (MCC). Mast cell activation/degranulation was menstrual cycle stage dependent, 
and their environment-specific phenotype revealed immunoexpression of ERβ and 
GR, suggesting they are a target cells for both oestrogens and glucocorticoids. 
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The limitation of the current study is in the limited availability of human samples 
which has led to a lack of statistical power in the results. Therefore, further 
investigations would be needed to confirm the findings of this chapter. 
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Chapter 4 Characterization of phenotype of 
mast cells in women with pain and 
endometriosis 
4.1 Introduction 
Endometriosis is a chronic incurable condition defined as the presence of 
endometrial tissue (“lesions”), composed of stromal and epithelial cells, outside the 
uterine cavity. Prevalent locations for endometriotic lesions are: the pelvic peritoneum, 
ovaries and recto-vaginal septum (Burney and Giudice, 2012). The aetiology and 
pathogenesis of endometriosis are still not clear, although one theory initially proposed 
by Sampson (1927), states that endometriotic lesions may originate from  retrograde 
menstruation and ectopic endometrial tissue adhesion and invasion after the reflux of 
endometrial cells via the Fallopian tubes. 
Endometriosis is most prevalent in women of reproductive age (affects one in 
ten women) and regresses after menopause, after circulating sex hormones decrease 
(Cramer and Missmer, 2002). The symptoms of endometriosis can be extremely 
debilitating including chronic pelvic pain, dysmenorrhea (painful menstruation), pain 
at ovulation, dyspareunia, irregular and/or heavy menstrual bleeding, fatigue and 
infertility (Giudice, 2010). Endometriosis, due to its presentation and multifactorial 
nature, is often under-diagnosed and is associated with an average of 7-year delay from 
the onset of symptoms to a definitive diagnosis (Simoens et al., 2012).  
Factors considered to be key regulators of the establishment and development of 
endometriotic lesions include: a) increased adhesion and invasiveness of shed 
endometrial cells in the peritoneal cavity; b) alterations of hormone levels in the 
peritoneum, with the lesion due to local biosynthesis of oestrogen; c) “progesterone 
resistance” resulting in endometrial dysfunction; and d) an aberrant inflammatory 
environment with increased secretion of growth factors and cytokines that triggers the 
influx and activation of immune cells (eg. macrophages, uterine natural killer cells, 
and mast cells (MCs) (Signorile and Baldi, 2010, Burney and Giudice, 2012, Taylor et 
al., 2012, Kobayashi et al., 2014).  
A role for mast cells in women’s health and disorders of the endometrium 
Chapter 4 - Characterization of phenotype of mast cells in women with pain and 
endometriosis.  117 
Development of endometriotic lesions is also sustained by neuro-angiogenic 
processes which enable nutrient supply and innervation of the lesions (Wang et al., 
2009). Chronic pelvic pain (CPP) is a debilitating symptom of several disorders, 
including endometriosis, irritable bowel syndrome, interstitial cystitis and 
musculoskeletal and neurological diseases (Triolo et al., 2013). Endometriosis-
associated pelvic pain is thought to be due to abnormal inflammation, oxidative stress, 
angiogenic, neurovascular, or neuropathic mechanisms in the lesion/peritoneum 
environment (Kobayashi et al., 2014). Different pathways are thought to be the cause 
of CPP experienced by women with endometriosis: one of these is that the 
endometriotic lesion could cause a compression or infiltration of nerves (Anaf et al., 
2000, Morotti et al., 2014). On the other hand, Triolo et al. (2013) suggested that a rise 
in perception of CPP could be a result of an increase in the release of nerve growth 
factor (NGF) and substance P in the endometriotic lesion area, and this may have an 
impact on subsequent nerve growth potentially increasing the links between new pain 
afferents and the central nervous system. 
Mast cells are immune cells of the myeloid lineage, derived from pluripotent 
precursors of the bone marrow (Kirshenbaum et al., 1999, Nielsen and McNagny, 
2009). Mature MCs may be found in most tissues of the body, but they are typically 
most abundant at sites of host-environment defence, such as the skin and other mucosal 
tissue; bronchi and intestine for example (Metcalfe et al., 1997). The most 
distinguishing morphological MC characteristic is their high content secretory 
granules, which occupy the majority of the cytoplasm of mature cells (Padawer, 1974). 
MCs are classified based on their granule content of serine proteases, such as tryptase 
and chymase (Metcalfe et al., 1997). 
MC secretory granules are filled with preformed compounds including: serine 
protease such as tryptase and chymase; biogenic amines such as histamine, serotonin 
and dopamine; and other cytokines and growth factors such as tumour necrosis factor 
(TNF), nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) 
(Wernersson and Pejler, 2014). Upon stimulation, MCs synthetize and store within 
their granules eicosanoids, such as prostaglandins D2 (PGD2) and E2 (PGE2), 
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leukotriene C4 (LTC4), as well as interleukins (IL-3, IL-5, IL-8) and chemokines, such 
as CCL3 (Abraham and St. John, 2010). 
Detailed studies during Chapter 3, demonstrated that the human endometrium 
contains MCs with a range of phenotypes, predominantly tryptase positive in the 
functional layer. Uterine MC activation was shown to be menstrual cycle stage 
dependent. It was further elucidated in chapter 3 MC ability to respond to steroids, due 
to their immunoexpression of ERβ and GR, suggesting they are a target cells for both 
oestrogens and glucocorticoids. 
The activation of MCs and subsequent release of the granule compounds from 
MC granules significantly modulates many aspects of physiological and pathological 
conditions. For example, mast cells may regulate vasodilation, vascular homeostasis, 
immune responses and angiogenesis.  
MCs are also known as key players in both physiological and pathological pain 
pathways and in the pathology of diseases. Interestingly, MCs are often found close to 
primary nociceptive neurons and can participate in neuro-immune synapse signalling 
(Dropp, 1972, Stead, 1989). MCs and sensory neurons are involved in an interactive 
activation loop: MC mediators sensitize sensory neurons, which further activate the 
surrounding MCs by releasing neuropeptides such as NGF, histamine and substance P 
(Rosa and Fantozzi, 2013). 
Recently, a few studies have described an increase in the number of activated 
mast cells in peritoneal endometriosis, indicating a potential function for mast cells 
and their mediators in the onset of fibrosis in lesions (Kempuraj et al., 2004, Sugamata 
et al., 2005, Kirchhoff et al., 2012). Additionally, Anaf et al. (2006) showed that deep 
infiltrating lesions were associated with a higher number of activated MCs located in 
intimate proximity with the sensory nerves. 
Taken together these findings suggest that activated MCs might play a key role 
in endometriosis, a condition where immune, neural, and apparently endocrine 
components are altered. 
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4.1.1 Summary 
Endometriosis is complex multifactorial gynaecological condition, which affects 
up to 10% of women of a reproductive age worldwide (Simoens et al., 2012). It is 
defined as the growth of endometrial tissue outside the uterine cavity, primarily in the 
peritoneal cavity and ovaries (Giudice and Kao, 2004). Its most common symptom 
reported, is chronic pelvic pain, which determines endometriosis as a condition with 
social impact (Simoens et al., 2012). 
The peritoneal environment of women affected by endometriosis has an 
increased inflammatory profile with regards to the numbers of immune cells recruited 
to the tissue and pro-inflammatory mediator release (Signorile and Baldi, 2010). 
Different immune cell types have been intensively studied in endometriosis patients 
(Burney and Giudice, 2012), but very few studies have investigated the role of mast 
cells in the pathophysiology of endometriosis and its chronic pelvic pain symptom. 
Taken together, the hypothesis of this study is that MCs are involved in the 
establishment and/or maintenance of endometriosis and chronic pelvic pain, through 
their sex hormone dependent degranulation and their role in neuro-inflammation. 
4.2 Aims of the Chapter 
1.  To explore the phenotype of mast cells in the eutopic endometrium and 
peritoneum of women with chronic pelvic pain and compare it to unaffected 
women. 
2. To investigate mast cells and their mediators in the peritoneal fluid of women 
suffering with chronic pelvic pain and/or endometriosis 
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4.3 Methods 
4.3.1 Human tissue resources 
Human tissue was obtained from women undergoing laparoscopy for non-
malignant gynaecological conditions or sterilisation procedures. All patients were 
within the 18-49-year age range and had menstrual cycles between 24-35 days in 
length (Table  4-1). Local ethical committee approval was granted and written 
informed patient consent was obtained prior to tissue collection. Local ethical approval 
was held by Professor A.W. Horne (11/AL/0376). 
Endometrium from the functional layer (eutopic endometrium) was collected 
by using a suction “pipelle” endometrial sampling device. The tissue biopsies collected 
during laparoscopy were “peritoneum prone”, from the recto-vaginal pocket (pouch of 
Douglas, “prone” site for endometriotic lesion formation) and “peritoneum distant” 
from the frontal abdominal peritoneal wall (“distant” site from endometriotic lesion 
formation), whether present, ectopic lesions were also collected. Peritoneal fluid was 
aspirated from the pouch of Douglas (Figure 4-2). 
Patients attending a chronic pelvic pain clinic were classified according the 
American Fertility Society’s guidelines (Canis et al., 1997). Patients were subdivided 
as follows: Grade 0 - women affected by chronic pelvic pain without endometriosis 
found during diagnostic laparoscopy; Grade I - women with chronic pain and with 
minimal endometriosis; Grade II - women with chronic pain and mild endometriosis; 
Grade III - women with chronic pain and moderate endometriosis and Grade IV - 
women with chronic pain and severe endometriosis. This control group was 
denominated as the “no pain” control group, because some of them were suffering by 
Figure 4-1 Laparoscopic view of the peritoneal cavityand sites for tissue biopsies collection. 
Images adapted from Hic and nunc (2011) and Blaus (2014) 
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asymptomatic endometriosis. Full details of patient characteristics including menstrual 
cycle stage (confirmed by histo-pathology) and whether they were receiving hormonal 











Endometriosis Pain Sample Application 
3454 0 NO NK 36 28 	  ELISA/FLOW 
3442 0 NO NK 30 NK 	  RNA/ELISA/FLOW 
3421 0 NO NK 41 30 	  ELISA 
3378 0 NO NK 29 NK 	  ELISA/FLOW 
3300 0 NO NK 21 NK 	  ELISA 
3180 0 NO Proliferative 40 28 	  ELISA 
3234 0 NO Proliferative 18 28 	  IF/ELISA 
3246 0 NO Proliferative 36 31 	  RNA 
3282 0 NO Proliferative 45 NK 	  IF 
3298 0 NO Proliferative 47 25 	  IF/ELISA 
3319 0 NO Proliferative 38 30 	  ELISA 
3484 0 NO Proliferative  NK   ELISA 
3491 0 NO Proliferative 49 24-31 	 	 RNA/IF/ELISA/ FLOW 
3185 0 NO Early Secretory 32 35 	  ELISA 
3190 0 NO Early Secretory 29 21 	  ELISA 
3205 0 NO Early Secretory 39 28 	  IF/ELISA 
3241 0 NO Early Secretory 32 30 	  IF/ELISA 
3295 0 NO Early Secretory 30 28 	  ELISA 
3438 0 NO Early Secretory 32 35 	  RNA/ELISA/FLOW 
3472 0 NO Early Secretory 26 32-38   FLOW 
3497 0 NO Early Secretory 34 <24 	 	 
RNA/IF/ELISA/ 
FLOW 
3247 0 NO Mid Secretory 36 35 	  RNA 
3290 0 NO Mid Secretory 37 29 	  ELISA 
3343 0 NO Mid Secretory 39 21 	  ELISA 
3443 0 NO Mid Secretory 38 28 	  RNA/ELISA 
3469 0 NO Mid Secretory  NK   ELISA/FLOW 
3203 0 NO Late Secretory 36 28 	  IF 
3272 0 NO Late Secretory 28 31 	  RNA/ELISA 
3384 0 NO Late Secretory 25 24 	  RNA/ELISA/FLOW 
3388 0 NO Late Secretory 36 NK 	  RNA/ELISA/FLOW 
3427 0 NO Late Secretory 27 28 	  RNA 
3450 0 NO Late Secretory 31 30 	  ELISA/FLOW 
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3245 0 NO Menstrual 28 28 	 IF/ELISA 
3334 0 NO Menstrual 32 28 	 IF 
3426 I NO NK 23 NK   ELISA/FLOW 
3376 I NO NK 33 32   ELISA/FLOW 
3192 I NO NK 28 26   ELISA 
3294 I NO Proliferative 30 31   IF 
3320 I NO Proliferative 40 23   IF/ELISA 
3355 I NO Proliferative 28 32   ELISA/FLOW 
3374 I NO Proliferative 35 28   FLOW 
3398 I NO Proliferative 23 30   RNA/ELISA/FLOW 
3404 I NO Proliferative 25 NK   RNA 
3448 I NO Proliferative 32 NK   ELISA/FLOW 
3459 I NO Proliferative 45 NK   ELISA 
3494 I NO Proliferative 31 24-31 	 	 RNA/IF/ELISA/ FLOW 
3221 I NO Early Secretory 30 30 	  IF/ELISA 
3232 I NO Mid Secretory 26 28   IF/ELISA 
3248 I NO Mid Secretory 43 NK   ELISA 
3254 I NO Mid Secretory 28 32   ELISA 
3306 I NO Mid Secretory 36 NK   ELISA 
3307 I NO Mid Secretory 40 28   IF/ELISA 
3446 I NO Mid Secretory 39 NK   RNA/ELISA 
3466 I NO Mid Secretory 35 32-38   FLOW 
3228 I NO Late Secretory 40 28   ELISA 
3451 I NO Late Secretory 26 21   RNA 
3278 II NO Proliferative 25 31   RNA/IF/ELISA 
3293 II NO Proliferative 45 28   IF 
3399 II NO Proliferative 25 NK   ELISA/FLOW 
3445 II NO Proliferative 38 28   RNA 
3495 II NO Proliferative 37 32-38   FLOW 
3476 II NO Early Secretory  24-31   ELISA 
3478 II NO Early Secretory  24-31   ELISA 
3493 II NO Early Secretory 30 32-38   FLOW 
3172 II NO Mid Secretory 33 NK   ELISA 
3482 II NO Mid Secretory  32-38   ELISA/FLOW 
3435 II NO NK 40 24   ELISA/FLOW 
3340 II NO NK 49 NK   ELISA 
3341 II NO NK 33 28   ELISA 
3279 II NO NK 40 35   ELISA 
3222 III NO Proliferative 35 33   IF/ELISA 
3286 III NO Proliferative 38 NK   RNA/ELISA 
3412 III NO Proliferative 25 30   RNA/ELISA/FLOW 
3483 III NO Proliferative  24-31   ELISA/FLOW 
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3182 III NO Mid Secretory 40 NK   ELISA 
3337 III NO Mid Secretory 31 27   IF/ELISA 
3358 III NO NK 29 30   ELISA/FLOW 
3360 III NO NK 41 30   ELISA/FLOW 
3179 III NO NK 29 NK   ELISA 
3366 IV NO Proliferative 32 28   ELISA 
3471 IV NO Proliferative  <24   ELISA 
3235 IV NO Early Secretory 28 28   ELISA 
3349 IV NO Early Secretory 42 NK   FLOW 
3489 IV NO Early Secretory 34 32-38   FLOW 
3309 IV NO Mid Secretory 40 30   ELISA 
3342 IV NO Inactive 32 18   ELISA 
3382 IV NO NK 22 30   ELISA/FLOW 
3322 IV NO Menstrual 28 28 	 ELISA 
3353 0 YES Proliferative 33 28 	  FLOW 
3460 0 YES Progesterone effect 20 NK 	  FLOW 
3437 0 YES Progesterone effect 28 NK 	  FLOW 
3414 0 YES Progesterone effect 25 NK 	  FLOW 
3422 0 YES Progesterone effect 25 NK 	  FLOW 
3394 0 YES Progesterone effect 24 28 	  FLOW 
3390 0 YES Proliferative 18 30 	  FLOW 
3391 0 YES Proliferative 26 NK 	  FLOW 
3418 0 YES NK 20 NK 	  FLOW 
3488 0 YES NK 25 24-31   FLOW 
3371 0 YES Early Secretory 33 32 	  FLOW 
3431 I YES Proliferative 24 21   FLOW 
3462 I YES Progesterone effect 39 28   FLOW 
3413 I YES Progesterone effect 30 35   FLOW 
3377 I YES Inactive 39 56   FLOW 
3389 I YES NK 31 NK   FLOW 
3473 I YES NK  24-31   ELISA/FLOW 
3465 I YES NK 35 NK   FLOW 
3403 I YES Mid Secretory 24 23   FLOW 
3498 I YES Mid Secretory 39 <24 	 	 
RNA/IF/ELISA/ 
FLOW 
3361 III YES Progesterone effect 26 NK   FLOW 
3428 III YES Mid Secretory 26 23   FLOW 
Table  4-1 Human samples used for profiling mast cells in women with chronic pelvic pain and or 
without endometriosis. (NK: not known) 
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3491 0 NO Proliferative 49 24-31 	 	 RNA/IF/ELISA/ FLOW 
3494 I NO Proliferative 31 24-31  	 RNA/IF/ELISA/ FLOW 
3497 0 NO Early Secretory 34 <24 	 	 
RNA/IF/ELISA
/ FLOW 
3498 I YES Mid Secretory 39 <24  	 
RNA/IF/ELISA
/ FLOW 
Table  4-2 No pain control group samples used during Chapter 4 experiments. 
4.3.2 Tissue processing 
Tissue samples were either placed into 4% neutral buffered formalin (NBF) for 
future tissue processing and paraffin embedding (Section 2.5.1) or into RNAlater for 
subsequent RNA extraction (Section 2.2.1).  
4.3.3 Processing of peritoneal fluids 
Peritoneal fluids were centrifuged for 10 minutes at 900g at 4°C, following the 
World Endometriosis Research Foundation EPHect guidelines (Becker et al., 2014, 
Vitonis et al., 2014, Greaves et al., 2014a). The peritoneal fluid was then aliquoted and 
stored at -80°C until required. Cells recovered from peritoneal fluid (PF cells) were 
incubated with red blood cell (RBC) lysis buffer (BioLegend, USA). Briefly, cell 
pellets were incubated in the dark with 5ml of 1x RBC buffer for 15 minutes then 
centrifuged for 5 minutes at 350g at room temperature (RT). The supernatant 
containing the lysed red blood cells was discarded. If the resultant cell pellet was 
contaminated by red blood cells after lysis, the aforementioned protocol was repeated. 
The resultant white blood cell pellet was resuspended in 1ml of freezing medium 
(RPMI, Gibco, UK, with 10% dimethyl sulfoxide, DMSO, Sigma Aldrich, UK). 
Before storage at -80°C, cell counting and viability assessment were performed: 10µl 
of cell suspension was mixed with 10µl of Trypan Blue (ThermoFisher Scientific, 
UK), and pipetted into a disposable chamber with Countess™ II automated cell 
counter (AMQAX1000, ThermoFisher Scientific, UK).  
4.3.4 RNA extraction from endometrial and peritoneal 
biopsies 
RNA was extracted as detailed in Section 2.2. 
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4.3.5 Preparation of cDNA 
Reverse transcription of RNA was performed as described in Section 2.3. 
4.3.6 Quantitative Real Time PCR (Taqmanâ method) 
The Taqmanâ method of polymerase chain reaction (PCR) was used for this 
study, gene targets, primer and probe combinations are detailed in Section 2.4.  
4.3.6.1 Relative mRNA expression and statistical analysis 
PCR analyses were conducted by using the standard curve method (Section 
2.4.2.2) and compared to tonsil control mRNA (ASD-0088, Applied StemCell, USA), 
which was used as known to contain mast cells.  
Statistical analysis was carried out using GraphPad Prism 6.0 (GraphPad 
Software, USA). Data are presented as median. One-way ANOVA was used, and 
Kruskal-Wallis was performed as a secondary test with Dunn’s multiple comparisons 
test. Criterions for significance was p<0.05. 
4.3.7 Immunofluorescence 
Immunofluorescence was carried out on endometrial and peritoneal tissue 
sections in accordance with the standard laboratory protocols, full details in Section 
2.5.10. Detection of colocalised target antigens was accomplished using the tyramide 
signal amplification (TSA™, details in Section 2.5.9.2, fluorophores). Primary 
antibody employed in chapter 4 are listed in Errore. L'origine riferimento non è 
stata trovata..  




Source Clone Dilution Secondary Antibody 
Tryptase Rabbit Abcam 
(ab134932) 
EPR8476 1:300 1:200 - Goat anti-rabbit 
peroxidase (ab7171) 
Chymase Mouse AbSerotec 
(MCA1930T) 
CC1 1:5000 1:200 - Goat anti-mouse 
peroxidase (ab6823) 
PAR-2 Mouse Abcam 
(ab184673) 
SAM11 1:500 1:200 - Goat anti-mouse 
peroxidase (ab6823) 
Table  4-3 Primary, secondary antibodies and dilutions used in immunofluorescence. 
Stock concentrations of the antibodies are reported in Table 2.5 
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4.3.8 Flow cytometry and FACS 
4.3.8.1 Sample preparation 
Following the isolation of cellular populations from peritoneal fluids (PF) 
(Section 4.3.3), samples were stored at -80°C. Samples were thawed at 37°C and 
centrifuged for 5 minutes at 1000g at 4°C. Cells were re-suspended in 1ml of FACS 
buffer and filtered to remove any cell clumps, using filter polystyrene FACS tubes (BD 
Falcon, UK). Cell suspensions were counted and viability assessed using the Countess 
II (AMQAX1000, ThermoFisher Scientific, UK). Human samples were incubated 
with AB human serum for one hour on ice (1% diluted in sterile PBS, H4522, Sigma 
Aldrich, UK). Samples were washed with 2 ml of FACS buffer (PBS w/o Ca2+ and 
Mg2+, 2% BSA) for 5 minutes at 1000g at 4°C.  
4.3.8.2 Conjugated antibody staining 
Samples were stained in 100µl of FACS buffer using a panel of anti-human 
antibodies: epitopes, concentrations and fluorochromes are illustrated in Table 2-7. 
Single staining beads (eBioscience, UK) and FMOs were performed for compensation 
settings at the same time (detailed in Section 2.7). Cell suspensions were kept in the 
dark, for 1 hour on ice. Following incubation, samples were washed with 3 ml of FACS 
buffer and centrifuged for 5 minutes at 1000g at 4°C. To assess cell viability Dapi was 
used (D9542, Sigma Aldrich, UK), added at 1:500 dilution to the cell suspension, 5 
minutes before running the sample through the flow cytometer or sorter. 
4.3.8.3 Flow cytometry data analysis 
Data gathered from flow cytometry and FACS were then analysed using the 
software FlowJo 8.7 (Flowjo, LLC, USA). Statistical analysis was conducted using 
GraphPad Prism 6.0. 
4.3.9  Enzyme-linked Immunosorbent Assay 
4.3.9.1 Sandwich human tryptase and chymase ELISA 
The concentration of tryptase, chymase and histamine molecules in human 
peritoneal fluid (PF; details of PF processing in Section 2.1.2) was determined by two-
site sandwich ELISA as described in Section 2.6.1. Peritoneal fluids were assayed in 
duplicate, information on standard samples in Errore. L'origine riferimento non è 
tata trovata. and Errore. L'origine riferimento non è stata trovata.. 
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(pg/ml) S2 S3 S4 S5 S6 S7 S8 
Tryptase 4000 2000 1000 500 250 125 62.5 31.2 
Chymase 2000 1000 500 250 125 62.5 31.2 - 
Table 4-4 Standards for tryptase and chymase sandwich ELISA.  





(pg/ml) S2 S3 S4 S5 S6 S7 S8 S9 
Histamine 
(Kit 1) 25000 12500 62500 32000 15600 7800 3900 1900 980 
Histamine 
(Kit 2) 100000 50000 25000 12500 6250 3200 1560 - - 
Table  4-5 Standards used for Histamine competitive ELISA kits.  
(Kit 1: ENZ-KIT 140, Enzo Life Sciences, Switzerland; Kit 2: CEA927Ge, CloudClone Corp., USA). 
4.3.9.2 ELISA data analysis 
Data analysis was conducted using the standard curve method. The data were 
statistically evaluated with GraphPad Prism 6.0. 
4.4 Results 
4.4.1 mRNA expression of mast cell specific receptors and 
proteases in endometrium of women with chronic pelvic 
pain and endometriosis 
Human mast cells are traditionally classified by the serine protease content of 
their granules, with tryptase and chymase being used for identification of their 
phenotype.  
To assess expression of mast cell specific mRNAs in the eutopic endometrial 
tissue of women with chronic pelvic pain with/without endometriosis homogenates 
were analysed using RT-PCR. Concentrations of TPSAB1 (gene encoding human 
tryptase α and β isoform) mRNAs were significantly lower in grade 0 patient group 
(chronic pain, no endometriosis) when compared to the control group. Endometrial 
biopsies from women with endometriosis (grade I-III) appear to have a lower 
expression of TPSAB1 mRNA compared to the control group, but higher compared to 
the grade 0 group but this did not reach significance (Figure 4-2-A). A similar 
expression pattern was seen for CMA1 (gene encoding human chymase), mRNAs 
which were significantly downregulated in grade 0 eutopic endometrium and lower in 
grade I-III when compared to no pain control group (Figure 4-2-B).  
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The study was extended to investigate the expression of genes encoding the 
protease-activated receptor 2 (PAR-2) and the histamine receptor 1 (HR1) on biopsies 
(Figure 4-2-C/D). Interestingly, mRNA expression of these receptors that may be 
activated by tryptase or histamine derived from mast cells are also down-regulated in 
grade 0 and grade I-III samples.  
 
Figure 4-2 Concentrations of mast cell proteases and effector receptors mRNAs were altered 
in eutopic endometrium of women with chronic pelvic pain and/or endometriosis.  
A-B-D) TPSAB1 (tryptase), CMA1 (chymase) and HR1 (histamine receptor): mRNA expression 
levels were significantly downregulated in eutopic endometrium from women with pelvic pain, 
and lower levels were detected in endometrial biopsies from women with endometriosis. C) The 
mRNA expression of PAR-2 (protease-activated receptor 2) was instead significantly 
downregulated in eutopic endometrium from women with different grades of endometriosis. Data 
shown as median, statistical test used was One-way ANOVA, Kruskal-Wallis post-test, *p<0.05, 
**p<0.01. No pain controls n=4, red dots indicate control patients with asymptomatic 




A role for mast cells in women’s health and disorders of the endometrium 
Chapter 4 - Characterization of phenotype of mast cells in women with pain and 
endometriosis.  129 
 
Expression of mast cell mediators and receptors was also examined in tissue 
homogenates from endometriotic lesions (Figure 4-3). TPSAB1 and HR1 mRNA 
concentrations in lesions was lower when compared to no pain control eutopic 
endometrium (Figure 4-3-A,D). PAR-2 mRNA expression was significantly 
downregulated in endometriotic lesions (Figure 4-3-C). A different expression pattern 
Figure 4-3 Expression of receptors and proteases of mast cell mRNAs in endometriotic biopsies.  
A-B-D) mRNA concentrations of mast cell proteases were not significantly different in 
endometriotic lesions compared to eutopic endometrium from control women (no pain group). 
TPSAB1 and HR1 expression resulted lower and CMA1 mRNA was instead higher in lesion 
homogenates. C) PAR-2 receptor expression was significantly downregulated in endometriotic 
lesions. Data shown as median, statistical test used was One-way ANOVA, Kruskal-Wallis post-
test *p<0.05, No pain controls n=4, red dots indicate control patients with asymptomatic 
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was found when assessing the mRNA concentrations of CMA1 mRNAs with a non-
significant trend towards increase in lesions compared to controls (Figure 4-3-B).  
The investigation of expression of mRNAs was expanded by exploring 
concentration of mast cell related genes in peritoneal tissue homogenates. Two kinds 
of peritoneum biopsies were taken during diagnostic laparoscopy: one from the 
“prone” site of the peritoneum where lesions are usually formed in a region named the 
pouch of Douglas (recto-uterine pocket) and one from the front pelvis peritoneum, the 
opposite site to where endometriotic lesions are usually found. These two samples 
were designated as peritoneum “prone” and peritoneum “distant” to the usual sites of 
endometriotic lesions. Tissue biopsies from the same locations were collected from the 
“no pain” control group patients. 
TPSAB1 mRNA concentrations were significantly lower in peritoneal “distant” 
tissue homogenates from women experiencing chronic pelvic pain (grade 0) and from 
those also affected by endometriosis (grade I-III, Figure 4-4-A) compared to the no 
pain control group peritoneum. CMA1 expression did not change across the different 
groups (Figure 4-4-B). Grade I-III had one sample outlier, with very high CMA1 
mRNA concentrations. The expression of receptors for mast cell mediators remained 
unchanged between the control group and chronic pain groups. Message RNAs of 
PAR-2 and HR1 appeared unchanged in grade 0 and I-III when compared to the no 
pain controls (Figure 4-4-C/D). 
Similarly, in peritoneal prone biopsies, the expression profile for mast cell 
mediators and receptors showed an apparent downregulation of TPSAB1 mRNA 
concentrations in grade 0 which was significant the grade I-III group, compared to no 
pain controls (Figure 4-5-A). CMA, PAR-2 and HR1 mRNAs did not vary within the 
different patient groups (Figure 4-5-B,D). 
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Figure 4-4 Investigation of mast cells mediators and receptors in distant peritoneum 
in women with chronic pelvic pain and/or endometriosis.   
A) mRNA expression of TPSAB1 was significantly altered in women experiencing 
chronic pelvic pain group and endometriosis group when compared to No pain group in 
peritoneal distant biopsies, *p<0.05. B-C-D) Gene expression of CMA1, PAR-2 and HR1 
remained unchanged within the groups. Data shown as median. No pain controls n=4, 
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Figure 4-5 mRNA expression of mast cells related genes in peritoneal prone biopsies from 
women attending the pain clinic.  
A) TPSAB1 gene was significantly downregulated in peritoneum prone from women with 
endometriosis, B-C-D) CMA1, PAR-2 and HR1 mRNA expression remained unchanged within 
the different groups of patients and controls. Data shown as median, statistical test used was 
One-way ANOVA, Kruskal-Wallis post-test *p<0.05, No pain controls n=4, red dots indicate 
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4.4.2 Profiling of mast cells in women attending a pain clinic 
identified changes in subtypes compared to controls 
Expression of mast cell proteases were also investigated at the protein level, by 
visualising their localization using immunofluorescent staining in all patient groups. 
Due to the high degree of patient variability, results are shown patient by patient for 
the “no pain” group and two representative patients of proliferative and secretory phase 
are illustrated for the group 0 and group I-III datasets. 
The following results are discussed based on the patient groups and different 
phases of the menstrual cycle. Starting with a sample collected during the proliferative 
phase from a control group patient (3491) (Figure 4-6), chymase positive mast cells 
were detected in the peritoneal tissue biopsies but were absent in the functional layer 
Figure 4-6 Identification of mast cell subtypes in eutopic endometrium and peritoneal 
biopsies of a control patient (no pain and no endometriosis).  
Mast cells were not detectable in the functional endometrial biopsy, MCs resulted chymase only 
phenotype and highly activated in both peritoneal biopsies. (White arrows: MCC cells) 
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of the endometrium. Interestingly, in this patient the peritoneal mast cells expressed 
chymase but not tryptase, suggesting there were of the MCC subtype. Furthermore, 
they appeared to be highly activated, as there was abundant extracellular 
immunostaining of chymase. This finding was consistent in both distant and prone 
peritonea. 
In contrast, mast cells were detected in the functional endometrium of patient 
3494, who was also in the proliferative phase (Figure 4-7), and in this sample two 
different subtypes were reported: MCs positive for tryptase and chymase (MCTC) and 
the very rare endometrial type, chymase only (MCC). Mast cells present in the 
endometrium appeared to be in a “resting” state where serine proteases are retained 
inside the cytoplasm. Remarkably, mast cells of the MCTC subtype had apparently 
degranulated and chymase was widely spread in the peritoneal biopsies. Patient 3494 
suffered from grade I asymptomatic endometriosis.  
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The MC phenotype was detected different during the secretory phase in the 
functional endometrium; cells were single positive for tryptase and in a resting state 
(Figure 4-8, Figure 4-9), a finding that was in line with the results reported in Chapter 
3. Mast cells in the peritoneal wall were again activated and intensively 
immunopositive for chymase (Figure 4-8). Patient 3498, presented with grade I 
asymptomatic endometriosis and showed mast cells degranulating chymase in the 
peritoneum prone however MCs were detected with lower intensity in the distant 
peritoneal biopsies (Figure 4-9). 
Figure 4-7 Mast cell identification in endometrial and peritoneal biopsies of a proliferative 
sample from no pain group. 
Mast cells resulted immunopositive for tryptase and chymase, and chymase positive in the eutopic 
endometrium, and were found in the resting phase (no extracellular release of proteases). MCs 
were instead highly activated and singly positive for chymase in both peritoneal biopsies, distant 
and prone to lesion. Need to be specified, patient 3494 had asymptomatic grade I endometriosis, 
therefore it was included in the “no pain” control group. White triangle indicates tryptase/chymase 
double positive MC. (White triangles: MCTC, white arrows: MCC) 
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Figure 4-8 Mast cells identification in a “no pain” control patient during secretory phase:  
MC subtype found in the eutopic endometrium corresponded to the typical functional 
endometrial MC type, tryptase single positive, intensively investigated in Chapter 3. Peritoneal 
MCs were detected degranulating chymase in both “distant” and “prone” wall (White triangles: 
MCTC, white Vs: MCT; white arrows: MCC). 
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MCs were also investigated in the group of patients affected by chronic pelvic 
pain who had no evidence of endometriosis at the time of laparoscopy, (grade 0, Figure 
4-10/14). In a proliferative sample 3298 (Figure 4-10), MCs were tryptase and 
chymase positive in the functional endometrium, showing an activated state, with 
chymase staining in the extracellular matrix. Compared to “no pain” controls, MCs 
were difficult to detect in the peritoneal samples, and the chymase and tryptase staining 
were reduced and in some cases absent, for example in the peritoneum prone of this 
patient (Figure 4-10).  
Figure 4-9 Immunolocalization of mast cells in a secretory phase patient with asymptomatic 
endometriosis.  
Endometrial MCs showed the “classical” functional endometrial phenotype: tryptase single 
positive, as described in Chapter 3. MCs were not detectable in the peritoneal distant, but were 
instead activated and chymase positive in the peritoneum prone biopsy. (White triangles: MCTC, 
white Vs: MCT; white arrows: MCC). 
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A similar result was shown by immunofluorescence in biopsies from patient 
3282; MCs were detectable with low expression of chymase, retained in the cytoplasm. 
Moreover, peritoneal MCs were detected that were double positive for both tryptase 
and chymase in the peritoneum prone (Figure 4-11). MCs were not detectable in the 
proliferative functional endometrium. 
 
 
Figure 4-10 Mast cell localization in one patient during proliferative phase affected by chronic 
pelvic pain and no endometriosis.  
Endometrial MCs resulted double positive for tryptase and chymase, with little extracellular 
chymase staining. Peritoneal MCs, when detectable, were single chymase or tryptase positive, 
with a lower staining if compared to “no pain” controls. Grade 0 patients during proliferative phase 
n=3.  (White triangles: MCTC, white Vs: MCT; white arrows: MCC) 
 
A role for mast cells in women’s health and disorders of the endometrium 
Chapter 4 - Characterization of phenotype of mast cells in women with pain and 
endometriosis.  139 
Two representative samples were selected to describe the MC phenotype in 
chronic pelvic pain patients during the secretory phase; the total number of patients 
used in this study was four. During the secretory phase, interrogation of biopsies from 
women experiencing chronic pelvic pain (no endometriosis) revealed they had all three 
MC subtypes present: tryptase only (MCT), tryptase and chymase (MCTC) (Figure 
4-12, Figure 4-13) and chymase only (MCC) (Figure 4-13) in the functional layer of 
their endometrium. MCs were chymase positive (MCC) and in a degranulating state in 
the peritoneum distant.  
Figure 4-11 Tryptase and chymase staining in tissue biopsies from a chronic pelvic pain patient  
during proliferative phase.  
MCs were not detectable in the eutopic endometrial biopsy. Peritoneal MCs were MCC in the 
distant peritoneum and MCTC in peritoneum prone. Grade 0 patients during proliferative phase 
n=3. (White triangles: MCTC, white Vs: MCT; white arrows: MCC). 
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Chymase staining was less intense when compared to the “no pain” control 
images, described above. Interestingly, chymase staining was not only detected in mast 
cells, but also in cuboidal cells, at the edge of the tissue suggesting these might be 
mesothelial cells (Figure 4-13). In peritoneal prone biopsies (Figure 4-12, Figure 
4-13), chymase staining was more specific to single MCs. Moreover, tryptase staining 
was detected in peritoneal MCs, in line with the finding in proliferative samples 
consistent with the MCTC phenotype. 
 
Figure 4-12 Mast cells detection in endometrial and peritoneal biopsies from a representative  
secretory phase sample from chronic pelvie pain group.. 
Two subtypes of MCs were found in the eutopic endometrium: MCT and MCTC. MCs resulted 
degranulating and MCC type in both the peritoneal biopsies. Grade 0 patients during secretory 
phase n=4. (White triangles: MCTC, white Vs: MCT; white arrows: MCC). 
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Figure 4-13 Identification of mast cell in eutopic endometrium and peritoneal wall in a 
representative secretory phase sample from chronic pelvic pain group.  
Endometrial MCs were found MCC and in the activated state, with extracellular staining. Different 
types of cells resulted positive for chymase in the peritoneum distant, cuboidal cells together with 
mast cells, suggesting mesothelial cells (white rectangle). Grade 0 patients during secretory phase 
n=4. (White triangles: MCTC; white arrows: MCC). 
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To complete the dataset, double immunofluorescence for mast cell proteases, 
tryptase and chymase, was carried out on samples from women classified as suffering 
from different grades of endometriosis (grades I-III). To display the results for each 
group two representative samples were selected to cover both the proliferative and 
secretory phase of the menstrual cycle within this group. Two MC subtypes were 
detected in the functional layer of the endometrium during the proliferative phase; 
MCTC and MCC (Figure 4-14, Figure 4-15). The staining pattern suggested that 
endometrial mast cells were in the “resting” state, with proteases contained in 
cytoplasmic granules. Peritoneal MCs showed phenotypical heterogeneity in the 
selected samples; MCs were predominantly chymase positive with a small portion of 
tryptase/chymase positive in prone peritoneum. The intensity of the immunostaining 
varied from “distant” to “prone” peritoneal wall being higher to lower respectively. 
MCs were also successfully detected in the ectopic endometrial-like lesions, with 
Figure 4-14 Detection of mast cell mediators in grade II endometriosis tissue biopsies. 
Chymase was the most predominant serine protease detected in the different tissue samples from a 
patient with grade II endometriosis during the proliferative phase. Tryptase was detected with lower 
intensity in MCs in peritoneum prone and ectopic lesion. Overall, the expression of MC mediators 
was lower if compared to “no pain” control. Grade I-III patients during proliferative phase n=4. 
(White triangles: MCTC, white Vs: MCT; white arrows: MCC). 
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intense positive staining for chymase. The MC state detected in the different peritoneal 
biopsies was considered as “activated”. 
Interestingly, MCs were not detectable in the eutopic endometrium of any of 
the secretory samples from women with endometriosis screened during this study 
(Figure 4-16, Figure 4-17). Furthermore, the MC phenotype changed in the peritoneal 
samples recovered during the secretory phase, both single positive MCC, as well as 
MCTC were also detected. Notably, both the intensity and quantity of the staining 
appeared reduced in comparison to the “no pain” control peritoneal samples. Chymase 
detection was restricted specifically to the mast cell population, with a lower 
activation/degranulation profile. MCs were found in a relatively high number in 
peritoneum prone and lesion biopsies. 
Findings of this sections are summarised in Table  4-6. 
  
Figure 4-15 A representative sample for MC identification in a proliferative grade II patient. 
In the eutopic endometrium MCs were MCTC and MCC. MCC phenotype was retained also in the 
ectopic lesions. MCs in peritoneal biopsies showed highly activated chymase single positive 
phenotype. Grade I-III patients during proliferative phase n=4. (White triangles: MCTC, white 
arrows: MCC) 
A role for mast cells in women’s health and disorders of the endometrium 
Chapter 4 - Characterization of phenotype of mast cells in women with pain and 
endometriosis.  144 
 
  
Figure 4-16 Tryptase and chymase staining on a representative secretory sample set of 
endometriosis group. 
MCs were detected in the peritoneal biopsies and endometriotic lesions. Chymase was the most 
prevalent protease in the MC granules. Tryptase was detected in a large number of peritoneal MCs 
which was different to results in the other patient groups. Grade I-III patients during secretory phase 
n=4. (White triangles: MCTC, white arrows: MCC). 
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Table  4-6 Summary table of MC phenotype in tissue samples studied in this project. 
EE: eutopic endometrium, PD: peritoneum distant, PP: peritoneum prone, L: lesion, nd: not detected 
 
  
Figure 4-17 Double positive MCs in representative samples from patient with endometriosis sample 
in secretory phase. 
MCs were present in peritoneum distant and ectopic lesion biopsies: MCTC and MCC. MCs resulted 
activated with extracellular chymase; tryptase was retained in the cytoplasm. Grade I-III patients 
during secretory phase n=4. (White triangles: MCTC; white arrows: MCC). 
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4.4.3 Identification of protease-activated receptor 2 (PAR-2) in 
the peritoneum of women suffering of chronic pelvic 
pain and endometriosis. 
PAR-2 receptor can be activated by MC proteases and in this study it was for 
the first time, it was immunolocalized in the human peritoneal lining, both in women 
with and without chronic pelvic pain. PAR-2 protein expression was dependent on the 
phase of the menstrual cycle, and more intense in secretory phase compared to 
proliferative phase samples, as shown in Figures 17/18/19. Notably, this was 
independent of the site of the biopsies, in prone or distant peritoneum. This result is in 
line with the endometrial expression of PAR-2 described in Chapter 3, Section 3.4.2, 
which demonstrated that PAR-2 mRNA and protein expression was unregulated during 
the secretory phase. Figure 4-18 illustrates the immunolocalization of PAR-2 protein 
in the peritoneum of “no pain” control women. Specifically, PAR-2 was detected in 
some but, not all the dapi positive cells; no tryptase positive MCs were detected 
consistent with the results detailed in Section 4.4.2.  
Remarkably, PAR-2 immunoexpression appeared strongly upregulated in the 
peritoneum from women with chronic pelvic pain, both in proliferative and secretory 
phases of the menstrual cycle, as shown in Figure 4-19. One exception to this pattern 
was noted in peritoneum “distant” biopsies, as PAR-2 protein expression appeared 
similar in intensity to that of “no pain” controls, both during proliferative and secretory 
phases (see Figure 4-18). Interestingly, tissue sections of peritoneum distant from 
patient 3210 showed that putative mesothelial cells also express PAR-2 protein 
(cuboidal cells indicated by white arrows in Figure 4-19).  
Furthermore, a striking pattern of PAR-2 protein expression was detected in 
the peritoneal biopsies from women with pelvic pain and endometriosis, including 
those containing samples with endometriotic lesions (Figure 4-20). There was no 
difference in the expression between the phases of the cycle, the location or the type 
of biopsies. PAR-2 was expressed homogenously in all the tissue sections, suggesting 
a ubiquitous upregulation throughout the peritoneal cavity of women suffering of 
endometriosis and pelvic pain. In addition, tryptase positive cells were detected in the 
different samples, as reported in Section 4.4.2. 
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Figure 4-18 Protease-activated receptor 2 (PAR-2) immunoexpression during proliferative and secretory phase in the peritoneal lining of “no pain” 
control women. 
Double immunofluorescence showed that PAR-2 expression was higher during secretory phase and confirmed that the absence of tryptase positive mast cells 
in the peritoneal environment. White rectangles: cuboidal mesothelial cells .Proliferative phase n=2, secretory phase n=2.  
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Figure 4-19 PAR-2 expression in peritoneal biopsies from women suffering from chronic pelvic pain. 
PAR-2 expression appeared higher in peritoneal prone biopsies compared the distant peritoneum. Expression did not change during different phases of the 
menstrual cycle. White rectangles: cuboidal cells, possible mesothelial nature. Proliferative n=2, secretory n=2.  
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Figure 4-20 Representative images of PAR-2 expression in the peritoneal cavity from women affected by endometriosis and chronic pelvic pain.  
PAR-2 protein was detected ubiquitously in the peritoneal cavity of women with endometriosis and chronic pain, in both peritoneal biopsies and endometriotic lesions. PAR-2 
immunoexpression appeared higher compared to the control group (Figure 4-18). Tryptase positive mast cells were also localized within the different tissue sections. Proliferative 
n=2, secretory n=2.  
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 Proliferative Secretory 
 PD PP L PD PP L 
CTRLs ­ ­ __ __ ­ __ 
Grade 
0 ­ ­­­ __ ­­ ­­­ __ 
Grade 
I-II ­­­ ­­­ ­­ ­­­ ­­­ ­­ 
Table  4-7 Summary table for intensity of PAR-2 staining with immunofluorescence. 
­: low intensity, ­­: medium intensity and ­­­: high intensity of fluorescence signal. 
 
4.4.4 Profiling of peritoneal fluid of women with and without 
endometriosis, identifying mast cells within the immune 
cell population. 
4.4.4.1 Experimental protocol for isolation of peritoneal fluid MCs 
Due to the limited literature on the quantification of mature mast cells by flow 
cytometry, the current investigation started with the optimization of a mast cell 
specific antibody panel for flow cytometry. Mast cells differentiate from the 
common leukocyte antigen positive cells (CD45+) as well as other immune cells, 
such as macrophages, granulocytes and lymphocytes. To accomplish an accurate 
quantification of mast cells within all the other CD45+ derived immune cells, it 
was necessary to establish exclusion criteria for the gating strategy, as shown in 
Figure 4-21. Mast cells were quantified by c-kit/FceRIa++ (Figure 4-21-G), when 
monocytes (CD14+), T and B lymphocytes (CD3+, CD19+), natural killer (CD56+), 
granulocytes (CD11b+) and macrophages (CD11b-HLADR++, CD163+) were 
excluded.  
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4.4.4.2 Analysis of MC populations in peritoneal fluids from women 
with or without endometriosis 
In addition to MCs, the percentage of macrophages was also analysed as there 
is the extensive evidence of their role in endometriosis (Bacci et al., 2009, Capobianco 
and Rovere-Querini, 2013), they were considered a useful comparator. 
MCs represented a small percentage of the total live CD45+ cells in the 
peritoneal fluid (median <0.2%), whilst macrophages accounted for a greater 
proportion at being between 10 and 20% of live CD45+ cells; there was considerable 
variation between individuals (Figure 4-22). Figure 4-22-A,B illustrates the frequency 
of MCs and macrophages in the peritoneal fluid from women not on hormonal 
treatments. The median percentage (middle line of box and whisker plot) of both 
macrophages and MCs did not change between control and pain/endometriosis groups.  
Figure 4-21 Representative gating strategy used during flow cytometry and sorting experiments on 
human peritoneal fluid isolated white cells.  
Mast cells belong to CD45+ population as well as B, T and NK cells, monocytes and macrophages. Thereby 
the gating strategy used for quantifying mast cells in the peritoneal fluid cell population during the current 
study, followed exclusion criteria. After size and doublets exclusion (A-B), cells were gated on CD45+ and 
dapi negative (C), CD3-19-56 (T-B-NK cells) and CD14 (monocytes) negative (D). For excluding 
macrophages, cells were gated on CD11b-HLADR negative (E) and CD163 negative (F). Finally, mast 
cells were identified using the unique combination of c-kit (CD117) and FceRIa antibodies, showed in 
panel G. These gates were then applied to all the subsequently analysed samples. 
A) B) C) D) 
F) G) E) 
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Interestingly, the distribution of values in the third quartile (values above the 
median) was higher in the minimal/mild endometriosis group (grade I-II) for 
macrophages and in the moderate/severe endometriosis group (grade III-IV) for MCs, 
although in neither case they did not reach statistical significance due to the wide 
variation between individuals. In peritoneal fluid of women undergoing hormonal 
therapy, macrophage and MC distribution showed a different pattern: the percentage 
of macrophages appeared to have a trend of non-significant increase in patient groups 
of grade 0 and grade I-II. In contrast, grade III-IV values were lower when compared 
to no pain controls, however not reaching statistical significance (Figure 4-22-C). MC 
median distribution remained unchanged between the difference groups (Figure 4-22-
D).  
Figure 4-22 Frequency of macrophages (HLADR-CD11b ++) and mast cells (c-kit-FceRIa ++) 
in live CD45+ cells from the peritoneal fluid isolated cells.  
Macrophages and mast cells were detectable in the peritoneal fluid (PF), macrophages 
represented a higher cell population compared to mast cells, in average 10% and 0.1% 
respectively. The median of distribution of both macrophages and mast cells did not change 
across the different groups. Interestingly, higher percentage of macrophages was detected in 
patients with chronic pelvic pain and minimal/mild endometriosis (A), and percentage of mast 
cells was higher in more severe endometriosis grades, such as III-IV (B). No pain controls n=4, 
grade 0 n=10, grade I-II n=9, grade III-IV n=4. Panel C showed a different pattern of macrophage 
frequency in the PF from women under hormonal therapy, an increase in group 0 and group I-II, 
although it did not reach statistical significance. 
A) B) 
C) D) 
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4.4.5 ELISA analysis of mast cell proteases and histamine in 
peritoneal fluid from women with pelvic pain and 
endometriosis 
Mast cell specific protease, tryptase and chymase were quantified in the 
peritoneal fluid from control, pelvic pain and endometriosis patient groups. Tryptase 
was detected at the median value of 1075.12 pg/ml in peritoneal fluid of the “no pain” 
control group (Figure 4-23-A); median values concentrations appeared lower in the 
pain group (grade 0), and in the minimal/mild (grade I-II) and moderate/severe 
endometriosis groups, but this was not statistically significant (Table 4-1). 
Concentrations of chymase remained unchanged between the different groups, with an 
median value of 461 pg/ml in the peritoneal fluid of control women (Table 4-1, Figure 
4-23-B). Moreover, the presence of histamine was also investigated in the peritoneal 
fluid samples. To complement the studies on MC granule-related mediators, 
concentrations of histamine (MCs and basophils) were measured. Histamine 
concentrations varied significantly between the different groups, being significantly 
lower in group 0 and groups III-IV compared with no pain controls (p<0.05, Figure 
4-23-C). 
Median pg/ml No Pain Ctrls Grade 0 Grade I-II Grade III-IV 
Tryptase 1075.12 122.83 737.33 727.33 
Chymase 461 434 454 188 
Histamine 151019 41634 44323 29941 
Table 4-1 Median values of protease and histamine concentrations in the peritoneal fluid. 
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Figure 4-23 Mast cell specific protease and 
histamine concentrations in peritoneal fluid (PF) 
from women with chronic pelvic pain 
with/without endometriosis.  
A) Tryptase concentrations in PF were not 
significantly affected by stage of disease, B) 
Chymase levels appeared to remain unchanged 
between the different groups. C) Histamine 
concentrations were signicantly reduced in women 
with pain (grade 0) and with moderate (grade III) 
and severe endometriosis (grade IV) compared to 
controls. Box and Whiskers plot, representation of 
minimum and maximum values; middle line 
represents the median value. One way ANOVA, 
Kruskal-Wallis post test, Dunn’s multicomparison 
test: *p<0.01. No pain controls n=4, tryptase: grade 
0 n=25, grade  I-II n=32, grade III-IV n=16; 
chymase: grade 0 n=13, grade I-II n=15, grade III-
IV n=1; histamine: grade n=21, grade I-II n=30, 
grade III-IV n=15. 
A) B) 
C) 
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4.5 Discussion 
Endometriosis is a chronic inflammatory disease characterized by the growth 
of endometrial-like lesions outside of the uterus, mainly in the peritoneal cavity 
(Giudice and Kao, 2004). The disease affects approximately 10–15% of women of a 
reproductive age (Simoens et al., 2012). Impairments in the decidualisation response, 
a transformation event that the stromal compartment of the endometrium must 
undertake to host pregnancy (Gellersen and Brosens, 2014), have often been reported 
in the eutopic endometrium of women with endometriosis (Wei et al., 2009). The 
leukocyte populations within the eutopic endometrium and ectopic lesions have been 
extensively described (Jones et al., 1998, Bacci et al., 2009, Braundmeier et al., 2012). 
These studies suggested that alterations in macrophages, T-cells and uterine natural 
killers might contribute to the pathology of the disease and its correlated infertility and 
chronic pelvic pain but less attention has been paid to the other immune cell subtypes.  
A few studies have reported MC infiltration into the peritoneum of women with 
endometriosis (Fujiwara et al., 2004, Kempuraj et al., 2004, Sugamata et al., 2005). 
However, MCs have not previously been investigated in the eutopic endometrium of 
women experiencing chronic pelvic and/or endometriosis. The current study is, to my 
knowledge, the first one to investigate the MC phenotype in the functional 
endometrium from women with pain and/or endometriosis. 
As demonstrated in the previous chapter, MCs are members of the uterine 
leukocyte population. Although, MCs do not appear to fluctuate in numbers during the 
menstrual cycle, and they are detectable in all the uterine compartments, from the 
myometrium to the functional endometrium. The largest numbers of MCs are detected 
in the myometrium and the basal endometrium and MCs are quite rare in the functional 
endometrium. In normal uterus, MCs have a tryptase/chymase phenotype (MCTC) in 
myometrium and basal endometrium, and tryptase only phenotype (MCT) in the 
functional endometrium, a finding in agreement with Jeziorska et al. (1995) and 
following the standard mast cell classification system based on their granule contents 
(Pejler et al., 2007). Furthermore, the rare MCC subtype represented a small number 
of resident uterine MCs, specifically it was detected in the basal endometrial and 
myometrial layers. 
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In the current study, immuno-profiling of the functional endometrium of 
women with chronic pain and of women with endometriosis detected MCs with MCTC 
or MCC phenotype, a result that was in contrast with the MC phenotype detected in 
control “no pain” control samples, and samples used during Chapter 3. This abnormal 
MC protease phenotype was also detected in two of the “no pain” control samples, 
3494 and 3498, in patients who suffered from asymptomatic endometriosis. I speculate 
that this altered endometrial MC phenotype is consistent with the concept of 
phenotypical plasticity of MCs (Galli et al., 2011), which stated that MCs can mature 
and adapt based on their surrounding microenvironment. The presence of MCTC and 
MCC is consistent with reports that the endometrial microenvironment is altered in 
women with endometriosis. Further, this finding might suggest the potential of 
invasiveness of the shed endometrium from women with endometriosis. It has been 
demonstrated that both tryptase and chymase can exert angiogenic effects. For 
example, it has been shown that tryptase may cause significant augmentation of 
capillary growth (Caughey et al., 1993, Blair et al., 1997). Chymase may to be a potent 
inductor of neovascularization via VEGF (Muramatsu et al., 2000a), an angiogenic 
mediator that has been demonstrated to be in high concentrations both in lesions and 
in the peritoneal fluid of women affected by endometriosis (Donnez et al., 1998, 
Young et al., 2015).  
High numbers of MCs has been reported to exist in endometriotic lesions 
(Matsuzaki et al., 1998a, Sugamata et al., 2005). Those studies only identified MCs 
using tryptase staining or toluidine blue dye. Missing from these results are any 
chymase positive cells and, by using the cationic dye on formalin fixed tissues they 
have also missed any MCs with a different composition of glycosilaminoglycans 
(strongly sulphated), which react differently with formalin fixation and so do not allow 
the cationic colour (toluidine blue) to enter the granules (Strobel et al., 1981, Wingren 
and Enerback, 1983). The current study is the first to have explored the MC phenotype 
in endometriotic lesions by considering both tryptase and chymase. Using double 
immunofluorescence MCTC cells were detected in peritoneum and lesions of women 
with endometriosis. Remarkably, the majority of MCs present in the endometriotic 
lesions were identified to be of the MCC phenotype, which would have been missed in 
previous studies. These findings suggest that the MCs in the lesions retain the 
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abnormal “endometrial” phenotype seen in these patients consistent with their origins 
being in endometriotic fragments that arrive in the peritoneum as a result of following 
after retrograde menstruation.  
There is increasing evidence from conditions such as interstitial cystitis and 
irritable bowel syndrome, that mast cells play a critical role in the pathogenesis of 
chronic and neuropathic pain (Heron, 2013, Chatterjea and Martinov, 2015). MCs can 
release mediators that increase excitability of neurons, due to their capacity to store 
neurotransmitters such as substance P or nerve growth factor (NGF) in their 
cytoplasmic granules (Wernersson and Pejler, 2014). Due to the fact that chronic 
pelvic pain is a frequent and debilitating symptom in women affected by 
endometriosis, the current study set out to explore the phenotype of MCs in the 
peritoneal wall, a predominant location for endometriotic lesion growth, angiogenesis 
and nerve sprouting (Arnold et al., 2012). 
Detailed analysis of human peritoneal biopsies conducted during this study has 
revealed that MCs are present in the peritoneal wall both in the recto-vaginal pocket 
(pouch of Douglas, “prone” site for endometriotic lesion formation) and in the frontal 
abdomen peritoneal wall (“distant” site from endometriotic lesion formation). This 
study is the first to report a substantial difference between samples from control and 
chronic pain/endometriosis patients. The pattern of immunoexpression of chymase in 
peritoneal sections was strikingly different between groups. Peritoneal MCs in control 
samples were MCC and appeared highly activated throughout the section, both in prone 
and distant peritoneum with intense extracellular chymase staining. In contrast, 
immunofluorescence on tissues from women of grade 0 (pain/no lesions) or grade I-
IV revealed a lower intensity of chymase staining, with the protease retained in the 
cytoplasm. Moreover, MCs appeared to have acquired a tryptase/chymase phenotype 
(MCTC) in the peritoneum “prone” samples from endometriosis group biopsies, again 
pointing to plasticity in response to an altered peritoneal environment.  
For the first time, this study has detected activated MCC cells in the peritoneal 
wall. It is well known that the peritoneal serous membrane permits the passive dialysis 
of significant quantities of substances between the peritoneal fluid and the blood 
plasma (Young et al., 2013). The intense immuno-expression of chymase might be 
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resulting in increased capillary dilation via its conversion product, angiotensin II 
(Batenburg et al., 2004), contributing to fluid exchange. Further, angiotensin II is 
detectable in peritoneal fluid during the menstrual cycle under normal conditions 
(Delbaere et al., 1996). Notably, preliminary findings suggested chymase also present 
in mesothelial cells, the epithelial-like monolayer interface between peritoneal 
membrane and fluid. This result supports the potential role of chymase during blood-
fluid dialysis. 
It has been reported that mesothelium damage, increased angiogenesis together 
with fibrosis in peritoneal compartments may result in a decrease in the number of 
MCs (Jimenez-Heffernan et al., 2006, Stavenuiter et al., 2011). The reduction in 
chymase expression in the peritoneum of women suffering of endometriosis would 
appear consistent with MC adaptation to the altered endometriosis-related peritoneal 
environment (Burney and Giudice, 2012). 
It is known that women affected by chronic pelvic pain and/or endometriosis 
show a central hyperalgesia (He et al., 2010). During the current study, both the 
number of MCs within the different groups and the concentrations of MC granule 
mediators in the peritoneal fluid were investigated. One potential source of mature 
MCs found in the peritoneal cavity could be the peritoneal fluid (Meurer et al., 2016). 
The current study established methods to quantifying the number of MCs in peritoneal 
fluid using flow cytometry. I found that the peritoneal fluid MCs represented a small 
portion of the total immune cell population, approximately 0.2% of live CD45+ cells, 
and their numbers appeared to remain constant between the different groups (no pain, 
grade 0, grade I-II), with a small but non significant increase in the percentage in the 
moderate/severe endometriosis group, which needs to be investigated in a larger group 
of patients. After isolation of the immune cells, the peritoneal fluid was also assayed 
for proteases and histamine content; no change between groups was detected for 
tryptase or chymase but histamine concentrations were significantly lower in fluids 
from women with pain and more severe endometriosis. This finding appears consistent 
with an increased sensitivity to pain of women affected by chronic pain and/or 
endometriosis, as low concentrations of MC neurogenic mediators, tryptase and 
histamine, may still trigger the abnormal nociception. 
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To provide a further link between MCs and pain pathways, PAR-2 a receptor 
expressed on primary afferent neurons that can play a role in neuronal sensitization, 
which can be activated by tryptase was also investigated (Compton et al., 2001, 
Hoogerwerf et al., 2001, Noorbakhsh et al., 2003). For the first time, PAR-2 was 
detected in the human peritoneum. PAR-2 immuno-expression was higher in 
peritoneal samples collected during the secretory phase compared to proliferative 
phase, suggesting an influence of sex hormones on PAR-2 expression. 
Notably, PAR-2 immuno-expression was reported to be of higher intensity in 
peritoneal biopsies from patients reporting chronic pelvic pain compared to controls 
whose were not attending the pain clinic. This observation may be explained by the 
different types of peritoneal biopsy, “prone” site corresponds to the cul-de-sac where 
the peritoneal fluid resides and is therefore, the primary location where effects of an 
altered environment would be detected. Remarkably, PAR-2 expression was much 
more intense in biopsies from women with pain and endometriosis and this was 
independent of the phase of menstrual cycle, and the location of the biopsy. Notably, 
PAR-2 immunoexpression was both increased and was detected in all the tissue 
samples, including the endometriotic lesions. Although, few MCs were localized 
within the sample tissue area. The findings brought new evidence consistent with 
neuronal sensitization in the peritoneum of women affected by endometriosis. 
In this study, one of the significant limitations was the small sample size of 'no 
pain' control patients. This patient category is becoming increasingly difficult to reach 
as laparoscopic practise for sterilisation is not often performed in the United Kingdom 
nowadays. Moreover, endometriosis can often be asymptomatic, and half of the 'no 
pain' control samples investigated were in fact affected by endometriosis. It was also 
challenging to overcome to the high variability within human patients, since it was not 
always possible to reach statistical power with the tissue resources available. 
Moreover, the stratification of patients and exclusion criteria employed during this 
study meant a high number of samples were not used. With these observations in mind, 
further studies should be planned. 
In summary, this is the first study to detect a different MC phenotype in eutopic 
endometrium from women affected by endometriosis, also present in the ectopic 
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lesions. The data also show that MCs are normally resident in the peritoneal wall, 
where they appear to be activated. In women with chronic pain and/or endometriosis, 
it appears that peritoneal wall MCs adapt their phenotype to the altered local micro-
environment, acquiring a MCTC phenotype. The presence of MCs in the peritoneal 
fluid was confirmed but their numbers and concentrations of tryptase and chymase did 
not change between cases of pelvic pain and/or endometriosis when compared to 
control samples. Women suffering from chronic pain and endometriosis present with 
a diffuse hyperalgesia, and the finding that PAR-2 protein was upregulated in these 
patient groups suggests a mechanism by which low concentrations of tryptase might 
still induce effects. Further studies are required to determine whether inhibition of 
PAR-2 might offer a therapeutic target in women with chronic pelvic pain.  
These results have elucidated the possible role of MCs in the endometriotic 
lesion formation and the establishment of chronic pain, offer a concrete platform for 
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Chapter 5  Exploring the use of in vitro and in 
vivo mast cell models 
5.1 Introduction 
Mast cells derive from CD34+/CD117+ pluripotent stem cells in the bone 
marrow. MC progenitors are recruited into peripheral tissue where they differentiate 
in situ (Metcalfe et al., 1997). The characteristics of mature human MCs are specific 
to the environment in which they mature and reside. MCs are present throughout the 
human body so they can vary considerably in morphology and granule content 
(Hoffmann, 2016).  
MCs are also present in human reproductive tissues, and they are thought to be 
key regulators for implantation, menstruation and labour (Menzies et al., 2011). As 
detailed in Chapter 3, during normal physiology, MCs reside in both myometrial and 
endometrial uterine compartments. The activation of uterine MCs appears to be 
menstrual cycle phase dependent, and it is thus possible that MCs respond to steroid 
hormone fluctuations due to their expression of oestrogen and glucocorticoid 
receptors. Furthermore, MCs have been reported to be involved in endometriosis. In 
Chapter 4, extensive investigation has provided evidence of environment adaptation 
and a phenotype alteration in MCs in tissue biopsies from women affected by chronic 
pelvic pain and endometriosis. These findings set the scene for further exploration on 
MC behaviour in physiological and pathological conditions using both in vitro and in 
vivo models. 
Few attempts have been made to isolate mature MCs from tissues, for example 
Kulka and Metcalfe (2001b) illustrated the isolation of mature human mast cells from 
skin biopsies, and Sperr et al. (1994) described the isolation of cardiac MCs. However, 
although it has been shown to be possible to isolate live mature MCs, issues may arise 
with both number and purity of the cells. MC phenotype can be also strongly 
influenced by the isolation techniques (Andersen et al., 2008). For this reason, both 
primary cultures of mast cells derived from stem cells and/or immortalised mast cell 
lines are typically used for the study of MC function in vitro.  
A role for mast cells in women’s health and disorders of the endometrium 
Chapter 5 – Exploring the use of in vitro and in vivo mast cell models 
 
162 
Several studies on MC biology have been accomplished using in vitro 
maturation of MC progenitors, such as CD34+ or CD133+ cells, which are typically 
isolated from peripheral blood or umbilical cord blood (Rådinger et al., 2010). At the 
end of an 8-week in vitro differentiation protocol as described by Kirschenbaum and 
Metcalfe (2006), peripheral blood-derived MCs appeared to be relatively mature, with 
a condensed non-segmented nucleus and numerous toluidine blue positive granules. 
Moreover, these mature blood-derived MCs have a tryptase/chymase phenotype 
(MCTC), in contrast to cord blood-derived MCs, which are relatively immature and 
chymase negative (Mitsui et al., 1993, Durand et al., 1994). Both PBMCs and CBMCs 
are functionally active; they can degranulate upon IgE-dependent and independent 
stimulation (Valent et al., 1992, Moon et al., 2003, Saini et al., 2009, Jensen et al., 
2014). 
However, because of the rarity of tissue MCs and the expense of the 
differentiation procedures used to mature, MC cell lines have been established and 
they are the most used in vitro models. The first MC line was derived by Butterfield et 
al (1988) who isolated MCs from a patient with MC leukaemia, and established the 
HMC-1 (Human Mast Cell-1) cell line. The HMC-1 was shown to have two point 
mutations in the c-kit receptor (Furitsu et al., 1993). The c-kit mutation means the 
HMC-1 cells remain in an undifferentiated state, with low granule content of tryptase 
and chymase (Nilsson et al., 1994a, Guhl et al., 2010).  
The importance of MCs in the aetiology of disorders such as asthma, has been 
explored in in vivo models, predominantly in the genetically modified animals. The c-
kit/SCF axis is vital for MC development, which has led to the extensive use of several 
strains of c-Kit/SCF mutant mice in MC research (Galli and Kitamura, 1987). The 
composite genotype KitW/KitW-v causes profound mast cell deficiency (Kitamura et al., 
1978), these animals are anaemic and also infertile. Thus, more widely used is a more 
recent MC deficient KitW-sh/KitW-sh strain (“sash”), as these animals do not present some 
of the more critical disadvantages that characterize the KitW/KitW-v strain (Lyon and 
Glenister, 1982). However, due to the important role of c-kit in the development of 
other immune cells, KitW-sh/W-sh mice are also deficient in neutrophils and T cells (Katz 
and Austen, 2011) which can complicate the interpretation of the role of MCs. KitW-
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sh/W-sh mice are described as “fertile”; however, “sash” colonies often present irregular 
birth rates and high natal and postnatal death rates. Further, KitW-sh/W-sh female mice 
display severely impaired implantation, although single females presented normal 
litter sizes (Zenclussen and Hammerling, 2015). 
Immune cells play important roles in reproduction (Salamonsen and Lathbury, 
2000) and the role of MCs has been studied in both wild type and genetically modified 
animal models (Menzies et al., 2012). In mice, MCs have been identified using 
toluidine blue staining in the uterus. Toluidine blue positive cells appear to vary in 
number through the different phases of the oestrus cycle, showing a peak during 
oestrus (fertile phase) and remaining high during early gestation (Woidacki et al., 
2013a, Woidacki et al., 2013b).  
The models described above offer the potential to be useful tools to investigate 
the contribution of MCs to health and disease of the endometrium, including processes 
physiologically and pathologically regulated by circulating sex steroid hormones, such 
as endometriosis (Critchley and Saunders, 2009, Burney and Giudice, 2012). Thereby, 
during the current study, a mouse model that efficiently recapitulates the endometriotic 
condition was employed, where syngeneic menstrual endometrial tissue was 
introduced into the peritoneum of immunocompetent recipient mice (Greaves et al., 
2014a). Whilst, MCs have been implicated in regulation of menstruation, due to their 
ability to secrete extracellular matrix proteases (Zhang et al., 1998), this role has not 
been explored using mouse models of menses, where key processes as tissue 
breakdown and remodelling are induced by administration of exogenous sex steroid 
hormones followed by progesterone withdrawal (Cousins et al., 2014).  
To complement and extend the studies on human tissues described in Chapter 3 
and 4, the studies in this chapter explored different methods currently available to 
investigate MC behaviours at baseline and under oestrogenic treatments using 
peripheral blood derived primary cells, the HMC-1 cell line and the in-house murine 
models of menstruation and endometriosis. 
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Mast cells are immune cells of the myeloid lineage, which are present in both 
mucosal and connective tissues throughout the body, including the endometrium. 
Their activation and degranulation notably regulates many aspects of physiological 
and pathological processes. Studies described elsewhere in this thesis have identified 
MCs in both normal uterine tissue and in endometriotic lesions and peritoneum. 
Notably, mature MCs expressed ERb and thus MCs may be a target for oestrogens.  
With these observations in mind, we hypothesised that MCs are able to respond 
to oestrogen action. The current investigation was designed to elucidate the phenotype 
of peripheral blood-derived MCs, the HMC-1 cell line and the mechanism of 
oestrogenic stimulation of the latter in vitro. Moreover, the potential role of MCs in 
murine models of menstruation and endometriosis was investigated for the first time. 
5.2 Aims of the Chapter 
1. To use in vitro cell model to determine whether the phenotype and function of 
MCs can be influenced by sex steroid hormones. 
2. To use mouse models of menstruation and endometriosis to investigate 
putative roles of MCs in the physiology and pathology of the endometrium. 
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5.3 Material and methods 
5.3.1 Peripheral blood derived-mast cell culture  
Peripheral blood, bone marrow and umbilical cord blood are the most common 
sources of CD34+ progenitor cells from which to differentiate MCs (Welker et al., 
2000, Kinoshita et al., 1999). For this study, we decided to isolate MC progenitors 
from peripheral blood under the LREC 08/S1103/38, held by MRC Centre for 
Inflammation Research, University of Edinburgh. 
5.3.2 Preparation of peripheral blood for CD34
+
 selection  
CD34+ pluripotent progenitor cells were collected from peripheral blood from 
female donors (24-47 age range), n=20. On average, peripheral blood contains 0.01–
0.1% CD34+ cells.  
Briefly, 50ml-polypropylene Falcon tubes (Fisher Scientific, UK) were 
preloaded with 4ml of sodium citrate (3.8% in H2O, Sigma Aldrich, UK). Samples 
(40ml to 80ml) of venipuncture-derived peripheral blood were collected from healthy 
donors. Each 10ml of peripheral blood and anti-coagulant solution was mixed with 
25ml of complete StemPro serum-free medium with nutrient supplement (Gibco, UK), 
2 mM L-glutamine, 100 IU/ml penicillin, and 50 µg/ml streptomycin (Life 
technologies, UK). This solution was layered onto 14ml of lymphocyte separation 
media (Histapaque, Sigma Aldrich, UK) and centrifuged at 675g for 20 minutes at 
room temperature. Following centrifugation, the red blood cells formed a layer below 
the separation media at the bottom of the tube, while mononuclear cells (cells of 
interest) were identified above the layer of separation media. Media above this layer 
was removed carefully before recovery of the monolayer cells. These recovered 
mononuclear cells were mixed with 25ml of complete StemPro media and centrifuged 
at 300g for 10 minutes to remove any debris. Following centrifugation, the supernatant 
was removed and the pellet of mononuclear cells resuspended in 25ml of StemPro 
serum-free complete medium. The aforementioned step was repeated twice. The final 
cell pellet was re-suspended in 1x phosphate buffered saline, pH 7.2 (PBS, Gibco, 
UK), containing 0.5% bovine serum albumin (BSA) (Sigma Aldrich, UK) and 2mM 
ethylene diamine tetra-acetic acid (EDTA, Gibco, UK) and cells were counted using a 
haemocytometer (Immune Systems, UK). 
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5.3.3 Magnetic labelling and magnetic separation  
The CD34+ MicroBead Kit contains MicroBeads conjugated to CD34 
antibodies for magnetic isolation of CD34-expressing cells from peripheral blood. In 
this study cells were labelled with the CD34+ MicroBead Kit from MACS Miltenyi 
Biotec, UK, which is designed to allow very high levels of CD34+ purity.  
The purified white blood cell suspension was centrifuged at 300g for 10 
minutes and the supernatant removed and the pellet re-suspended in 300 µl of PBS-
EDTA buffer (1x phosphate buffered saline (PBS) + 0.5% BSA + 2mM EDTA) and 
mixed with (FcR) Blocking Reagent and CD34+ MicroBeads (100µl each) and 
incubated for 30 minutes at 4°C. After incubation, cells were washed with 300 µl PBS-
EDTA buffer and centrifuged at 300g for 10 minutes. The supernatant was removed 
and the cells were re-suspended in 500µl of buffer. Magnetic separation was performed 
according manufacturer’s protocol using a mini MACS separator (Miltenyi Biotec, 
UK). The final cell number was recorded using a haemocytometer (Immune Systems, 
UK).  
5.3.4  Differentiation protocol  
The differentiation protocol of PBMCs employed during this study was 
described by Kirschenbaum and Metcalfe (2006). In detail, isolated CD34+ cells were 
cultured in serum-free complete culture media (Stem-Pro34® SFM, Gibco, Paisley, 
UK) containing recombinant human stem cell factor (rhSCF), recombinant human 
interleukin 6 (rhIL-6), and recombinant human interleukin 3 (rhIL-3, supplemented to 
the media only for first week) (Figure 5-1-A); rhSCF, rhIL-6 and rhIL-3 purchased 
from Peprotech, London, UK). Hemidepletion was performed weekly, by removing 
adherent cells and debris. The cell suspension, containing differentiating mast cells, 
was centrifuged at 150g for 5 minutes. The cell pellet was then resuspended in 25ml 
of fresh complete StemPro media with rhIL-6 and rhSCF. Differentiation of MCs 
within the cultures was assessed weekly using acidic toluidine blue staining (TB: 0.1% 
toluidine blue, Scientific Laboratory Supplies, East Riding, UK; in 0.5N HCl, Sigma 
Aldrich, Dorset, UK). Cells were isolated using a cytospin method at 300rpm for 3 
minutes (Cytospin2, Shandon, ThermoScientific, Paisley, UK). They were 
subsequently fixed in Carnoy’s for 1 hour (60% absolute alcohol, VWR Prolabo, UK, 
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30% chloroform and 10% acetic acid, Sigma Aldrich, UK), incubated in 70% ethanol 
and then stained in acidic toluidine blue for 45 minutes before air-drying overnight. 
Slides underwent 95% alcohol dehydration before mounting with Permafluor 
(ThermoFisher Scientific, UK). A complete differentiation (95-100% of mature MCs, 
Figure 5-1-B) was achieved over a 810-week culture period (Kirshenbaum and 
Metcalfe, 2006).  
5.3.5 Human mast cell (HMC-1) cell culture 
The human mast cell line, HMC-1, was originally established in 1988 using 
cells recovered from the peripheral blood of a patient with mast cell leukaemia 
(Butterfield et al., 1988). This cell line has been used extensively for in vitro studies 
of human mast cell behaviour (Kitayama et al., 1993, Nilsson et al., 1994a). An aliquot 
of HMC-1 cells was generously gifted by Dr Butterfield allowing me to conduct in 
vitro mast cell investigations described in this chapter. 
HMC-1 cells were cultured at a density of 4x105 cells/ml in Iscove’s Medium 
containing phenol red as a pH indicator (IMDM, with 25mM 4-(2-hydoxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 3.024g/l sodium bicarbonate buffer, 4mM L-
glutamine; ThermoFisher Scientific, UK) with 10% iron-supplemented calf serum 
Figure 5-1 Summary of protocol used to derive human mast cells derived from CD34+ peripheral blood 
progenitors  
A) Weekly interleukins addition, B) Percentage of expected mast cells, C) Toluidine blue staining for 
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(Hyclone, USA), 1.2mM α-thioglicerol (Sigma Aldrich, UK) and 10ml/l 
penicillin/streptomycin (10,000 units of penicillin and 10 mg streptomycin per every 
10ml of culture media, (Sigma Aldrich, UK). Cells were incubated at 37°C with 5% 
CO2 (Heraerus, HERACell 150, ThermoFisher Scientific, UK). HMC-1 cells were 
seeded at an optimal concentration of 4x105 cells/ml for cell expansion once a week. 
5.3.6 Oestradiol treatment 
To avoid exposure to oestrogens during culture, HMC-1 cells were seeded at 
105 cells/ml in phenol red–free complete (white) Iscove’s Medium (ThermoFisher 
Scientific, UK) containing steroid-stripped foetal calf serum (FCS, Life Technology, 
UK) and 10,000 units of penicillin and 10 mg streptomycin per every 10ml of culture 
media, Sigma Aldrich, UK). After 72 hours in this white “complete” medium, cells 
were collected, centrifuged for 5 minutes at 800 rpm, acceleration and brake 9/10 
(MSE Centrifuges, Mistral 3000i, UK) at room temperature. The supernatant was 
discarded and the cell pellet resuspended in a small volume (approximately 200µl) of 
serum free white IMDM with antibiotics (as above); 10µl of this cell suspension were 
mixed 1:1 with trypan blue (Invitrogen, UK), and the HMC-1 cells were counted with 
the Countessa Ô (Invitrogen, UK). After counting, cells were seeded at 105 cells/ml in 
serum-free IMDM for 16h before treatments. 
17b-oestradiol and fulvestrant (E2: Sigma Aldrich, UK; fulvestrant or ICI: 
Tocris, UK) were dissolved into dimethyl sulfoxide (DMSO, Sigma Aldrich, UK) to 
form stock concentrations of 10-2 M. Working stock solutions were made in sterile 
PBS without Ca2+ and Mg2+ (Invitrogen, UK) to the 10-4 M for E2 and 10-5 M for ICI. 
Final concentrations (in well) used were at 10-7 M and 10-8 M for E2 and 10-6 M ICI. 
Cells were pre-treated for 1 hour with ICI 10-6 M before conducting the experiment, 
for allowing full antagonism for both ER isoforms (Osborne et al., 2004). 
 
5.3.7 RNA extraction from primary cells and cell lines 
The differentiating CD34+ progenitor cells and HMC-1 cell line used in this 
study were grown in suspension (differentiation protocol for CD34+ progenitor cells: 
Section 5.3.4 and HMC-1 cell line: Section 5.3.5), cultures were centrifuged for 5 
minutes at 800rpm (MSE Centrifuges, Mistral 3000i, UK) at RT before proceeding 
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with RNA extraction. The conditioned media was removed and cells were resuspended 
and lysed with 350µl PureLink Lysis buffer with RNA carrier and  1% b-
mercaptoethanol (Sigma-Aldrich, UK) for primary cells (concentration <106 cells) and 
with 350µl RNase Lysis Buffer (RLT, Qiagen, UK) with 1% b-mercaptoethanol for 
samples with >106 cells. For homogenization, the cell lysate was transferred into a 
QIAshredder spin column (Qiagen, UK). QIAshredder columns were centrifuged for 
2 minutes at 12,000g at RT. An equal volume (350µl) of 70% ethanol was added to 
each sample, the solution from HMC-1 samples was then pipetted into a RNeasy spin 
column and the solution from primary differentiated mast cells was added to a 
PureLink spin column. RNA extraction protocol was carried out by following the steps 
described in Section 2.2.1. 
5.3.8 Preparation of cDNA 
Reverse transcription of RNA was performed as described in Section 2.3. 
5.3.9 Quantitative Real Time PCR (Taqmanâ method) 
The Taqmanâ method of polymerase chain reaction (PCR) was used for this 
study, according to principles and reagents in Section 2.4; probes and primers are 
detailed in Table 2.2. 
5.3.9.1 Relative mRNA expression and statistical analysis 
PCR analysis was conducted by using the standard curve method (Section 
2.4.2) and compared to concentrations of mRNAs in week1 undifferentiated CD34+ 
mRNA for primary cells or the Ishikawa cell line (European Collection of Cell Culture, 
ECACC n.99040201, UK) as control mRNA for HMC-1. 
Statistical analysis was carried out using GraphPad Prism 6.0 (GraphPad 
Software, USA). Data are presented as mean ± standard error. For two group analysis, 
an unpaired two-tailed t-test was used, with Mann-Whitney post-test. One-way 
ANOVA was further used for multiple group comparison, followed by Kruskal-Wallis 
as a secondary test and Dunn’s multiple comparisons test. Criterion for significance 
was p<0.05. 
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5.3.10 Separation of DNA in polyacrylamide gels 
DNA separation was carried out using polyacrylamide gels as described in 
Section 2.4.3. 
5.3.11 Protein extraction from primary blood-derived mast 
cells 
Proteins were extracted from PBMCs following the application of the 
differentiation protocol, in Section 5.3.4. All cells (concentration was not assessed due 
to limited cell number at the end of differentiation protocol) were collected into a 1.5 
ml microcentrifuge tube and centrifuged at 800rpm for 5 minutes at RT (MSE 
Centrifuges, Mistral 3000i, UK). Cell media was discarded and the cell pellet was 
washed with ice cold PBS. After centrifugation cells were lysed using 350µl of our 
laboratory adapted RIPA buffer (Table 5-1). The resulting lysate was vortexed and 
centrifuged for 10 minutes at 13,000g at 4°C to eliminate cellular debris. The 
supernatant containing total protein extract was transferred to a fresh pre-chilled 1.5ml 
microcentrifuge tube and stored at -80°C until further use. 
Reagents – Stock concentration Final concentration 
Tris pH 7.5 1M (Sigma-Aldrich, 252859) 50mM 
EDTA pH 8.5 0.5M (Sigma-Aldrich, E5134-500g) 5mM 
NaCl 1M (Sigma-Aldrich, S3014-500G) 150mM 
Triton-X (Sigma-Aldrich, T8787) 1% 
Aprotinin  (protease inhibitor; Sigma-Aldrich, 
10981532001) 2µg/ml 
Halt Protease Inhibitor Cocktail (x100; ThermoFisher 
Scientific, 87786) 1x 
Table 5-1 Saunders laboratory adapted RIPA buffer for protein extraction.  
 
5.3.12 Extraction of nuclear and cytoplasmic fractions from 
the human mast cell-cell line (HMC-1) 
In this study, some proteins of interest were present in the nuclei; therefore 
separation of the nuclear and cytoplasmic fractions was undertaken for a more robust 
quantification. Nuclear extraction was performed using the Active Motif kit (40010, 
Active Motif, La Hulpe, Belgium). The manufacturer’s instructions were followed 
throughout the protocol; buffers are as described in Table 5-2. 
For preparation of nuclear extracts, 8.8x106 cells were resuspended in 3ml ice 
cold PBS containing phosphatase inhibitors (Table 5-2). Samples were centrifuged for 
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5 minutes at 200g at 4°C. The supernatant was discarded and the cell pellet was gently 
resuspended in 500µl of 1x hypotonic buffer (Table 5-2), transferred into a pre-chilled 
1.5ml microcentrifuge tube and kept on ice for 15 minutes. The addition of hypotonic 
buffer together with 25µl of detergent caused the cell membranes to swell thereby 
releasing cytoplasmic protein into the supernatant. The samples were then centrifuged 
at 14,000g for 30 seconds at 4°C, to separate the intact nuclei from the ruptured 
cytoplasmic membranes and the cytoplasmic proteins. Supernatant containing the 
cytoplasmic fraction was transferred and stored at -80°C until further use. The nuclear 
pellet was resuspended in 50µl of complete lysis buffer (Table 5-2) with 2.5µl of 
Active Motif detergent and mixed by vigorously pipetting up and down to disrupt cell 
nuclei and facilitate solubilisation of membrane-associated nuclear proteins. Due to 
the formation of a very viscous pellet, high speed vortexing for 10 seconds was 
required before proceeding to the following step. The nuclear suspension was 
incubated on wet ice for 30 minutes on a rocking platform set at 3g/min (Heidolph 
Polymax 2040, Schwabach, Germany). Samples were vigorously vortexed then 
centrifuged at 14,000g for 10 minutes at 4°C, to separate nuclear proteins from nuclear 
membrane residues. The resultant nuclear fraction was stored at -80°C prior to further 
analysis. 
Reagent Components Volume needed for 8.8x106 cells 
PBS/Phosphatase Inhibitors 
10x PBS 0.8 ml 
Distilled water 6.8 ml 
Phosphatase Inhibitors 0.4 ml 
Volume required 8 ml 
1x Hypotonic buffer 
10x Hypotonic buffer 50 µl 
Distilled water 450 µl 
Volume required 500 µl 
Complete lysis buffer 
10 nM DTT 5 µl 
Lysis Buffer AMI 44.5 µl 
Protease Inhibitor Cocktail 0.5 µl 
Volume required 50 µl 
Detergent Volume required 27.5 µl 
Table 5-2 Active Motif buffers recipes used for nuclear and cytoplasmic fraction extraction. 
 
5.3.13 Western Blotting  
Western blotting (WB) is an analytical technique used to quantify proteins in 
biological samples and it is dependent on the specificity of the interaction between the 
protein of interest and an antibody. Western blotting relies on specific antibodies 
binding to proteins that have been separated based on size by gel electrophoresis and 
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then transferred onto a membrane made of nitrocellulose or polyvinylidene fluoride 
(PVDF). In this study, PVDF membranes were used. After electrophoresis, the gel was 
placed directly onto the membrane and proteins were transferred from the gel onto the 
membrane by application of an electrical current. The membrane was then processed 
as described in details in section 5.3.13.1. 
Protein samples were placed on ice, before mixing with NuPage® LDS sample 
buffer (ThermoFisher Scientific, UK) and the NuPage® reducing agent (ThermoFisher 
Scientific, UK); concentrations and the final volume are detailed in Table 5-3. Sample 
preparation is used to break protein disulphide proteins bonds releasing secondary 
structure and maintaining the proteins in a denatured state for electrophoresis. Lithium 
dodecyl sulphate (LDS), present in the sample buffer, together with DTT (reducing 
agent), facilitates protein bond breakage. Samples were heat-denatured at 70°C for 10 
minutes on a hot dry block and placed on ice until loading into individual wells on the 
polyacrylamide gel. 
Reagents Final Concentration/Volume 
NuPage LDS sample buffer (4x) 1x 
NuPage reducing agent (10x) 1x 
Deionized water Based on protein volume 
Protein sample 30-40µg per well 
Total volume 37µl – 10 well comb, 1mm thick gel 25µl – 15 well comb, , 1mm thick gel 
Table 5-3 Protein samples preparation recipe for NuPage® gel loading. 
 
NuPage® Novex Bis-Tris Precast polyacrylamide gels (4%-12%; Life 
Technologies, UK) were fitted in a XCell SureLock™ Mini-Cell (ThermoFisher 
Scientific, UK) gel tank, filled with 1X NuPAGE® MOPS SDS Running Buffer 
(ThermoFisher Scientific, UK). NuPAGE Antioxidant (500µl, ThermoFisher 
Scientific, UK) was added to the running buffer in the upper (cathode) chamber 
allowing the antioxidant to migrate with reduced proteins, to maintain reducing 
conditions and prevent reoxidation of amino acids. 
The protein samples were added (volume dependent on gel type, as described 
in Table 5-3) to the wells together with the tracking dye, the Chameleon SeeBlue® 
Plus 2 pre-stained molecular weight markers (Life Technologies, LC5925, UK) using 
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gel loading pipette tips (Alpha Laboratories, GL20037NTRS, UK). The gel tank was 
run at 200V for 50 minutes with an expected current between 60-70mA. 
5.3.13.1 Semi-dry electrophoretic protein transfer  
Once electrophoresis was complete, the gels were transferred using the semi-
dry electrophoretic transfer method. Firstly, the gel was equilibrated in 1x Transfer 
Buffer (Table 5-4) for 15 minutes to remove electrophoresis buffer salts and 
detergents. The Immobilon®-FL membrane (Millipore IPFL00010, UK) was pre-cut 
to the dimensions of the gel and soaked in methanol for 15 seconds for equilibration. 
The membrane used during this study, was made of polyvinylidene fluoride (PVDF). 
PVDF membranes have very low auto-fluorescence across a wide range of 
excitation/emission wavelengths, making then ideal for fluorescence-based immune 
detection.  
Six sheets of Whatman 3 mm Chr filter paper (Sigma Aldrich, UK) per gel 
together with the membrane were soaked in 1x Transfer buffer for 5 minutes (recipe 
in Table 5-4). Three sheets of Whatman paper were placed on the anode plate of a 
Trans-Blot SD semi-dry electrophoretic transfer cell (BioRad 1703940, UK), followed 
by the membrane and three filter papers. Air bubbles were removed before performing 
the transfer. The semi-dry transfer took place at 14V for 90 minutes. 
Western Transfer Buffer (10X) 
Tris 30.28g 250mM 
Glycine 144g 1.92M 
SDS 1g 0.1% 
Distilled water added to 1 litre. For 1x 20% methanol was added 
Table 5-4 Western Blot Transfer buffer composition 
 
5.3.13.2 Antigen blocking and antibody incubation 
The membrane was washed three times with 1x PBS and blocked to avoid non-
specific binding of the antibodies, after transfer was completed. The Odyssey blocking 
buffer (at 1:1 dilution in 1xPBS, LiCor P/N 928-40000, UK) was used to reduce non-
specific binding as it contains a mix of non-mammalian proteins dissolved in Tris. The 
membrane was incubated with the aforementioned blocking buffer for one hour at 
room temperature on a shaker. The membrane was then incubated with the primary 
antibody diluted in the blocking buffer, see Table 5-4, with the addition of 0.1% 
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Tween-20 overnight at 4°C on a shaker. For quantification purposes, the addition of a 
second primary antibody that recognises an endogenous protein control was required. 
Primary antibodies used for WB studies are illustrated in Table 5-5. 
Antibody Species Clone and Supplier Concentration Dilution used 
ERa Mouse ER6F11 - Vector Laboratories 7.5mg/ml 1:20 
ERb Mouse PPG5/10 - AbSerotec 1.0mg/ml 1:20 
PCNA Rabbit FL-261 - Santacruz 20mg/ml 1:500 
b-Actin Rabbit Abcam 10mg/ml 1:500 
Table 5-5 Primary antibodies used for detection of human cell extracts during Western Blotting 
protocol. 
 
5.3.13.3 Secondary antibody detection 
After primary antibody incubation, the membrane was washed three times with 
0.1% Tween-20 in PBS at room temperature on a shaker followed by incubation with 
the secondary antibody diluted in blocking buffer + 0.1% Tween-20 for 1 hour at RT 
on a shaker. The secondary antibodies used (Infra-Red Dye secondary antibodies, 
LiCor Biotechnology, UK) were conjugated with a fluorescent dye as illustrated in 
Table 5-6. 


















10mg/ml 1:10000 680CW Green 
Table 5-6 Conjugated secondary antibodies used during Western blotting. 
 
Two secondary antibodies were added at the same time to the buffer; to enable 
detection of both the protein of interest and the endogenous control protein. They were 
raised in different species and conjugated to different fluorochromes with separate 
excitation and emission spectra to avoid cross-reactivity. The membrane was washed 
four times with 0.1% Tween-20 in PBS at RT on a shaker. It was covered in 1xPBS to 
prevent it drying out before performing the scan with a LiCor detection system (LiCor, 
Odyssey CLx, UK).  
5.3.14 Immunocytofluorescence 
Protein localization in cells cultured in vitro was achieved by fluorescent 
immunocytochemistry. Cells from the human mast cell line (HMC-1, Section 5.3.5) 
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were centrifuged at a concentration of 104 cells/100µl onto uncharged slides (VWR 
Collection, UK) at 300 rpm for 3 minutes using a cytospin centrifuge (Cytospin2, 
Shandon, ThermoScientific, UK). Slides were washed in 1x PBS and cells were fixed 
with ice cold methanol (VWR Prolabo, UK) for 20 minutes at -20°C. Endogenous 
peroxidase was blocked with methanol containing 0.15% H2O2 for 15 minutes at RT. 
Slides were then washed with tap water followed by TBS for 5 minutes each. Detection 
of cytoplasmic or nuclear antigens required a permeabilisation step, which was 
accomplished by using a permeabilisation solution comprised of 0.2% Triton-X 
(Sigma Aldrich, UK), 5% NGS and 1% BSA in 1x PBS. The permeabilisation solution 
was applied for 20 minutes at RT in a humidity chamber. The same solution was used 
as the diluent for primary antibodies which were incubated overnight at 4°C.. The 
following steps for detection of protein are as described in immunofluorescence 
sections 2.5.11. 
5.3.15 Enzyme-linked Immunosorbent Assay 
5.3.15.1 Human tryptase ELISA 
The non-competitive ELISA, SEB070Hu for tryptase (Cloud-Clone Corp., 
USA) was used for quantifying levels of tryptase in the culture medium of HMC-1. 
Details of the protocol are described in Chapter 2, Section 2.6.  
5.3.15.2 Mouse tryptase (MCP-6) and chymase (MCP-5) ELISAs 
Non-competitive “sandwich” ELISA kits were also used for animal studies: 
CSB-EL024128MO for tryptase beta-2 and CSB-EL005599MO for chymase (Cusabio 
Life Science, China). Standards were respectively: tryptase 5000pg/ml to 78pg/ml 
(5000, 2500, 1250, 625, 312, 156, 78 pg/ml) and chymase 10 ng/ml to 0.56 ng/ml (10, 
5, 2.5, 1.25, 0.625,0.312, 0.156 ng/ml). 
The protocol was performed by following manufacturer’s instructions. Capture 
antibodies were pre-coated onto microplates. Standards, samples and blank were 
pipetted into the wells; plates were incubated for 2 hours at 37°C. After removing any 
unbound substances, a biotin-conjugated antibody specific for tryptase or chymase was 
added to the wells (100µl of 1x biotin-antibody) and incubated for 1 hour at 37°C. 
After washing (3x with ELISA kit washing buffer), 100µl of avidin conjugated-HRP 
was added to the wells, and the plate was re-incubated at 37°C for 1 hour. Following 
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3 washes to remove any unbound avidin-enzyme reagent, 90µl of TMB substrate 
solution was added to each well and colour developed in proportion to the amount of 
tryptase or chymase bound in the initial step. The colour development was stopped 
after 15-30 minutes by adding 50µl of stop solution to each well and the intensity of 
the colour is measured, as described in Section 4.3.9.1. 
5.4 Studies using mouse models 
All animal procedures were performed according to the Home Office Animals 
(Scientific procedures) Act 1986, under Professor Saunders project licence number 
PPL 60/4208 and under the personal licence number PIL I3FD3D49F. 
Wild type C57BL/6J mice were either supplied by the University of Edinburgh 
Central Biological Services from in-house breeding stock or they were purchased from 
Charles Rivers Laboratories (Charles Rivers Laboratories International, UK). 
Mice were housed in standard conditions, with food and water ad libitum and a 
light/dark cycle of 12 hours, under controlled temperature. 
5.4.1 Collection of mouse tissues and peritoneal lavage  
Cycling female C57BL/6J and animals undergoing the menstruation or 
endometriosis model protocols (Section 5.4.3 and 5.4.4) were sacrificed by 
asphyxiation using increasing levels of carbon dioxide (CO2). Uterine horns and 
peritonea were dissected and fixed in Carnoy’s for 6 hours before being embedded in 
paraffin, sectioned and used to localize MCs using toluidine blue staining. 
5.4.2 Oestrus cycle assessment in cycling animals 
 Uteri from adult female mice were collected for spatial and temporal evaluation 
of MC numbers. Female C57BL/6J mice were sacrificed by asphyxiation using 
increasing levels of carbon dioxide (CO2); 1ml PBS flushes of the vaginal secretions 
were carried out on each mouse and pipetted onto individual uncharged glass slides 
and allowed to air-dry overnight. Vaginal cells were fixed in ice cold methanol for 20 
minutes, placed in Harris’ haematoxylin for 30 seconds, in Scott’s tap water for 30 
seconds and eosin for 2 seconds, washed in tap water between the steps.  
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The stage of the cycle was determined using a bright field microscope by two 
independent observers. The four stages of the oestrus cycle are characterised by the 
presence or absence of immune cells and the shape of the epithelial cells as shown in 
Figure 5-2. At the time of cull, uterine horns were dissected and fixed in Carnoy’s for 
6 hours before paraffin embedding followed by toluidine blue staining (Section 5.4.5). 
5.4.3 Mouse model of menstruation 
 The mouse model of menstruation used during this study followed the protocol 
adapted in house and published by Cousins et al. (2014). In this study uterine tissues 
were retrieved from mice 24h and 48h after removal of progesterone pellets. A 
summary of the protocol is shown in Figure 5-3 and it is described in detail in the 
following sections. 
  
Figure 5-2 Cytological appearance of 
vaginal smears during different 
phases of the oestrus cycle.  
A-B-C) Images represent the visual 
tool to assess stage of oestrus cycle in 
mice. A-B) show the different nuclear 
and cellular shape of epithelial cells. 
C) illustrates the presence of immune 
cells, such leukocytes. During the first 
phase, the proestrus (D) cells present 
in the smear are mainly rounded and 
nucleated epithelial cells, which 
transformed into cornified squamous 
cells during oestrus (E). Influx of 
immune cells starts during metestrus 
phase (F) and the ratio of immune 
cells to epithelial cells increases 
during diestrus (G). Black arrows 
indicate leukocytes, white arrows 
point nucleated epithelial cells, and 
black arrowheads show cornified 
squamous epithelial cells. Images 
taken from McLean et al. (2012). 
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5.4.3.1 Preparation of oestrogen for subcutaneous injection 
Two E2 stock solutions were prepared; a 1mg/ml stock solution and a 50µg/ml 
stock solution, using crystallised E2 (E8875, Sigma-Aldrich, UK) and absolute ethanol 
(VWR Prolabo, UK). Final working solutions of 1µg/ml and 50ng/ml were prepared 
using a 1:1000 dilution of stock solutions in sesame seed oil (S3547, Sigma Aldrich, 
UK). Solutions were protected from light and left on the roller overnight at RT to allow 
complete solubilisation of E2. 
5.4.3.2 Preparation of progesterone silastic pellets 
Rubber tubing (Silastic tubing Cat #508-008, 1.57mm I.D x 3.18mm OD, Dow 
Corning, UK) was washed in 70% ethanol and rinsed in distilled water, air dried before 
cutting into 1.5 cm pieces. One end of the 1.5cm tubes was sealed using adhesive 
sealant (Dow Corning, UK), and then filled with crystalline P4 (Sigma Aldrich, Dorset, 
UK) and sealed on the other side. 
P4 pellets were equilibrated for 48h prior to insertion, by soaking them in 1% 
charcoal stripped foetal calf serum (CSFCS, ThermoFisher Scientific, UK) in PBS at 
37°C. 
Figure 5-3 Overview of the Edinburgh mouse model of menstruation (Cousins et al., 2014). 
Endogenous ovarian hormones were reduced by bilateral ovariectomy at day 0. After 7 days of 
recovery, animals were injected with E2, to mimic the E2 dominated human proliferative phase (E2 at 
100ng/100µl dose was repeated daily, for a total of 3 days, until day 9). At day 13, to mimic the human 
secretory phase, animals reduced injections of E2 (5ng/100µl daily, for 3 days) and a silastic mini 
pump of P4 was inserted under the skin at the neck site. Decidualisation was induced by a mechanical 
stimulus, 20µl sesame oil delivery into the uterine lumen via cervix. P4 withdrawal was induced by P4 
pellet removal at day 19. Samples were then collected 24h and 48h after P4 withdrawal (day 20 and 
21, respectively). OVEX: ovariectomy, E2: 17β-oestradiol, P4: progesterone. The 17β-oestradiol 
concentrations are reported in brackets. 
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5.4.3.3 Mouse model of menstruation protocol (Figure 5-3) 
Briefly at start of the protocol (day 0), 8-10 week old female C57BL/6J mice 
were ovariectomised by dorsal bilateral ovariectomy under isofluorane-induced 
anaesthesia (Isofluorane-Vetä, Merial Animal Health, UK). Mice received an 
injection of 0.1ml of sterile saline and a dose of the analgesic, buprenorphine 
(Vetergesic, 0.1mg/kg, Alstoe Animal Health, UK) for pain management at the time 
of surgery. A 7-day recovery period was needed to complete depletion of endogenous 
ovarian derived hormones before starting the protocol. On days 7, 8 and 9, mice 
received sub-cutaneous injections (0.1ml) of β-oestradiol (E2) in sesame seed oil 
(1µg/ml, oestradiol and sesame oil purchased by Sigma Aldrich, UK), resulting in a 
final dose of 100ng/mouse. This stimulated cell proliferation and simulated the human 
proliferative phase. At day 13 of the protocol, mice were anaesthetised under 
isofluorane and progesterone (P4) secreting pellets were inserted sub-cutaneously 
(neck site), to simulate secretion of progesterone by the corpus luteum in women 
following ovulation. On days 13, 14 and 15 mice also received sub-cutaneous 
injections (0.1ml) of E2 in sesame seed oil (50ng/ml) daily, resulting in a final dose of 
5ng/mouse. To induce endometrial decidualisation on day 15, mice were anaesthetised 
as above and a single embryo transfer device (NSets, Paratech, USA) was used to inject 
20µl of sesame seed oil trans-vaginally via the cervix into the uterine lumen of one 
horn. The contra-lateral horn remained untreated and was used as an internal control.  
P4 withdrawal was induced by progesterone pellet removal at 90 hours after oil 
injection (morning of day 19). Animals were culled by asphyxiation using increasing 
levels of CO2 gas at 24h or 48h after removal of P4 pellet (day 20-21). Uteri were 
collected, separated from the surrounding fat layer and then weighed. Weight was used 
to complement visual inspection for assessing whether the decidualisation response 
had been robust. Tissues were placed in Carnoy’s for 6-hour fixation prior to paraffin 
embedding according to standard protocols. 
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5.4.4 Mouse model of endometriosis 
 The mouse model of endometriosis used during this study followed the 
protocol established in house and published by Greaves et al. (2014a). Dr Greaves 
generously shared tissue samples she had generated using the mouse model to reduce 
the number of mice used during these studies. Briefly (Figure 5-4), menstruation was 
induced in adult donor mice (approximately 8 weeks of age) using the protocol detailed 
above (Section 5.4.3). The decidualized horn was recovered from donor mice culled 
on day 19, 4-6 hours after P4 withdrawal (induced by pellet removal). Endometrial 
tissue was collected by scraping it away from the myometrium using a scalpel.  
The tissue mass was prepared for intra-peritoneal injection by suspension in 
200µl of sterile PBS (ThermoFisher Scientific, UK) and homogenised through a 19-
gauge needle (BD Scientific, UK). This tissue suspension was then injected into 
anesthetized recipient mice (6-8 weeks of age). Recipient animals were 
ovariectomized at the same time as the donor, and they received an E2 implant (Sigma 
Aldrich, UK; silastic implant: Dow Corning, UK) on day 7 of the protocol. The E2 
Figure 5-4 Endometriosis model timeline, protocol for donor and recipient females. 
(A) Overview of the procotol that both donor and recipient animals underwent. For the donor group, it 
is illustrated above of the bar and followed the previous protocol. On day 19, donor animals were 
sacrificed 4-6 hours after P4 removal and “donor” endometrial tissue was collected for i.p. injection into 
recipients. Recipients underwent ovx at the same time as donors, an E2 implant was inserted at day 7, 
and they received by i.p. injection the decidualized material at day 19. (B) Decidualized uterine donor 
material, (C) endometrial tissue suspension for intraperitoneal injection (D) and location of 
endometriotic lesions at the time of tissue harvest. Image taken from Greaves et al. (2014a). 
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implant was prepared in the same way as the P4 pellet, described in Section 5.4.3.2. 
Three weeks after i.p. injection, recipient mice were sacrificed. Peritoneal lavages 
were performed by injecting 2ml of sterile PBS into the peritoneal cavity to collect 
immune cells before tissue dissection. The uterine horns and peritoneal wall were fixed 
in Carnoy’s for 6 hours, before performing toluidine blue staining. Peritoneal lavages 
were kept at 4°C, centrifuged at 900g for 10 minutes at 4°C and the supernatant 
solution was pipetted off and stored at -80°C for analysis by ELISA. Cell pellets were 
incubated in the dark with 5ml of 1x diluted RBC buffer for a maximum of 15 minutes 
(BioLegend, USA). They were centrifuged for 5 minutes at 350g at room temperature 
(RT). The supernatant containing the lysed red blood cells was discarded. The white 
blood cell pellet was re-suspended in 1ml of freezing medium (RPMI, ThermoFisher, 
UK, with 10% dimethyl sulfoxide, DMSO, Sigma Aldrich, UK) and stored at –80°C 
until flow cytometry analysis (Section 2.7). 
5.4.5 Toluidine blue staining for murine mast cell localization 
Uteri and peritoneal tissue samples from mice were fixed in Carnoy’s for 6 hours 
before placing them in 70% alcohol and embedding them in paraffin (this was 
performed by the “Shared University Research Facility”, SURF Histology team, 
University of Edinburgh). Paraffin blocks were sectioned using standard methods and 
5µm sections were stained with 0.1% toluidine blue (Scientific Laboratory Supplies, 
East Riding, UK) in 0.5N HCl (Sigma Aldrich, UK) overnight and counterstained with 
water based-eosin for 2 seconds (ThermoFisher Scientific, UK). Slides were mounted 
with Permaflour (ThermoFisher Scientific, UK) and sealed with coverslips (Leica 
Biosystems, UK). Sections were visualized and scanned with the Zeiss Axioscan Z1 
(Zeiss, UK). Image analysis was carried out using Zen Blue software (Zeiss, UK).  
5.4.6 Flow cytometry and fluorescence-activated cell sorting 
(FACS) 
5.4.6.1 Sample preparation 
Following isolation of mouse peritoneal lavages (Section 5.4.4), samples 
stored at -80°C were thawed at 37°C in a water bath, transferred into polystyrene flow 
cytometry tubes (BD Falcon, Oxford, UK) and washed with 3ml of filtered FACS 
buffer (phosphate-buffered saline without calcium and magnesium, PBS, 
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ThermoFisher Scientific, Paisley, UK; 2% BSA, Sigma Aldrich, Dorset, UK). Samples 
were centrifuged for 5 minutes at 1000g at 4°C and the resultant cell pellets were re-
suspended in 1ml of FACS buffer and filtered to remove cell clumps using filter 
polystyrene FACS tubes (BD Falcon, UK). The single cell suspensions were counted 
and viability assessed using the Countess II. 
5.4.7 Conjugated antibody staining 
Samples were stained in 100µl of FACS buffer with the panel of anti-mouse 
antibodies; the target proteins, concentrations and their fluorochromes are detailed in 
Table 2-8. Cell suspensions and antibodies were incubated in the dark, for 30 minutes. 
Following incubation, 3 ml of FACS buffer were added to the mix and centrifuged for 
5 minutes at 1000g at 4°C. See Table 2.9 in materials and methods for antibodies 
information. 
5.4.8 Viability staining 
Quantification of dapi was used to assess cell viability before running the 
sample through the flow cytometer or sorter. 
5.4.9 Equipment used for flow cytometry and FACS 
Flow cytometry was achieved using a 6 laser BD Fortessa flow cytometer (BD, 
UK). FACS was performed by the Centre for Inflammation Research Flow Cytometry 
facility team, using the BD Aria Fusion sorter (BD, UK). 
5.4.10 Flow cytometry data analysis 
Data gathered from flow cytometry and FACS were analysed using the software 
FlowJo 8.7 (Flowjo, LLC, USA). Statistical analysis was conducted using GrapPad 
Prism 6.0. One-way ANOVA was further used for multiple group comparison, 
followed by Kruskal-Wallis as a secondary test with Dunn’s multiple comparisons test. 
Criterions for significance was p<0.05. 
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5.5.1 Differentiation of human MCs from blood precursors 
During the peripheral blood CD34+ differentiation protocol, a time dependent 
pattern of proliferation was recorded, with a rapid proliferation during the first 10 days 
of cell culture. 
MC differentiation was monitored on a weekly basis by performing the MC 
specific metachromatic staining, toluidine blue. Positive cells (purple staining) were 
first detected after 15 days of culture (end of week 2) as illustrated in Figure 5-5. As 
the duration of the culture increased, positive cells started to increase in size (21 days 
– end of week 3) and by the end of the culture they had differentiated into mature MCs, 
with their distinctive mononuclear morphology and well-organized granules. 
Maturation of MCs was further confirmed by analysing mRNA concentrations 
of inflammatory markers such as prostaglandin E receptor 2 (PTGER2) and 
glucocorticoid receptor (GR), together with the MC specific proteases, tryptase and 
Figure 5-5 Transition of immature mast cells to mature mast cells during in vitro differentiation 
protocol. 
Peripheral blood CD34+ progenitor cells were isolated and enrolled into the differentiation protocol 
described by Kirshenbaum et al (2006). Cationic dye staining was performed throughout the in vitro 
protocol; here are illustrated week 2-3 as intermediate stages and week 8 as the last week of 
differentiation. MCs started to acquire positivity for toluidine on week 2, but mature MCs were detected 
only in week 8 samples, which had cells with rounded nuclei and equally distributed purple staining in 
their cytoplasm, indicating they had developed and well-structured glycosaminoglycan granules. n=3 
each stage of differentiation. Scale bar 20µm. 
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chymase encoded by TPSAB1 and CMA1 respectively, and the receptors protease-
activated receptor 2 (PAR-2) and histamine receptor 1 (HR1) (Figure 5-6).  
Concentrations of messenger RNAs encoded by TPSAB1 (gene for tryptase α 
and β isoforms) were significantly upregulated at the end of week 4 and remained 
elevated at week 8 of culture compared to the undifferentiated cells (week 1). 
Similarly, CMA1 mRNA concentrations were significantly upregulated at week 4 and 
remained elevated at week 8. The MC mediators such as tryptase and histamine 
mediate their effect through specific receptors, PAR-2 and HR1 respectively. PAR-2 
and HR-1 mRNA concentrations appeared to remain constant at both week 1 and week 
4, however they were significantly upregulated in the cell homogenate from week 8 
samples (Figure 5-6-C/D). Together with mRNA profile consistent with MC 
maturation cells at week 8 of culture also contained PTGER2 and had significantly 
higher GR mRNA concentrations (Figure 5-6-E/F). 
Figure 5-6 Expression of mRNAs encoding mast cell specific proteases and other ininflammatory 
markers is upregulated in mature peripheral blood derived MCs. 
Real-time PCR on different stages of the differentiation of CD34+ into mature peripheral blood derived 
MCs, identified as significant increased expression of mast cell specific proteases and other 
inflammatory markers compared to undifferentiated cells. Data expressed as median, One-way ANOVA 
and Kruskal-Wallis as secondary test with Dunn’s multiple comparisons test. *p<0.05, **p<0.01, 
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These findings are consistent with a “switching on” of an inflammatory 
expression profile as the MCs differentiated from their precursors, which started to 
appear after week 4 and increased by week 8, consistent with successful differentiation 
into mature MCs. 
Additional confirmation of MC maturity at the end of culture of a single 
sample, was achieved by using Western blotting analysis with both isoforms a and b 
of tryptase detectable in a protein homogenate harvested at week 8 (Figure 5-7).  
Previous studies have often reported that human MCs express oestrogen 
receptors (Jensen et al., 2010), and studies described in Chapter 3 highlighted the 
presence of ERaneg and ERbpos MCs in the endometrium. In this study peripheral blood 
derived MCs differentiated in vitro had higher mRNAs concentrations of both ERa 
and ERb in cells at week 4 compared to week 1. Notably, whilst week4 had 
significantly higher concentrations of ERa, these were not detectable in the week 8 
samples. In contrast, week 8 cells (mature MCs) had ERbpos and ERaneg phenotype 
(Figure 5-8). 
  
Figure 5-7 Tryptase protein isoforms were 
detected in the cytoplasm of fully 
differentiated peripheral blood mast cells.  
Western blotting analysis of a cell homogenate 
indicated the presence of the two a and b 
isoforms of tryptase in the mature peripheral 
blood derived MCs. n=1 
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5.5.2 Studies using the human mast cell line (HMC-1) as a 
model system, profiling the phenotype. 
The HMC-1 human cell line is widely used as an in vitro model for exploring 
MC behaviour. In the current study, the molecular/cellular phenotype of unstimulated 
HMC-1 cells was investigated to determine whether it mirrored the profile of 
inflammatory markers and oestrogen receptors.  
When mRNA concentrations in HMC-1 cells were compared to those of the 
differentiated peripheral blood derived MCs (week 8 of culture), concentrations of all 
mRNAs were significantly lower (Figure 5-9). This finding would appear to be 
consistent with the immature/undifferentiated state of HMC-1 cells reported by 
Nilsson et al. (1994a). 
Expression of GR, chymase and tryptase proteins was also investigated (Figure 
5-10). Immunocytofluorescence on HMC-1 detected glucorticoid receptor protein in 
the cell nuclei. Chymase was detected at low intensity in the cell cytoplasm and, HMC-
1 cells in culture were immunonegative for tryptase.  
Figure 5-8 Concentrations of mRNA encoding ERa and ERb in peripheral blood derived mast cells. 
peripheral blood derived MCs MCs showed an increase of mRNA encoding both ERa and ERb at week 4 
of the differentiation protocol, which was significant for ERa. ERa mRNA concentrations were not 
detectable in mature peripheral blood derived MCs MCs (week 8). In contrast, significantly higher 
concentrations for ERb were detected in mature MCs at week 8. n.d.: not detectable, Data expressed as 
median, One-way ANOVA and Kruskal-Wallis as secondary test with Dunn’s multiple comparisons test. 
*p<0.05, week 1 n=10, week 4 n=6 and week 8 n=2. 
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Interestingly, tryptase was readily detectable in the HMC-1 culture medium, 
and not inside the cytoplasm. This finding is in agreement with what was previously 
shown by Schwartz et al. (2003), where the continuous release of granule content by 
HMC-1 was monitored.  
 
Figure 5-10 Mast cell proteases and glucorticoid receptor expression in HMC-1 and detection of 
tryptase in culture medium. 
A) Immunolocalisation studies demonstrated that HMC-1 express glucorticoid receptor (GR) in their 
nuclei; low intensity staining for chymase was detected in HMC-1 cytoplasm. Interestingly, tryptase was 
not detectable in HMC-1 cytoplasm n=5. B) Medium from HMC-1 contained detectable tryptase 
continuously, after 2 or 24 hours of culture. Data expressed as mean ± SEM, two tailed t test with Mann-
Whitney post-test, n=5. 
hours of culture. Data expressed as mean ± SEM, two tailed t test with Mann-Whitney post-test, n=5. 
A) B) 
Figure 5-9 mRNA concentrations of 
mast cell specific proteases, PAR-2 
and HR-1 and GR in HMC-1 cells. 
The mRNA concentration of TPSAB1 
(A) was significantly decreased in 
HMC-1 cells compared to week 8 
peripheral blood derived MCs 
(**p<0.01). Similarly, CMA1, PAR-
2, HR1 and GR were all lower in 
HMC-1 (*p<0.05, B-E) Week 8 
peripheral blood derived MCs MCs 
n=2-4, HMC-1 n= 3-5. Data 
expressed as mean ± SEM, two tailed 
t test with Mann-Whitney post-test. 
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HMC-1 cells were also tested for the expression of oestrogen receptors. Real-
time PCR detected the expression of mRNAs encoded by ESR2 the gene encoding 
(ERb), while mRNA concentrations for ERa (ERS1) were undetectable (Figure 5-11-
A). This finding was further confirmed by running the RT-PCR products on an 8% 
(w/v) polyacrylamide gel, with results illustrated in Figure 5-11-B. 
Protein localisation analysis by immunocytofluorescence was carried out using 
cells fixed on slides following cytospin (Figure 5-12). This technique resulted in 
detection of ERa and ERb in the cytoplasm of the positive control Ishikawa cells. 
Nuclear localisation of ERs requires active shuttling and cytoplasmic localisation 
would be consistent with cell hypoxia during the cytospin. In the HMC-1 cells no ERa 
was detected and ERb was present in the cytoplasm, consistent with the data of 
Western blots (Figure 5-13). 
  
A) B) 
Figure 5-11 Real-time PCR analysis on mRNA expression of ERa and ERb in HMC-1 cells. 
To complement data obtained by real-time PCR (A), the reaction products were run on an 8% acrylamide 
gel (B). This confirmed that HMC-1 cells did not contain detectable mRNA encoded by ESR1, products 
for ERb were detectable. n=3, LAD: 100bp Ladder, ISH: Ishikawa cells, POS: positive pooled RNA, 
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5.5.3 Effects of oestradiol on HMC-1 cell culture. 
Jensen et al. (2010) reported that oestrogen treatment induced an upregulation 
in the expression of chemokine receptors in HMC-1. The current study was designed 
to elucidate the effects of 17b-oestradiol on mRNA expression of mast cell specific 
proteases and their extracellular release. 
Two different doses of 17b-oestradiol (E2) were assayed, 10-7M and 10-8M, 
which were chosen to reflect the physiological E2 concentrations found in the human 
body. HMC-1 cells were harvested after 2 hours and 24 hours of treatment and in some 
cultures its pure anti-oestrogen ICI (fulvestrant) was included to determine specificity. 
Figure 5-12 Identification of ERa and ERb 
proteins on cytospins of HMC-1 cells. 
Immunocytofluorescence staining showed that 
HMC-1 cells highly express ERb (red) and are 
immunonegative for ERa. Ishikawa cells were 
used as a positive control for the expression of 
oestrogen receptors. HMC-1 and Ishikawa n=6.  
Figure 5-13 Protein 
quantification of isoform of 
oestrogen receptor a and b 
in nuclear fraction of 
HMC-1.  
Western blot analysis 
confirmed that HMC-1 cells 
do not express ERa but 
express only the isoform b at 
protein level as well as 
mRNA, as shown in Figure 
5-11. Ishikawa cells were 
for both ERs as expected. 
n=1. 
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Concentrations of messenger RNA encoded by TPSAB1 and CMA1 remained 
unchanged between the different treatments (Figure 5-14), regardless of the addition 
of E2 or fulvestrant. Concentrations of mRNAs were highly variable after 24h; notably 
in these culture cell number and viability was decreased (data not shown). This may 
be consistent with a dependency of HMC-1 on serum constituted medium, as the cells 
were cultured in serum-free medium for 16 hours prior to performing the treatments. 
The activation/degranulation profile of HMC-1 cells in response to an E2 
stimulus was also explored. Consistent with results presented above (see Figure 5-10) 
tryptase release was detected in the conditioned medium of controls, and notably these 
remained unchanged regardless of treatment (Figure 5-15-A). In the 24h cultures there 
was an apparent increase in tryptase following addition of E2 with or without ICI 
(fulvestrant), but this did not reach significance.  
Figure 5-14 mRNA concentrations of genes encoding mast cell proteases in HMC-1 in response to 
oestradiol remained unchanged. 
The mRNA expression of tryptase and chymase, TPSAB1 and CMA1 respectively, was investigated after 
2 and 24 hours of E2 treatments. Concentrations of mRNA did not vary with the different combinations of 
treatments at 2-hour time point. High variability of expression was detected after 24 hours of culture. .2h 
n=7 (ICI n=2), 24h n=5 (ICI n=1-2). Data expressed as median. 
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5.5.4 Localisation of mast cells in the uterus of murine 
models of menstruation. 
Mast cells have been documented to be part of the immune cell population of 
the uterus, both in the human myometrial and endometrial compartments, as shown in 
Chapter 3. A few studies have investigated uterine MCs during the oestrus cycle in the 
mouse, which reported a peak in MC numbers during a specific phase of the cycle 
(oestrus), and during the first weeks of implantation (Woidacki et al., 2013b). 
To complement and extend studies on human uterus reported in Chapter 3 of 
this thesis, methods were developed to localise MCs in the mouse uterus during the 
oestrus cycle. This was a necessary first step, as antibodies against human tryptase and 
chymase do not cross react with mouse proteins. Acidic toluidine blue staining using 
Carnoy’s fixed uterine horns revealed the spatial and temporal pattern of localisation 
of MCs in the mouse uterus. MCs were most abundant in the inner myometrial 
compartment (towards the uterine cavity); no MCs were detected in either the stromal 
or the epithelial compartments of the endometrium. Uterine MCs were not abundant 
and their numbers only varied slightly during the oestrus cycle, showing an apparent 
A) 
Figure 5-15 Detection of tryptase in HMC-1 culture media after 2 and 24 hours of E2 treatment. 
Tryptase levels were readily detected after 2 hours of culture and remained unchanged within the 
different groups, as shown in panel (A). After 24 hours of E2 and ICI (fulvestrant) treatments, levels of 
tryptase appeared to have slightly increased but this was not significant or was blocked by ICI (B). 2h 
n=2-4, 24h n=4. 
 
B) 
A role for mast cells in women’s health and disorders of the endometrium 
Chapter 5 – Exploring the use of in vitro and in vivo mast cell models 
 
192 
increase in oestrus and early metestrus and a reduction at diestrus; results are illustrated 
in Figure 5-16. MCs were also localised next to uterine vessels.  
The location and number of MCs was also investigated for the first time in a 
mouse model of menstruation. Uterine horns were collected at two different time 
points, 24 and 48 hours after progesterone withdrawal to model both tissue breakdown 
and repair as MCs have been predicted to be involved in both these processes in the 
human endometrium. 
Unexpectedly, toluidine blue positive MCs were not detected the endometrial 
compartment at either time points studied (Figure 5-17). In these tissue sections MCs 
remained in close proximity to blood vessels in the myometrium, consistent with their 
localisation in the oestrus cycle sample. 
  
Figure 5-16 Mast cells detected in the murine uterus during the different phases of oestrus cycle. 
Toluidine blue staining performed on Carnoy’s fixed sections revealed the spatial and temporal 
localization of murine uterine MCs across the oestrus cycle. MCs were resident in the myometrial 
compartment, near the blood vessels (black arrows). MCs were not detected in the endometrium at any 
stage of the cycle. An increase in number of MCs was apparent at oestrus and early metestrus phases. 
Proestrus n=4, oestrus n=5, metestrus n=3 and diestrus n=3.  
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Figure 5-17 Localisation of mast cells in uterine cross sections 24 and 48 hours after 
progesterone withdrawal. 
Cationic staining with toluidine blue revealed that MCs are located in the peripheral layer 
of the myometrium; but were not detectable in the endometrium during tissue breakdown 
and remodelling. Black arrows indicate blood vessels. T-24h n=10, T-48h n=2 
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5.5.5 Investigation of mast cells in a mouse model of 
endometriosis 
5.5.5.1 Mast cells in endometriosis-like lesions 
There is evidence for the presence of MCs in peritoneal lesions of patients 
suffering from endometriosis (Sugamata et al., 2005), which was extended during 
studies in Chapter 4. The presence of MCs in endometrial-like lesions from rodent 
models of endometriosis has however never been investigated. 
The current project explored the presence of MCs using our in-house murine 
model of endometriosis (Greaves et al., 2014a). Strikingly, MCs were readily detected 
in the endometrial-like lesions harvested at the end of the protocol, a representative 
image is presented in Figure 5-18. Typically, the lesions recovered at the end of the 
study, look heterogeneous. They are often constituted by endometrial stroma, fat and 
fibrotic tissue and a peritoneal fraction, as reported by Greaves et al., 2014. During the 
current study, MCs were predominantly located in the stromal compartment, which is 
probably of endometrial origin, and in the fibrotic and fat sites, as shown in Figure 
5-19. 
Figure 5-18 Representative toluidine blue staining on endometrotic lesion in the murine model of 
endometriosis 
Mast cells were easily detected in the “endometrial-like” lesions, as shown by the purple staining. MCs 
were often located in stromal-like fraction and in close proximity with fat cells. Lesions screened n=48 
Scale bars: 200µm in (A) and 50µm in (B). 
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5.5.5.2 Mast cell localisation in peritoneal fluid in a mouse model of 
endometriosis 
To complement the study conducted on MCs in women affected by chronic 
pelvic pain and endometriosis detailed in Chapter 4, MCs were also examined in the 
peritoneal lavages of mice undergoing the endometriosis model. 
Firstly, the presence of MC was confirmed within the immune cell populations 
present in the peritoneum using toluidine blue staining of cytospins of prepared from 
peritoneal lavages. Figure 5-20 illustrates MCs identified in peritoneal lavage and 
shows that they were representative of two murine subtypes: connective and mucosal. 
This classification is based on the different colour reaction after toluidine blue staining, 
“connective” type cells acquiring a more intense purple colour compared to the 
Figure 5-19 Localization of mast cells in endometriotic lesions in a mouse model of endometriosis. 
Acidic toluidine blue staining enabled the detection of MCs in the “endometrial-like” lesions harvested 
at the end of Greaves et al. (2014) protocol. Purple cells were easily observed throughout the tissue 
sections, with the specific localization in the stromal endometrial compartment. MCs were often found 
in fibrotic and fat tissue (black dotted line surrounds brown colour for haemorrhagic staining, red arrow 
indicates fat tissue). Peritoneal tissue fraction indicated by black arrow within the lesion. Lesions n=48. 
Scale bar 100µm. 
 
C) B) A) 
Figure 5-20 Identification of mast cells in peritoneal lavages using toluidine blue staining. 
Toluidine blue staining of peritoneal cell cytospins showed the presence of both mucosal and 
connective type murine MCs, which differ on the intensity of staining. Example of co(A,C) and 
mucosal type in (B). Scale bar 50µm, n=3. 
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“mucosal” type. The distinctive colouration detected is due to the different 
composition of their granules, as previously reviewed by Galli et al. (2011). 
This study was also able to quantify the number of MCs present in the lavage 
of different groups of mice in the endometriosis model. MCs usually represent a very 
small percentage of CD45+ cells; therefore, an effective exclusion gating strategy is 
required to perform accurate quantification. Figure 5-21 shows a representative gating 
strategy, including two plots with the FMO gates (fluorescence minus one), in this 
case, showing the specific surface makers for MCs: c-kit and FceRIa. The use of FMO 
D) 
Figure 5-21 Representative gating strategy for quantifying MCs in peritoneal lavages. 
An exclusion criterion gating strategy was employed during flow cytometry studies. After size and 
doublets were excluded (A-B), cells were gated on dapi negative (C), CD45+ (D), CD45+/CD3- (E, T 
cells excluded), CD45+/B220- (F, B cells), CD45+/CD335- (G, NK cells). For excluding macrophages, 
cells were gated on CD11b-F4/80 negative (H) and Ly6C-G (I). Finally, mast cells were identified using 
the unique combination of c-kit (CD117) and FceRIa antibodies, shown in panel J. Panels K panels 
show the FMOs used. These gates were applied on all the analysed samples 
 
A) B) C) 
E) F) H) 
I) 
G) 
J) L) K) 
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was extremely important for the evaluation of the small number of MCs in the 
peritoneal lavages, avoiding any artefact during the gating. The markers used to fulfil 
the “exclusion” criteria were: CD3 for T cells, B220 for B cells, CD335 for natural 
killers and CD11b-F4/80-Ly6C/G for macrophages, Ly6G excluded also neutrophils. 
This method and gating strategy allowed the frequency of MCs as a percentage 
of the total live CD45+ cells (blood cells) to be identified. MCs represented on average 
<0.3% of total live CD45+, and this percentage was lower in animals treated with E2 
alone, animals treated with PBS as a control groups, and the animals in which 
endometriosis was simulated when compared to intact animals (Figure 5-22-A). Mice 
injected with intraperitoneal PBS showed a significantly lower percentage of MCs, if 
compared to any of the other groups. This finding was similar to the one that was firstly 
reported by Katakura et al. (1988), where ip injection of distilled water induced a 
complete depletion of MCs in the peritoneal cavity. Peritoneal MCs, therefore, appear 
to be sensitive to low osmotic pressure, following the addition of only solution and not 
“particles” (cells) in the environment. This event is not caused by endometrial tissue 
injection in endometriosis animals, because endometrial cells together with PBS 
suspension are introduced into the peritoneum, without changing the total osmotic 
pressure. 
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 Quantitative measurement of MC proteases was also performed on the 
peritoneal lavage solutions (Figure 5-22-B). Concentrations of tryptase and chymase 
were lower in the lavages from treated animals compared to naïve animals, however 
these did not reach statistical significance due to the large variation in controls.  
5.6 Discussion 
Female sex steroid hormones have often been suspected to exert a stimulatory 
effect on tissue resident MCs. This assumption seems plausible due to the clear 
difference in incidence and severity of MC related disorders between women and men 
(Bonds and Midoro-Horiuti, 2013). There are reports that both human and murine MCs 
express oestrogen receptor isoforms (Zhao et al., 2001, Zaitsu et al., 2007, Jensen et 
al., 2010). Additionally, the studies in this thesis show that human uterine MCs are 
ERbpos and ERaneg. 
The current study set out to evaluate the methods currently available to 
investigate the effects of oestrogen on human MCs using in vitro model systems that 
included the use of in vitro matured peripheral blood-derived MCs and use of the 
leukaemia cell line HMC-1. Both approaches resulted in novel findings. 
Figure 5-22 Frequency of mast cells and concentrations of proteases in the peritoneal lavages.  
A) MCs were detectable and quantifiable in peritoneal lavages from different groups of animals. E2 
and endometriosis groups showed lower median compared to näive controls. Significantly decreased 
was the percentage of MCs in lavages from PBS controls. One way ANOVA and Kruskal-Wallis as 
secondary test with Dunn’s multiple comparisons test. *p<0.05, **p<0.01, naïve n=10, E2 ctrls n=9, 
PBS ctrls n=6, Endometriosis animals n=15. B) Levels of tryptase and chymase were measured in the 
peritoneal lavages. Lower concentrations of both proteases were detected in E2, PBS and endometriosis 
groups. Naïve n=6, E2 ctrls n=2, PBS ctrls n=7, Endometriosis animals n=9. 
 
A) B) 
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Interrogation of oestrogen receptor expression over the time course of peripheral 
blood derived MCs differentiation revealed dynamic changes in mRNA concentrations 
for both ESR1 (ERa) and ESR2 (ERb) with both present at the mid-differentiation 
stage (week 4), but fully mature peripheral blood derived MCs being ERbpos and 
ERaneg. To my knowledge, this is the first study that has investigated oestrogen 
receptor expression in peripheral blood derived MCs. This result was consistent with 
in situ studies reported in Chapter 3, and suggests mature in vitro derived peripheral 
blood derived MCs are a suitable model system.  
Notably, it has been shown that oestrogen can stimulate the differentiation of 
CD34+ progenitor cells into megakaryocytes via ERa and ERb. Similar to our culture 
system, expression of ERa was suppressed at later stages of the in vitro culture, while 
ERb increased and remained constant in mature megakaryocytes (Bord et al., 2004). 
It can be speculated that oestrogens acting via ERa may be involved in the recruitment 
of progenitors and early MC development, while ERb may be responsible for exerting 
oestrogen dependent effects within mature MCs. This ERaneg and ERbpos phenotype 
detected in the peripheral blood derived MCs mimics that of other immune endometrial 
cells, including natural killer cells (uNKs) and CD68+ macrophages (Henderson et al., 
2003, Thiruchelvam et al., 2013). 
Whilst peripheral blood derived MCs were formed, the differentiation protocol 
was lengthy and cell numbers were very low. To overcome this limitation the 
leukaemia-derived HMC-1 cell line as established by Butterfield et al. (1988), was also 
investigated. It has been reported that HMC-1 cells are able to respond to oestrogenic 
stimuli via ERa (Zaitsu et al., 2007, Jensen et al., 2010). Several techniques were 
employed to explore oestrogen receptor expression in HMC-1 cells obtained by Dr 
Butterfield during the current study. Using multiple tests, including RT-PCR, gel PCR, 
Western blotting and immunofluorence the HMC-1 cells in our culture work were 
ERaneg and ERbpos, which supported the peripheral blood derived MCs data but 
appeared at odds with previous reports. The HMC-1 did not show significant response 
to physiological oestradiol concentrations after 2h or 24h of treatment, the rapid non-
genomic action that was suggested by Zaitsu et al. (2007). 
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The presence of MCs in the uterus and their oscillations during the menstrual 
and oestrus cycle has been described in humans (Drudy et al., 1991a, Jeziorska et al., 
1995) and other mammals, firstly in the hamster (Harvey, 1964) and later in the mouse 
(Padilla et al., 1990). In humans, we and others have shown MCs are most abundant 
in the basal layer of the endometrium and in the myometrium (Sivridis et al., 2001). 
Mori et al. (1997a) reported that MCs do not change in number during the different 
phases of the menstrual cycle, following the fluctuation of the ovarian sex hormones 
and therefore MCs are considered a tissue resident immune cell population. In the 
mouse, MC number has been reported to vary during the four phases of the oestrus 
cycle, reaching a peak during oestrus (Woidacki et al., 2013b). It has been postulated 
that a higher number of uMCs during oestrus may correspond to the maximum 
circulating levels of 17b-oestradiol and to the minimum circulating levels of 
progesterone (Fata et al., 2001).  
This was the first study, to my knowledge, that has used toluidine blue staining 
on Carnoy’s fixed murine uterus sections to detect tissue resident MCs. Other fixatives, 
such as formalin derived (PFA or NBF), did not permit the detection of the full 
complement of murine MCs. For example, mucosal type MCs are reported to be 
“formalin sensitive”, due to their low content of heparin in the architecture of the 
granules (Irani and Schwartz, 1989, Sridharan and Shankar, 2012). In this study, 
similar results to that of Woidacki et al.’s (2013b), which employed PFA fixed tissue, 
were obtained. Murine MCs reside primarily in the myometrial compartment of the 
uterus, located around blood vessels and their number and localisation did not appear 
to change with the phase of the cycle. No MCs were detected in either the stromal or 
epithelial compartments of the endometrium. MC number was higher in oestrus 
tissues. For the first time, due to the more appropriate fixation method, a notable 
increase in early metestrus tissue was observed, suggesting a stage specific influx of 
mucosal type MCs. 
The role of MCs in the menstruation process has been postulated, due to their 
potential for biosynthesis of metalloproteases (MMPs) (Schwartz, 1994). MCs are 
known to be part of the leukocyte population of the human endometrium and they are 
reported to be activated before tissue breakdown (Jeziorska et al., 1995). My previous 
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data, reported in Chapter 3, has revealed that mature uterine MCs express the isoform 
b of the oestrogen receptor, supporting evidence that MC activation may be hormone 
dependent. Moreover, Zhang et al. (1998) demonstrated that MCs can stimulate the 
local production of MMPs by primary endometrial stromal cells, suggesting MC 
involvement during the tissue breakdown process. 
Chapter 5 study was set up to explore the location and number of MCs in a 
well-established murine model of menstruation (Cousins et al., 2014). The model 
elegantly mimics the human menstrual cycle with cellular proliferation during the 
early stage of the protocol in response to oestrogen injections, angiogenesis and 
cellular differentiation in response to the progesterone implant and induction of 
decidualisation: and finally tissue breakdown after progesterone withdrawal. Most 
importantly, this model has been used to explore dynamic changes in other uterine 
immune cell populations including monocyte, macrophages and neutrophils.  
Unexpectedly, in this mouse model MCs were not identified in the shed or the 
newly proliferating stromal compartment of the endometrium 24 hours after 
progesterone withdrawal, or at the stage of complete endometrial regeneration (48h 
time point). Regardless of hormonal manipulation, MCs were detected within the 
smooth muscle fibres of the myometrium, as in normal cycling animals. This model 
thus does not shed light on whether MCs are involved in endometrial shedding and 
remodelling during menstruation in women. On the contrary, due to their constant and 
unchanged localisation in the myometrium, MCs may be associated with regulation of 
muscular contractions, which the uterus spontaneously undergoes, both in humans and 
in rodents (Talo and Karki, 1976, Bulletti et al., 2000). Smooth muscle fibres, 
including myometrial fibres, are a powerful source of stem cell factor (Mori et al., 
1997a), which critically regulates the migration of MC precursors and promotes MC 
proliferation and maturation (Galli et al., 1993). Notably, it has been demonstrated that 
MC mediators secreted after degranulation alter myometrial fibres, augmenting 
spontaneous contractions (Bytautiene et al., 2003, Bytautiene et al., 2004). Moreover, 
in mice oestrus and early metestrus are described as the phases during which more 
frequent myometrial contractions are reported (Crane and Martin, 1991). Therefore 
from these data it is worth considering whether MCs may be involved in myometrial 
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hyperactivity during the perimenstrual phase, reported to occur during painful 
menstruation (Dawood, 2006).  
The results reported in Chapter 4 along with previous literature on MCs have 
described their infiltration into the stroma of human endometriotic lesions (Matsuzaki 
et al., 1998b, Sugamata et al., 2005). Prior to this study the presence of MCs in rodent 
models of endometriosis has not been reported. The current investigation identified 
MCs in endometrial-like lesions in a well-established mouse model of endometriosis 
(Greaves et al., 2014a). Not only were toluidine blue positive MCs detectable but they 
appeared to be present in relatively high numbers in the endometriotic “lesions”, 
detectable in the stroma, as well as the fat and fibrotic tissue that contributed to the 
microenvironment of the lesions.  
This result was rather unexpected, as mature MCs were not detected in the 
endometrium during the different time points of the menstruation protocol and this is 
recapitulated with the “donor” tissue used to induce lesions. It is possible that MC 
progenitors present in the endometrial stroma might have differentiated into mature 
MCs after the establishment of the lesion. Other scientists have reported that the 
endometrial stromal compartment contains a fraction of cells that are immunopositive 
for CD34+ (Lindenmayer and Miettinen, 1995, Mai et al., 2008). Therefore, the donor 
material injected into recipient animals may have brought a pool of MC progenitors 
into a different and inflamed environment, which then, with a pro-inflammatory array 
of molecules, have differentiated into MCs.  
Furthermore, in agreement with the patient data reported in Chapter 4, results 
obtained using the endometriosis model have shown an apparent decrease in the 
number of MCs and concentrations of tryptase and chymase, in the peritoneal lavages 
of animals that had been ovariectomised and treated with E2 and undergone the 
endometriosis model. This might suggest that a “hyperalgesic state” is present in the 
abdominal cavity, where lower numbers of cells can trigger higher pain/discomfort. It 
has been demonstrated that MCs can be critical players in the pathogenesis of chronic 
and neuropathic pain (Chatterjea and Martinov, 2015). Colleagues (Greaves et al. 
paper under review) have showed during the aforementioned model that the recipient 
animals experience significant discomfort and hyperalgesia, compared to naïve 
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controls. Thereby the reported increase of number of MCs in endometriotic lesions 
during the current study supports the veracity of the model and the potential 
involvement of MCs in endometriosis-induced pain. 
Limitations have been encountered during the current in vitro and in vivo 
studies. Derivation of peripheral blood derived MCs was an extremely complex cell 
culture protocol which was time consuming and expensive, despite resulting in MCs 
that showed a similar expression pattern to mature uterine MCs. The HMC-1 cell line 
generated large numbers of cells instantly however these presented as immature 
inflammatory state (low tryptase and chymase) which limited their utility as a model 
for tissue resident MCs. The main obstacle for mouse models in MC research, is the 
lack of commercially available antibodies that specifically detect MC proteases. 
Thereby, only toluidine blue dye can be employed for for the identification of murine 
MCs, which doesn not allow for a deeper investigation of the protein content of tissue 
resident MCs.  
In summary, using these different in vitro cell models this study demonstrated 
that MCs can respond to oestrogen action since both peripheral blood derived MCs 
and HMC-1 express ERb, a finding that was in agreement with MCs detected in situ 
during studies reported in Chapter 3. Importantly, these findings do not support 
previous studies claiming MCs to be ERapos. The preliminary studies in mouse models 
offer a valid platform for further studies on the implications of MCs in pain associated 
with endometriosis or menstruation.  
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Chapter 6 Final discussion 
6.1 Introduction 
The cellular and extracellular composition of the human endometrium undergoes 
substantial remodelling during the menstrual cycle. Ovarian derived steroid hormones, 
oestrogen and progesterone, and their fluctuating serum levels are responsible for the 
dynamic tissue reorganization. The endometrial immune cell population has been 
implicated in regulation of tissue adaptation across the different phases of the cycle 
(Evans and Salamonsen, 2012b) with both the total number of leukocytes and the 
relative numbers of most immune cell subtypes varying according to the different 
stages of the menstrual cycle. Endometrial leukocytes include uterine natural killer 
cells (uNKs), macrophages, eosinophils, neutrophils and mast cells (MCs). While the 
number of macrophages and natural killer cells increases immediately after ovulation 
and during the decidualisation process, the influx of eosinophils and neutrophils occurs 
during the late secretory and pre-menstrual phases (Kamat and Isaacson, 1987, 
Kammerer et al., 2004). In contrast, the number of mast cells has been reported to be 
constant regardless of the phase of the menstrual cycle (Salamonsen et al., 2002). 
Whereas other uterine leukocytes have been extensively studied, only a few studies 
have investigated the phenotype of the mature mast cells resident in the human uterus.  
Endometriosis is common gynaecological disorder that is often associated with 
debilitating chronic pelvic pain (CPP). It is an oestrogen-dependent inflammatory 
condition characterized by growth of endometrial tissue in ectopic locations, generally 
on the peritoneum (Nisolle and Donnez, 1997). Ectopic lesions are reported to develop 
small diameter nerve fibres typical of afferent sensory innervation (Mechsner et al., 
2007), and it has been postulated that these nerve endings are activated by 
inflammatory mediators within the endometrial fragments, which may contribute to 
endometriosis-associated pelvic pain (Triolo et al., 2013). MCs are immune cells that 
have recently been proposed as key cellular sensors in inflammation and immunity. 
When stimulated, MCs release a wide range of mediators and may orchestrate an 
aberrant inflammatory response. MC mediators can directly influence tissue responses 
by resident cells, fibroblasts and endothelial cells, and may interact with other immune 
cells. New evidence indicates the involvement of MCs in the development of pain 
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processes as well as in the transition from acute, to chronic and neuropathic pain 
(Graziottin et al., 2014). The important feature of MC biology is the tissue dependency 
of their mature phenotype, with MC differentiation from precursors being strongly 
influenced by the surrounding tissue microenvironment (Metcalfe et al., 1997). A 
number of lines of evidence have suggested that female sex steroid hormones may 
influence MC phenotype but this has never been comprehensively investigated in the 
uterus even though this is a hormone-dependent organ. 
During the current study, novel insights into the biology and potential impact of 
steroids on uterine MCs were gained from detailed studies using tissues from women 
who were considered to have a normal uterine environment and those attending a 
chronic pelvic pain clinic, some of whom had endometriosis. To complement these 
studies both in vitro (cell based) models and a mouse model of endometriosis were 
investigated. 
6.2 Uterine mast cells and their tissue specific 
phenotype 
In chapter 3, it was demonstrated that the phenotype and activation profile of 
MCs resident in the human uterus are influenced by the fluctuation of sex hormones 
during the different phases of the menstrual cycle. The phenotype of MCs was not only 
phase-dependent; it appeared different between the three layers of the human uterus. 
For the first time, the presence of the MCC subtype in the human uterus was shown. 
MCC were only detected in the basal endometrium and in the myometrium specifically 
during the early, mid secretory and menstrual phases.  
During the 1990s studies on the distribution of uterine MCs used a range of 
metachromatic staining techniques, such as toluidine blue and alcian blue stains (Drudy 
et al., 1991a, Drudy et al., 1991b). All studies encountered problems during the 
quantification of positive cells due to difficulties in detecting low granule content after 
degranulation. Notably, the pioneering investigation on uterine MCs was the one 
conducted by Jeziorska et al (1995). In this study they used antibodies specific for the   
MC proteases tryptase and chymase to conduct immunostaining of sections throughout 
the normal menstrual cycle of fertile women. It was reported after quantification of 
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tryptase immunopositive cells that whilst MCs were members of the tissue resident 
population of endometrial leukocytes, they didn’t vary in number across the different 
phases. Staining for tryptase and chymase was conducted using serial tissue sections 
and the authors reported that uterine MCs belonged to the classical protease-content 
subtypes: MCTC and MCT a finding that was later confirmed by Mori et al. (1997b) by 
using double staining with alkaline phosphatase for chymase and DAB for tryptase. 
However, neither of these studies reported detection of the MCC subtype. Therefore, 
the current study is the first to detect all three subtypes of MCs in the uterine 
compartments by using the sensitive method of double immunofluorescence coupled 
with the tyramide amplification system which is reported to have 1000-fold signal 
amplification compared to DAB detection.  
Notably, uterine MCs showed a different phenotype based on their locations in 
the different compartments of the uterus. As confirmation of previous studies, MCTC 
were predominantly resident in the basal endometrium and in the myometrium and MCT 
were found in functional endometrium. The rare MCC type was detected in the basal 
endometrium and myometrium and completely absent in the functional layer. These 
findings reinforce the principle that tissue specific MC phenotypes can exist within 
different regions within the same organ. It is well known that the three uterine 
compartments are different to each other in terms of cellular composition and 
cytokine/chemokine microenvironments. Interestingly, the majority of MCs were 
detected around the endometrial-myometrial junction. Previous studies have 
demonstrated that a large number of CD34+ MC progenitor cells reside in this area of 
the tissue independent of phase of the menstrual cycle (Cho et al., 2004, Mai et al., 
2008). MCs were also in close proximity to smooth muscle fibres, the main source of 
stem cell factor, and a vital mediator for MC maturation and survival, specific growth 
factor of this microenvironment (Zhang et al., 1996). 
Another important aspect that is influenced by the microenvironment is the 
activation profile of MCs. Thus, the phenotype and activation/degranulation profile of 
uterine MCs appeared to be menstrual phase dependent, being most evident specifically 
during early and mid secretory stages, suggesting angiogenic processes taking place in 
the endometrium at this time may be mediated by MC degranulation. It is well known 
that histamine and prostanoids from MCs are important in the regulation of the vascular 
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tone and permeability (Kunder et al., 2011). Furthermore, tryptase and chymase, by 
promoting synthesis of MMPs may support tissue remodelling and ECM structure 
modification at time of menses (Pejler et al., 2007). Moreover, in contrast with other 
studies (Sivridis et al., 2001), the MCs detected in our study appeared to be phase-
specifically activated in the myometrial layer the during secretory phase and at menses, 
indicating that MC mediators may play a role in arteriole sprouting during the secretory 
phase and muscle contraction during menses. 
Due to the new data consistent with MC activation in particular phases of the 
cycle, the influence of sex steroid hormone on MC behaviour was also investigated. 
Evidence of the potential impact of steroid hormones on MC behaviour prior to the 
current study was reported by Drudy et al. (1991b). They used electron microscopy to 
demonstrate that MC numbers appeared to be significantly lower in uterine biopsies 
from postmenopausal women in whom sex hormones levels are low (Stone et al., 1975). 
Moreover, in that study an insufficiency in granule content in the MC cytoplasm was 
shown, and no activation (by evaluation of extracellular staining) was detected in any 
of the uterine compartments including the myometrium, suggesting that high levels of 
oestrogens and progesterone are required for the physiological activation/degranulation 
of MCs. 
I believe this is the first study to carefully explore the capability of uterine MCs 
to respond to hormones, by directly investigating the MC immunoexpression of sex 
steroid receptors. Uterine MCs appeared to be ERaneg, ERβpos and PRneg independent 
of the uterine compartment or phase of the menstrual cycle (Summary table in chapter 
3). This result was in contrast to previous reports (Pang et al., 1995, Zhao et al., 2001, 
Nicovani and Rudolph, 2002), which demonstrated ERa and PR immunopositivity of 
human MCs in non-reproductive tissues including bladder and upper airways. 
Moreover, it is difficult to interpret the past results due to the employment of 
immunohistochemistry antibodies that are non-specific to the different isoforms of 
oestrogen receptors. Zhao et al. were the first authors to investigate expression of PR 
in human MCs but unfortunately the staining they performed on nasal polyps is 
questionable due to the poor quality of the published images. 
The current findings suggest that high levels of progesterone are involved in 
triggering the degranulation of uterine MCs, and since MCs do not express PR, it is 
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believed that there is an indirect action of sex steroid hormones on MC phenotype. For 
example, from day 20, the stroma of the endometrium appears oedematous, in response 
to PGE2 and F2 secreted by endometrial stromal cells, and this process is known to be 
regulated by high levels of progesterone (Baird et al., 1996a). Furthermore, PGE2 
stimulates capillary permeability either directly or by means of increased histamine 
release which enhances the appearance of oedema in the stroma (Bergeron, 2000).  
Interestingly, the activation of uterine MCs appears to be coincident with early 
stages of the secretory phase (early and mid). This specific temporal degranulation may 
be involved in the recruitment of other immune cells through secretions of 
chemoattractant factors such as TNFa and/or IL-8 (Moon et al., 2010), which occurs 
during the late secretory phase and after progesterone withdrawal (Maybin and 
Critchley, 2011).  
6.3 Potential role for mast cells in endometriosis 
In chapter 4, the potential role of MCs in endometriosis was investigated by 
analysing their phenotype in the three tissues that are predominantly altered in the 
condition: eutopic endometrium (functional layer), ectopic endometrium 
(endometriotic lesions) and the pelvic peritoneal wall. These studies revealed an 
abnormal MC phenotype in every tissue explored with detection of both MCTC and 
MCC in the eutopic endometrium and retention of this phenotype in the lesions. 
Investigation of MCs resident in the peritoneal wall was accomplished for the first 
time during this study. Notably peritoneal MCs had a MCC phenotype with an intensely 
activated profile during normal conditions (no pain – no endometriosis), whereas in 
the peritoneum from women affected by chronic pelvic pain their phenotype was 
MCTC, MCT or MCC and extracellular protease staining was not detected (no 
activation).  
No previous studies have explored the phenotype of MCs in the eutopic 
endometrium of women with CPP or endometriosis. As detailed in chapter 3 and in 
previous studies, MCs resident in the functional layer of the normal endometrium were 
quite rare, and not detectable in every sample. Furthermore, in the functional 
endometrial layer of the control women MCs appeared to show a specific protease 
phenotype, MCT, and no other phenotype was detected. These features were confirmed 
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in the biopsies from control patients in our endometriosis study (no pain – no 
endometriosis), however in two patients the eutopic endometrium was found to contain 
MCTC. Notably this MC phenotype found in endometrial samples from the CPP and 
endometriosis patients independently of the phase of the menstrual cycle. The 
unexpected finding in the two “controls” may be explained by the finding that both 
women had previously undiagnosed endometriosis lesions and are should therefore be 
reclassified as “asymptomatic” endometriosis. A growing body of evidence indicates 
that the primary defect in endometriosis may be an alteration within the eutopic 
endometrium, and these findings support the concept of an environmental modification 
in the functional endometrium in endometriosis patients, which is having an impact on 
MC phenotype. It is notable that recent studies have demonstrated that the eutopic 
endometrium also presents with other immune cell abnormalities with macrophages 
reported to be higher in number and the ratio of M1/M2 subtype being increased 
suggestive of a higher percentage of “proinflammatory” cells (Braun et al., 2002, 
Berbic et al., 2009, Takebayashi et al., 2015). The MC phenotype “switch” is also 
supported by the evidence of an altered inflammatory protein production and gene 
expression in the endometrial microenvironment of women with endometriosis 
(Ulukus et al., 2006). For example, it has been demonstrated that the 
immunoexpression of IL-8 and its receptors was higher in endometrial biopsies from 
women with endometriosis than controls (Arici, 2002, Li et al., 2012) and IL-8 has 
been shown to exert a potent chemoattraction for mature MCs and other immune cells 
(Nilsson et al., 1999). We might also speculate that more hematopoietic progenitor 
cells might be recruited in the eutopic endometrium due to the increase of expression 
of CXCR2 (Ulukus et al., 2004), which is one of the key regulators of CD34+ cell 
influx (Hallgren et al., 2007). To support this theory, it is notable that Franco-Murillo 
et al. (2015) have reported a significant increase in SCF in the functional endometrium 
from women with endometriosis, consistent with the presence of an endometrial 
environment predisposed to support MC proliferation and survival. 
The complete phenotype of MCs in endometriotic lesions was not identified until 
the current study as although high numbers were detected in previous studies 
(Matsuzaki et al., 1998a, Sugamata et al., 2005), they did not explore the expression 
pattern of chymase. Remarkably, MCs identified in the endometriotic lesions strongly 
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expressed the MCTC and MCC phenotype, independent of the phase of the cycle or the 
grade of the disease, a finding that was in accordance with their phenotype in eutopic 
endometrial biopsies and would thus support the “retrograde menstruation” aetiology 
of endometriosis. The preliminary evidence provided in this study suggests MC 
number is increased in the lesions compared to the eutopic endometrium and appears 
consistent with sloughed endometrium from women with endometriosis providing a 
pro-differentiation and pro-survival environment for MCs. Additionally, MC 
survival/differentiation may also be augmented within the peritoneal 
microenvironment as peritoneal fluid has been demonstrated to contain elevated 
concentrations of SCF in women affected by endometriosis (Osuga et al., 2000).  
The presence of MCs in the human peritoneum has been documented in 
nephrology reports describing the use of peritoneal dialysis and the associated 
development of fibrosis (Zareie et al., 2001). To date no publications have appeared 
describing MCs in healthy female peritonea or in cases of chronic pelvic pain and/or 
endometriosis. The exploration of MC phenotype in this study has brought new 
evidence that the pelvic peritoneal wall appeared to be altered in women affected by 
chronic pain and/or endometriosis compared to controls (no pain). Surprisingly 
abundant evidence of chymase in the samples from control women was almost absent 
in both groups of patients. Information presented in peritoneal dialysis studies 
(Jimenez-Heffernan et al., 2006, Stavenuiter et al., 2011, Lima et al., 2013), 
demonstrated that increased angiogenesis and fibrosis, both processes often reported 
in endometriosis, might result in peritoneal membrane damage. There are reports of an 
altered mesothelium permeability and increased osmotic pressure in the peritoneal 
cavity in women affected by endometriosis, as a result of higher levels of peritoneal 
fluid (PF; independently from the phase of the cycle) and an increased PF protein 
content (Syrop and Halme, 1987, Hurst and Rock, 1991, Oral et al., 1996b). Therefore, 
it is possible that an alteration induced by lesion formation (supported by angiogenesis) 
and an extensive inflammatory response may contribute to peritoneal damage and 
altered MC number and phenotype and this merits further investigation. 
The pain associated with the growth of ectopic lesions in women with 
endometriosis is common and may be severely disabling (Triolo et al., 2013). Chronic 
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pelvic pain (CPP) is often resistant to standard analgesic treatments, probably because 
they do not directly address specific mediators that are involved in the endometriosis-
associated pain. This is the first study to examine expression of the PAR-2 receptor in 
the pelvic cavity of patients suffering with CPP and/or endometriosis. PAR-2 is 
thought to play a critical role in inflammatory and visceral pain; it can be cleaved and 
consequently activated by MC tryptase and other proteases (Ossovskaya and Bunnett, 
2004). Its activation controls neurogenic inflammation, pain and neuronal excitability 
(Amadesi et al., 2006). In this study, the immunoexpression of PAR-2 was extremely 
high in patients affected by CPP and/or endometriosis compared to no pain controls 
(with or without asymptomatic endometriosis) and this was independent of the stage 
of the disease. This novel finding extends and complements the nociceptive changes 
commonly detected in the peritoneum and lesions of women with endometriosis. For 
example, studies on the TRPV1 and TRPA1, ion channels expressed on neuronal 
central and peripheral projections (Bautista et al., 2006, Sipe et al., 2008) are both 
highly expressed in CPP/endometriosis patients compared to no pain controls (Poli-
Neto et al., 2009, Rocha et al., 2011, Greaves et al., 2014b). Furthermore, it has been 
demonstrated that there is an interaction between PAR-2 and TRPV1 or TRPA1 in the 
establishment of inflammatory pain. For example, PAR-2 activation may sensitise 
neurons via TRPV1 stimulation and induce hyperalgesia (Amadesi et al., 2004, Terada 
et al., 2013). Thus this overexpression of PAR-2 and TRPV1 may be the cause of the 
generalized hyperalgesia reported by He et al. (2010) in women with endometriosis, 
which showed a much lower pain threshold compared to controls. The increased 
sensitivity to pain in CPP and endometriosis patients may also explain the results on 
MC counts and quantification of MC proteases in the peritoneal fluid of these women 
if similar numbers of MCs and low concentrations of MC neurogenic mediators, 
tryptase and histamine, can still trigger nociception due to increased sensitivity. 
6.4 Current tools for investigation into mast cell 
phenotype and activation 
Studies that set out to explore MC “behaviour” in using current in vitro and in 
vivo models have been described in chapter 5. Data gathered from in vitro 
differentiation of peripheral blood derived MCs were consistent with the in situ results, 
showing a full mature inflammatory MC phenotype at the end of the culture, with 
A role for mast cells in women’s health and disorders of the endometrium 
Chapter 6 – Final discussion   212 
expression of ERb and GR. This has been the first study to interrogate the expression 
of steroid receptors during MC development from their progenitors to mature state in 
vitro. The differentiation method employed during the current study has provided 
evidence of the potential influence of oestrogens on different stages of CD34+/MCs 
development, which is important for our understanding of CD34+ recruitment and MCs 
maturation within the human uterus. Whilst the results obtained with peripheral blood 
derived MCs appeared to perfectly mirror the MC mature phenotype reported in the 
endometrium, the protocol followed (Kirshenbaum and Metcalfe, 2006) several 
limitations. It was extremely complex and time consuming and incurred a high expense 
considering the low MC numbers generated after an 8-week culture period. 
Additionally, only 5 out of the 20 cultures survived the entire culture period and hence 
this was not perceived as a viable and reliable method. 
To overcome the limitations of the peripheral blood MC cultures, the leukaemia 
derived HMC-1 cell line, a well-established in vitro model (1988) was used. The 
phenotypical investigation conducted on HMC-1 cells during the current study, 
confirmed Nilsson et al.’s report (1994a), with a battery of molecular techniques 
showing that HMC-1 cells have an immature MC phenotype with low expression of 
proteases, tryptase and chymase consistent with the origins of the original cells. 
Surprisingly, the HMC-1 cells investigated using our standard in house culture systems 
(both with phenol-red and phenol-free media) revealed an ERaneg and ERbpos 
phenotype which appeared in agreement with data from the studies in tissue samples 
and peripheral blood derived MCs although it appeared to contrast to previous reports 
using cells obtained from the same source. For example, HMC-1 cells have been 
extensively reported to express ERa, but the methods employed appeared to be non-
specific. For example, by “blasting” the published primer sequences using the Basic 
Local Alignment Search Tool of the US National Library of Medicine (NIH), it 
appears that although some match the ESR1 (gene encoding ERa) others correspond 
to ESR2 instead (ERb) (Ellem et al., 2014a). Furthermore, some of the studies showing 
immunopositivity for ERs on HMC-1 cells have employed antibodies that cannot 
distinguish between the two isoforms of oestrogen receptor (Pang et al., 1995, 
Letourneau et al., 1996). The HMC-1 cell line has two variants with a distinct set of 
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mutations of the c-kit receptor, thus HMC-1.1 and HMC-1.2, have one point mutation 
(V560G) or two point mutations (V560G and D816V) respectively (Sundstrom et al., 
2003). As Dr Butterfield had generously gifted both of the two variants of HMC-1 
cells, the phenotype of both was examined and there was no difference in the 
expression of ERs, with both variants ERaneg and ERbpos. In most of our studies HMC-
1.1 were used due to their higher mRNA concentration of chymase compared to HMC-
1.2. Interestingly, the results obtained investigating degranulation induced by 
oestradiol confirmed previous studies (Zaitsu et al., 2007), which showed HMC-1 cells 
did not respond to physiological E2 concentrations of 107M and 10-8M. The 
contradictions between the results in different studies may be explained by the culture 
conditions used or the passage number of the cells which are likely to vary between 
laboratories and/or operator. HMC-1 cells recapitulated the pattern of steroid receptor 
expression documented in the uterine MCs, and their proliferation rate is extremely 
high compared to primary cells however, their immature inflammatory state (low 
tryptase and chymase) limits their usefulness as a model for tissue resident MCs. 
In chapter 5, the presence of MCs in the mouse uterus was explored both during 
the normal oestrus cycle and using an in house model of menstruation in which tissue 
breakdown, hypoxia, angiogenesis and remodelling have been documented, 
recapitulating key features of menses in women (Cousins et al., 2014). In the mouse 
uterus MCs were not detected in the endometrial compartment a result in contrast to 
that in women. The current study was conducted on Carnoy’s fixed tissues as 
preliminary investigations conducted during optimisation of techniques showed that 
this fixative allowed for detection of both MC populations (mucosal and connective 
subtypes). Surprisingly the results obtained appeared to be consistent with other 
studies, which employed paraformaldehyde, that excludes “formalin sensitive” 
mucosal MCs (Woidacki et al., 2013b), suggesting that in mice uterine MC 
populations belong to only one of the murine MC subtypes, the connective type. This 
conclusion is further supported by a recent study, which used double-transgenic 
C57BL/6J Mcpt5-Cre ROSA26-EYFP mice, with high expression of enhanced yellow 
fluorescent protein in MC protease 5 (Cma1 (Mcpt5))-expressing cells in the uterus 
(Schmerse et al., 2014). Mcpt5 (or mMCP-5) is expressed by the connective MC 
subtype and mucosal MCs contain mMCP-1 and mMCP-2 chymases. Unfortunately, 
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these two different MC types don’t share any of the MC specific proteases and 
therefore genetically modified mice do not fully recapitulate the phenotypes in women.  
Despite our belief that the results using human uterine tissues suggest MCs may 
play a role in menstruation in our mouse model MCs did not appear to be involved in 
endometrial breakdown or tissue regeneration. However, in the mice MCs were 
consistently located near the muscle fibres in the myometrial layer, suggesting instead 
a role for MCs in myometrial hyperactivity raising the possibility that MCs may be 
implicated in primary dysmenorrhea, characterized by intense and acute abdominal 
pain during the first days of menstrual flow that affects up to 40-50% of women 
(Bulletti et al., 2000). A recent study by Yang et al. (2015) has recapitulated in vivo 
the clinical features of dysmenorrhea in a mouse model but did not investigate the role 
of MCs in the painful contractions. It would be interesting to study MC number in the 
myometrium in the animals of that model to explore whether compounds blocking 
activation of MCs can have an impact on behavioural tests.  
To my knowledge, this was the first study that has demonstrated the presence of 
MCs in a mouse model of endometriosis (Greaves et al., 2014a). Similar to the human 
results in chapter 4, MCs were detected in the endometriotic “lesions” although in the 
mice MCs were absent in the “donor” material (endometrial tissue). Based on the 
current literature and the principle that MCs differentiate in situ from CD34+ 
progenitors, I speculate that there might be two possible origins of the lesion-
associated MCs: an endometrial or peritoneal origin of a CD34+ cell pool which 
differentiated at the site of the lesions. Since CD34+ cells are reported in the stromal 
compartment of the basal endometrium (Cho et al., 2004), it is feasible that cells 
resident in the basal endometrium and inner myometrium may become constituents of 
the lesions as collection of “donor” endometrial material involved scraping the 
endometrium from the myometrium with a scalpel. Alternatively, an interesting study 
on the “intraperitoneal foreign body reaction”, a common reaction of the body against 
implanted materials like medical devices, reported the influx of CD34+/c-kit+ 
hematopoietic cells around the implanted devices (Vranken et al., 2008). Although the 
endometriosis tissue is not a “device”, it is possible the reaction in the peritoneum is 
similar with recruitment of immune cells and ECM deposition. Further investigations 
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on CD34+/MC origin need to be conducted but the mouse model offers one platform 
for studying MCs in endometriosis. 
6.5 Study limitations  
Some limitations of the study must to be highlighted for better address the future 
directions of project. Firstly, the use of human samples meant there was a relatively 
small sample size and high patient variability. Sample size was further reduced over 
the time of the project due to strict criteria for patient inclusion in an attempt to limit 
factors that would introduce more variability, as detailed in the methods sections of 
chapter 3 and 4. Another limitation encountered in chapter 3 was access to full 
thickness uterine sample biopsies. Total abdomen hysterectomy is a gynaecological 
surgical practice that is becoming less frequent and often replaced by medical 
treatment. A similar problem was encountered during the investigation of MCs in 
endometriosis, where it was challenging to collect 'no pain and no endometriosis' 
control samples. Laparoscopic sterilisation is a rare procedure in developed countries, 
where other methods of birth controls are available. Therefore, the sample size could 
not be easily augmented since new prospective tissue collection has been sporadic 
during the time of the study.  
6.6 Future directions 
The current study has brought together evidence that oestrogens may have an 
impact on the recruitment of progenitors and their in situ differentiation within the 
different uterine tissue layers. Based on the preliminary data in peripheral blood 
derived MCs it appears ERa may be activated during CD34+ recruitment and during 
the first phases of MC differentiation, but binding to ERb may be responsible for 
exerting oestrogen-dependent effects on mature MCs behaviour. Interestingly, the 
time-dependent expression pattern of oestrogen receptors in the cultures suggests that 
further investigations on full thickness sections of uterine tissue should evaluate the 
phenotype of MCs in the region, where MC progenitors and mature MCs are most 
abundant – the myometrial-endometrial junction and examine the CD34+ during the 
different phases of the cycle. An exploration of the immunoexpression of ERa and 
ERb on uterine CD34+ cells could reveal whether the environment specific phenotype 
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is also true of progenitors or involves initial expression of ERa before a switch to ERb 
during differentiation.  
It is important to note that standard “flat” 2D culture systems may not be able to 
replicate the endometrial microenvironment (Ellem et al., 2014b). Thus it could be 
more appropriate to explore MC development in a 3D system to better mimic, in our 
case, the “uterine environment”. In our laboratory, a 3D “endometrial” culture system 
has been well established with stromal and epithelial cells, using cell lines (SHT-290 
and Ishikawa cells, Dr Simitsidellis personal communication), and this could be 
adapted by using a myometrial cells instead of epithelial cells. For example, uterine 
layers with a co-culture of myometrial cells and endometrial stromal cells might 
provide a platform for seeding CD34+ (peripheral blood or cord blood derived) and 
exploring their differentiation and the impact of oestrogens and progestins. The 3D 
culture would be also useful to explore the abnormal MC phenotype by using cells 
from women with endometriosis, which are already available in our laboratory.  
Studies carried out using tissues from women with CPP and/or endometriosis 
during chapter 4, have highlighted the potential that the impact of MCs on the 
pathophysiology of these conditions may be mediated via the PAR-2 receptor. These 
promising results need to be validated by using a larger number of samples particularly 
those from women who do not have CPP or endometriosis, as in the current study we 
found some of our small number of controls actually had asymptomatic endometriosis. 
Notably, finding increased expression of PAR-2 in the human peritoneum and 
in the patient group has brought new evidence consistent with the neuronal 
sensitization in the peritoneum of women affected by CPP and/or endometriosis, and 
it may offer a valid therapeutic target in these women. It has also been reported that 
PAR-2 is upregulated in dorsal root ganglia in association with thermal hyperalgesia 
and cAMP-dependent neuronal hyper-excitability (Zhang et al., 2011, Huang et al., 
2012), offering additional evidence of a link with pain. It is important that additional 
studies also investigate the cleaved form of the PAR-2, to inform a complete 
understanding of the activation status of the receptor. There are two antibodies 
available for PAR-2 (clones H99 and C17), other than the one used during the project 
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(clone SAM11, N-terminus specific), which recognise the extracellular loops or the 
intracellular domain of the receptor, both sites that remain unchanged after N-terminus 
cleavage by proteases. Its investigation could be further complemented using both of 
the mouse models employed during the investigations in chapter 5, which appeared to 
be promising platforms for further studies on implications of MCs in pain associated 
with common gynaecological conditions, such endometriosis or painful menstruation. 
As a first step it would be worth investigating whether the expression pattern of PAR-
2 in human peritoneum and endometriotic lesions is recapitulated in the mouse model 
of endometriosis and if there is any expression in their dorsal root ganglia. Importantly 
experiments on PAR-2 antagonism and PAR-2 knockout animals have reported pain 
relief in mouse models of rheumatoid arthritis (Russell and McDougall, 2009) and 
irritable bowel syndrome (Cenac et al., 2007).  
Unfortunately, the use of mouse models for MC studies has one major limitation; 
there are no antibodies currently available that recognise the MC specific proteases in 
this species. Therefore, the “old” method of toluidine blue staining is routinely 
employed for identification of murine MCs and was used in the current study. A 
significant step forward in the MC field was made by Schmerse et al. (2014) with the 
development of the C57BL/6J-Mcpt5-Cre ROSA26-EYFP mouse which labels 
connective tissue type MCs. As the evaluation conducted in the current project showed 
MCs resident in the uterus are of this subtype, the “Mcpt5” mouse may be a useful tool 
for exploring the role of MCs in both our menstruation and endometriosis models.  
6.7 General conclusions 
Mast cells are a component of the leukocyte population of the human uterus and 
it has been demonstrated that MCs may play an important role in both physiology and 
pathology of the endometrium. Mast cell activation/degranulation is menstrual cycle 
stage dependent, and their environment-specific phenotype has suggested the 
oestrogens influence in progenitor/MC development, via different ER receptors. This 
study has provided an insight into the potential that MCs may play a role in formation 
of the endometriotic lesion and the establishment of chronic pain and hyperalgesia. 
The preliminary results from mouse models have offered a valid platform for further 
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studies on the implications of MCs in pain associated with endometriosis or 
menstruation.  
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